<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02769065</url>
  </required_header>
  <id_info>
    <org_study_id>TAK-071-1001</org_study_id>
    <secondary_id>U1111-1176-7435</secondary_id>
    <nct_id>NCT02769065</nct_id>
  </id_info>
  <brief_title>Study of TAK-071 in Healthy Participants and Participants With Mild Cognitive Impairment/Mild Alzheimer Disease and Relative Bioavailability (BA) and Food Effect of TAK-071 in Healthy Participants</brief_title>
  <official_title>A Phase 1 Safety, Tolerability, and Pharmacokinetic Study of Escalating Single and Multiple Oral Doses of TAK-071 in Healthy Subjects and Subjects With Mild Cognitive Impairment/Mild Alzheimer Disease and Relative Bioavailability and Food Effect of TAK-071 in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Takeda</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Takeda</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study was to assess the safety, tolerability, and pharmacokinetic (PK) of
      TAK-071 when administered as single rising dose (SRD) and multiple rising dose (MRD) orally
      in healthy participants and participants with mild cognitive impairment (MCI) or mild
      Alzheimer disease (AD).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      TAK-071 was being tested to find a safe and well-tolerated dose in healthy participants
      (non-Japanese and Japanese) and participants with MCI or mild AD (non-Japanese).

      The study enrolled 179 participants. The study consisted of 4 parts: Single-rising dose (SRD)
      part (Cohorts 1-6, and 18-22), multiple-rising dose (MRD) part (Cohorts 7-15), Cohort 16 with
      2-arm parallel design, and Cohort 17 relative bioavailability and food effect 3 period
      crossover design.

      Participants in each cohort were randomized to receive treatment with TAK-071 or matching
      placebo using drug-in-capsule (DIC) in the morning following a minimum fast of 8 hours. In
      Cohort 16, participants were assigned to 1 of 2 possible treatments, TAK-071 or matching
      placebo. In Cohort 17, participants were assigned to 1 of 3 treatment sequences (ABC, BCA, or
      CAB) with treatment A being fasted state and capsule formulation, treatment B being fasted
      state and tablet formulation, and treatment C being fed state and tablet formulation. In
      Cohorts 20-22, participants were administered as a single dose of TAK-071 or placebo on Day
      1, and a single dose of donepezil or placebo approximately 24 hours later on Day 2.

      This multi-center trial was conducted in United States. The overall time to participate in
      this study was approximately 41 days. Participants made multiple visits to the clinic and
      were also contacted for the follow-up through the telephone.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Terminated prematurely as data from cohort no longer needed due to indication change.
  </why_stopped>
  <start_date type="Actual">May 5, 2016</start_date>
  <completion_date type="Actual">June 8, 2017</completion_date>
  <primary_completion_date type="Actual">June 8, 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants Who Experienced at Least One Treatment-Emergent Adverse Event (TEAE)</measure>
    <time_frame>Day 1 up to Day 41</time_frame>
    <description>An Adverse Event (AE) is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. A TEAE is defined as an adverse event with an onset that occurs or gets worse after receiving study drug.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Who Meet the Markedly Abnormal Criteria for Clinical Laboratory Tests at Least Once Post-dose</measure>
    <time_frame>Day 1 up to Day 41</time_frame>
    <description>Clinical laboratory tests included serum chemistry, hematology, coagulation and urinalysis. ULN=upper limit of normal range.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Who Meet the Markedly Abnormal Criteria for Vital Sign Measurements at Least Once Post-dose</measure>
    <time_frame>Day 1 up to Day 41</time_frame>
    <description>Vital Sign measurements included systolic blood pressure (SBP), diastolic blood presssure (DBP), pulse, temperature, orthostatic SBP, orthostatic DBP and orthostatic pulse.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Who Meet the Markedly Abnormal Criteria for 12-lead Electrocardiogram (ECG) Parameters at Least Once Post-dose</measure>
    <time_frame>Day 1 up to Day 41</time_frame>
    <description>A standard 12-lead electrocardiogram (ECG) was performed. The percentage of participants with markedly abnormal ECG findings during the study.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Tmax: Time of First Occurrence of Cmax for TAK-071 Single-Rising Dose (SRD) Non-Japanese Participants</measure>
    <time_frame>Pre-dose on Day 1 and at multiple time points (up to 168 hours) post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Tmax: Time of First Occurrence of Cmax for TAK-071 Multiple-Rising Dose (MRD) Non-Japanese Participants [Day 1]</measure>
    <time_frame>Pre-dose on Day 1 and multiple time points (up to 24 hours) post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Tmax: Time of First Occurrence of Cmax for TAK-071 MRD Non-Japanese Participants [Day 21]</measure>
    <time_frame>Pre-dose on Day 21 and multiple time points (up to 24 hours) post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Tmax: Time of First Occurrence of Cmax for TAK-071 MRD Non-Japanese Participants [Day 1]</measure>
    <time_frame>Pre-dose on Day 1 and multiple time points (up to 96 hours) post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Tmax: Time of First Occurrence of Cmax for TAK-071 MRD Non-Japanese Participants [Day 8]</measure>
    <time_frame>Pre-dose on Day 8 and multiple time points (up to 24 hour) post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Tmax: Time of First Occurrence of Cmax for TAK-071 MRD Non-Japanese Participants [Day 28]</measure>
    <time_frame>Pre-dose on Day 28 and multiple time points (up to 36 hours) post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Tmax: Time of First Occurrence of Cmax for TAK-071 MRD Japanese Participants [Day 1]</measure>
    <time_frame>Pre-dose on Day 1 and multiple time points (up to 96 hours) post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Tmax: Time of First Occurrence of Cmax for TAK-071 MRD Japanese Participants [Day 8]</measure>
    <time_frame>Pre-dose on Day 8 and multiple time points (up to 24 hours) post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Tmax: Time of First Occurrence of Cmax for TAK-071 MRD Japanese Participants [Day 28]</measure>
    <time_frame>Pre-dose on Day 28 and multiple time points (up to 24 hours) post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Tmax: Time of First Occurrence of Cmax for TAK-071 MRD Non-Japanese Participants [Day 1]</measure>
    <time_frame>Pre-dose on Day 1 and multiple time points (up to 24 hours) post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Tmax: Time of First Occurrence of Cmax for TAK-071 Relative Bioavailability and Food Effect</measure>
    <time_frame>Pre-dose on Day 21 and multiple time points (up to 168 hours) post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Tmax: Time of First Occurrence of Cmax for TAK-071 SRD Non-Japanese Participants TAK-071+Donepezil</measure>
    <time_frame>Pre-dose on Day 1 and at multiple time points (up to 168 hours) post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax: Maximum Observed Plasma Concentration for TAK-071 Single-Rising Dose (SRD) Non-Japanese Participants</measure>
    <time_frame>Pre-dose on Day 1 and at multiple time points (up to 168 hours) post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax: Maximum Observed Plasma Concentration for TAK-071 Multiple-Rising Dose (MRD) Non-Japanese Participants [Day 1]</measure>
    <time_frame>Pre-dose on Day 1 and multiple time points (up to 24 hours) post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax: Maximum Observed Plasma Concentration for TAK-071 MRD Non-Japanese Participants [Day 21]</measure>
    <time_frame>Pre-dose on Day 21 and multiple time points (up to 24 hours) post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax: Maximum Observed Plasma Concentration for TAK-071 MRD Non-Japanese Participants [Day 1]</measure>
    <time_frame>Pre-dose on Day 1 and multiple time points (up to 96 hours) post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax: Maximum Observed Plasma Concentration for TAK-071 MRD Non-Japanese Participants [Day 8]</measure>
    <time_frame>Pre-dose on Day 8 and multiple time points (up to 24 hour) post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax: Maximum Observed Plasma Concentration for TAK-071 MRD Non-Japanese Participants [Day 28]</measure>
    <time_frame>Pre-dose on Day 28 and multiple time points (up to 36 hours) post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax: Maximum Observed Plasma Concentration for TAK-071 MRD Japanese Participants [Day 1]</measure>
    <time_frame>Pre-dose on Day 1 and multiple time points (up to 96 hours) post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax: Maximum Observed Plasma Concentration for TAK-071 MRD Japanese Participants [Day 8]</measure>
    <time_frame>Pre-dose on Day 8 and multiple time points (up to 24 hours) post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax: Maximum Observed Plasma Concentration for TAK-071 MRD Japanese Participants [Day 28]</measure>
    <time_frame>Pre-dose on Day 28 and multiple time points (up to 24 hours) post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax: Maximum Observed Plasma Concentration for TAK-071 MRD Non-Japanese Participants [Day 1]</measure>
    <time_frame>Pre-dose on Day 1 and multiple time points (up to 24 hours) post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax: Maximum Observed Plasma Concentration for TAK-071 Relative Bioavailability and Food Effect</measure>
    <time_frame>Pre-dose on Day 1 and multiple time points (up to 168 hours) post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax: Maximum Observed Plasma Concentration for TAK-071 SRD Non-Japanese Participants TAK-071+Donepezil</measure>
    <time_frame>Pre-dose on Day 1 and at multiple time points (up to 168 hours) post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC(0-24): Area Under the Plasma Concentration-Time Curve From Time 0 to 24 Hours for TAK-071 Single-Rising Dose (SRD) Non-Japanese Participants</measure>
    <time_frame>Pre-dose on Day 1 and at multiple time points (up to 168 hours) post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC(0-24): Area Under the Plasma Concentration-Time Curve From Time 0 to 24 Hours for TAK-071 Multiple-Rising Dose (MRD) Non-Japanese Participants [Day 1]</measure>
    <time_frame>Pre-dose on Day 1 and multiple time points (up to 24 hours) post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC(0-24): Area Under the Plasma Concentration-Time Curve From Time 0 to 24 Hours for TAK-071 MRD Non-Japanese Participants [Day 21]</measure>
    <time_frame>Pre-dose on Day 21 and multiple time points (up to 24 hours) post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC(0-24): Area Under the Plasma Concentration-Time Curve From Time 0 to 24 Hours for TAK-071 MRD Non-Japanese Participants [Day 1]</measure>
    <time_frame>Pre-dose on Day 1 and multiple time points (up to 96 hours) post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC(0-24): Area Under the Plasma Concentration-Time Curve From Time 0 to 24 Hours for TAK-071 MRD Non-Japanese Participants [Day 8]</measure>
    <time_frame>Pre-dose on Day 8 and multiple time points (up to 24 hour) post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC(0-24): Area Under the Plasma Concentration-Time Curve From Time 0 to 24 Hours for TAK-071 MRD Non-Japanese Participants [Day 28]</measure>
    <time_frame>Pre-dose on Day 28 and multiple time points (up to 36 hours) post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC(0-24): Area Under the Plasma Concentration-Time Curve From Time 0 to 24 Hours for TAK-071 MRD Japanese Participants [Day 1]</measure>
    <time_frame>Pre-dose on Day 1 and multiple time points (up to 96 hours) post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC(0-24): Area Under the Plasma Concentration-Time Curve From Time 0 to 24 Hours for TAK-071 MRD Japanese Participants [Day 8]</measure>
    <time_frame>Pre-dose on Day 8 and multiple time points (up to 24 hours) post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC(0-24): Area Under the Plasma Concentration-Time Curve From Time 0 to 24 Hours for TAK-071 MRD Japanese Participants [Day 28]</measure>
    <time_frame>Pre-dose on Day 28 and multiple time points (up to 24 hours) post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC(0-24): Area Under the Plasma Concentration-Time Curve From Time 0 to 24 Hours for TAK-071 MRD Non-Japanese Participants [Day 1]</measure>
    <time_frame>Pre-dose on Day 1 and multiple time points (up to 24 hours) post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC∞: Area Under the Plasma Concentration-Time Curve From Time 0 to Infinity for TAK-071 Relative Bioavailability and Food Effect</measure>
    <time_frame>Pre-dose on Day 21 and multiple time points (up to 168 hours) post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC(0-24): Area Under the Plasma Concentration-Time Curve From Time 0 to 24 Hours for TAK-071 SRD Non-Japanese Participants TAK-071+Donepezil</measure>
    <time_frame>Pre-dose on Day 1 and at multiple time points (up to 168 hours) post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC∞: Area Under the Concentration-Time Curve From Time 0 to Infinity, Calculated Using the Observed Value of the Last Quantifiable Concentration for TAK-071 SRD Non-Japanese Participants</measure>
    <time_frame>Pre-dose on Day 1 and at multiple time points [up to 168 hours] post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC∞: Area Under the Concentration-Time Curve From Time 0 to Infinity, Calculated Using the Observed Value of the Last Quantifiable Concentration for TAK-071 SRD Non-Japanese Participants TAK-071 + Donepezil</measure>
    <time_frame>Pre-dose on Day 1 and at multiple time points [up to 168 hours] post-dose</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>AUClast: Area Under the Concentration-time Curve From Time 0 to Time of the Last Quantifiable Concentration for TAK-071 MRD Non-Japanese Participants</measure>
    <time_frame>Pre-dose on Day 1 and at multiple time points (up to 168 hours) post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUClast: Area Under the Concentration-time Curve From Time 0 to Time of the Last Quantifiable Concentration for TAK-071 MRD Non-Japanese Participants</measure>
    <time_frame>Pre-dose on Day 1 and multiple timepoints (up to 24 hrs) post-dose for Cohorts 7 and 8 and Pre-dose on Day 1 and multiple timepoints (up to 96 hrs) post-dose for Cohort 9</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUClast: Area Under the Concentration-time Curve From Time 0 to Time of the Last Quantifiable Concentration for TAK-071 MRD Japanese Participants</measure>
    <time_frame>Pre-dose on Day 1 and multiple time points (up to 96 hours) post-dose and Pre-dose on Day 8 and multiple time points (up to 24 hours) post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUClast: Area Under the Concentration-time Curve From Time 0 to Time of the Last Quantifiable Concentration for TAK-071 MRD Non-Japanese</measure>
    <time_frame>Pre-dose on Day 1 and at multiple time points (up to 24 hours) post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUClast: Area Under the Concentration-time Curve From Time 0 to Time of the Last Quantifiable Concentration for TAK-071 Relative Bioavailability and Food Effect</measure>
    <time_frame>Pre-dose on Day 1 and multiple time points (up to 168 hours) post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUClast: Area Under the Concentration-time Curve From Time 0 to Time of the Last Quantifiable Concentration for TAK-071 SRD Non-Japanese Participants TAK-071+Donepezil</measure>
    <time_frame>Pre-dose on Day 1 and multiple time points (up to 168 hours) post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal Disposition Phase Half-life (t1/2z) for TAK-071 SRD Non-Japanese Participants</measure>
    <time_frame>Pre-dose on Day 1 and at multiple time points (up to 168 hours) post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal Disposition Phase Half-life (t1/2z) for TAK-071 Relative Bioavailability and Food Effect</measure>
    <time_frame>Pre-dose on Day 21 and multiple time points (up to 168 hours) post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal Disposition Phase Half-life (t1/2z) for TAK-071 SRD Non-Japanese Participants TAK-071+Donepezil</measure>
    <time_frame>Pre-dose on Day 1 and multiple time points (up to 168 hours) post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CL/F: Apparent Clearance After Extravascular Administration for TAK-071 SRD Non-Japanese Participants</measure>
    <time_frame>Pre-dose on Day 1 and at multiple time points (up to 168 hours) post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CL/F: Apparent Clearance After Extravascular Administration for TAK-071 Relative Bioavailability and Food Effect</measure>
    <time_frame>Pre-dose on Day 21 and multiple time points (up to 168 hours) post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CL/F: Apparent Clearance After Extravascular Administration for TAK-071 SRD Non-Japanese Participants TAK-071+Donepezil</measure>
    <time_frame>Pre-dose on Day 1 and at multiple time points (up to 168 hours) post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vz/F: Apparent Volume of Distribution During the Terminal Disposition Phase After Extravascular Administration for TAK-071 SRD Non-Japanese Participants</measure>
    <time_frame>Pre-dose on Day 1 and at multiple time points (up to 168 hours) post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vz/F: Apparent Volume of Distribution During the Terminal Disposition Phase After Extravascular Administration for TAK-071 Relative Bioavailability and Food Effect</measure>
    <time_frame>Pre-dose on Day 21 and multiple time points (up to 168 hours) post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vz/F: Apparent Volume of Distribution During the Terminal Disposition Phase After Extravascular Administration for TAK-071 SRD Non-Japanese Participants TAK-071 + Donepezil</measure>
    <time_frame>Pre-dose on Day 1 and at multiple time points (up to 168 hours) post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Accumulation Ratio Based on AUCτ (Rac[AUC]) for TAK-071 MRD Non-Japanese Participants</measure>
    <time_frame>Pre-dose on Day 21 and at multiple time points (up to 24 hours) post-dose for Cohorts 7 and 8 and Pre-dose on Day 28 and at multiple time points (up to 36 hours) post-dose for Cohort 9</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Accumulation Ratio Based on AUCτ (Rac[AUC]) for TAK-071 MRD Japanese Participants</measure>
    <time_frame>Pre-dose on Day 28 and at multiple time points [up to 24 hours] post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Accumulation Ratio Based on AUCτ (Rac[AUC]) for TAK-071 MRD Non-Japanese Participants</measure>
    <time_frame>Pre-dose on Day 21 and at multiple time points [up to 24 hours] post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Accumulation Ratio Based on Plasma Cmax (Rac[Cmax]) for TAK-071 MRD Non-Japanese Participants</measure>
    <time_frame>Pre-dose on Day 21 and at multiple time points [up to 24 hours] post-dose for Cohorts 7 and 8 and Pre-dose on Day 28 and at multiple time points (up to 36 hours) post-dose for Cohort 9</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Accumulation Ratio Based on Plasma Cmax (Rac[Cmax]) for TAK-071 MRD Japanese Participants</measure>
    <time_frame>Pre-dose on Day 28 and at multiple time points [up to 24 hours] post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Accumulation Ratio Based on Plasma Cmax (Rac[Cmax]) for TAK-071 MRD Non-Japanese Participants</measure>
    <time_frame>Pre-dose on Day 21 and at multiple time points [up to 24 hours] post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AEt: Amount of Drug Excreted in Urine From Time 0 to Time t for TAK-071 SRD Non-Japanese Participants</measure>
    <time_frame>Pre-dose on Day 1 and at multiple time points [up to 96 hours] post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AEt: Amount of Drug Excreted in Urine From Time 0 to Time t for TAK-071 MRD Non-Japanese Participants</measure>
    <time_frame>Pre-dose on Day 1 and 21 and at multiple time points (up to 24 hours) post-dose for Cohorts 7 and 8, and pre-dose on Day 1 and 28 and multiple time points (up to 96 hours) post-dose for Cohort 9</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AEt: Amount of Drug Excreted in Urine From Time 0 to Time t for TAK-071 MRD Japanese Participants</measure>
    <time_frame>Pre-dose on Day 1 and at multiple time points (up to 96 hours) post-dose and pre-dose on Day 28 and multiple time points (up to 24 hours) post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fet: Fraction of Administered Dose of Drug Excreted in Urine From Time 0 to Time t for TAK-071 SRD Non-Japanese Participants</measure>
    <time_frame>Pre-dose on Day 1 and at multiple time points (up to 96 hours) post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fet: Fraction of Administered Dose of Drug Excreted in Urine From Time 0 to Time t for TAK-071 MRD Non-Japanese Participants</measure>
    <time_frame>Pre-dose on Days 1 and 21 and at multiple time points (up to 24 hours) post-dose for Cohorts 7 and 8 and Pre-dose on Days 1 and 28 and multiple time points (up to 96 hours) post-dose for Cohort 9</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fet: Fraction of Administered Dose of Drug Excreted in Urine From Time 0 to Time t for TAK-071 MRD Japanese Participants</measure>
    <time_frame>Pre-dose on Day 1 and at multiple time points (up to 96 hours) post-dose and pre-dose on Day 28 and multiple time points (up to 24 hours) post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CLR: Renal Clearance for TAK-071 SRD Non-Japanese Participants</measure>
    <time_frame>Pre-dose on Day 1 and at multiple time points [up to 96 hours] post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CLR: Renal Clearance for TAK-071 MRD Non-Japanese Participants</measure>
    <time_frame>Pre-dose on Days 1 and 21 and at multiple time points (up to 24 hours) post-dose for Cohorts 7 and 8 and Pre-dose on Days 1 and 28 multiple time points (up to 96 hours) post-dose for Cohort 9</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CLR: Renal Clearance for TAK-071 MRD Japanese Participants</measure>
    <time_frame>Pre-dose on Day 1 and at multiple time points (up to 96 hours) post-dose and pre-dose on Day 28 and multiple time points (up to 24 hours) post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CSF Cmax: Maximum Observed Concentration in Cerebrospinal Fluid (CSF) for TAK-071</measure>
    <time_frame>Pre-dose on Day 1 and at multiple time points (up to 12 hours) post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CSF Cmax: Maximum Observed Concentration in Cerebrospinal Fluid (CSF) for TAK-071</measure>
    <time_frame>Pre-dose on Day 28 and at multiple time points (up to 36 hours) post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CSF AUC(0-12): Area Under the CSF Concentration-time Curve From Time 0 to 12 Hours for TAK-071</measure>
    <time_frame>Pre-dose on Day 1 and at multiple time points (up to 12 hours) post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CSF AUC(0-36): Area Under the CSF Concentration-time Curve From Time 0 to 36 Hours for TAK-071</measure>
    <time_frame>Pre-dose on Day 28 and multiple time points (up to 36 hours) post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ratio of CSF AUC(0-12) to the Plasma AUC(0-12) for TAK-071</measure>
    <time_frame>Pre-dose on Day 1 and at multiple time points [up to 168 hours] post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ratio of CSF AUC(0-36) to the Plasma AUC(0-36) for TAK-071</measure>
    <time_frame>Pre-dose on Day 28 and multiple time points (up to 36 hours) post-dose Cohort 9</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for Donepezil MRD Non-Japanese Participants</measure>
    <time_frame>Pre-dose on Days -1 and 21 and multiple time points (up to 24 hours) post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax: Maximum Observed Plasma Concentration for Donepezil MRD Non-Japanese Participants</measure>
    <time_frame>Pre-dose on Days -1 and 21 and multiple time points (up to 24 hours) post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC(0-24): Area Under the Plasma Concentration-Time Curve From Time 0 to 24 Hours Post-dose for Donepezil</measure>
    <time_frame>Pre-dose on Days -1 and 21 and multiple time points (up to 24 hours) post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ratio of Geometric Mean of Cmax for Donepezil After 21 Daily Doses of TAK-071</measure>
    <time_frame>Pre-dose on Days -1 and 21 and multiple time points (up to 24 hours) post-dose</time_frame>
    <description>A linear mixed effect model on the natural log-transformed parameters was performed with day as a fixed effect and participant as a random effect. Ratio is the exponentiated geometric mean value Day 21/Day -1 on the original scale.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ratio of Geometric Mean of AUC(0-24) for Donepezil After 21 Daily Doses of TAK-071</measure>
    <time_frame>Pre-dose on Days -1 and 21 and multiple time points (up to 24 hours) post-dose</time_frame>
    <description>A linear mixed effect model on the natural log-transformed parameters was performed with day as a fixed effect and participant as a random effect. Ratio is the exponentiated geometric mean value Day 21/Day -1 on the original scale.</description>
  </secondary_outcome>
  <number_of_arms>30</number_of_arms>
  <enrollment type="Actual">179</enrollment>
  <condition>Alzheimer Disease</condition>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>SRD: Placebo Cohorts 1-6, 18 and 19</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>TAK-071 placebo-matching capsules, orally, once on Day 1 to non-Japanese healthy participants in the single-rising dose (SRD) period.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SRD: Cohort 1: TAK-071 1 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TAK-071 1 mg, capsule, orally, once on Day 1 to non-Japanese healthy participants.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SRD: Cohort 2: TAK-071 3 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TAK-071 3 mg capsule, orally, once on Day 1 to non-Japanese healthy participants. Dose of TAK-071 was based on the 24-hour post-dose safety, tolerability and pharmacokinetic (PK) data from cohort 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SRD: Cohort 3: TAK-071 9 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TAK-071 9 mg capsule, orally, once on Day 1 to non-Japanese healthy participants. Dose of TAK-071 was based on 24-hour safety, tolerability, and preliminary plasma PK and 12-hour CSF PK data.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SRD: Cohort 4: TAK-071 20 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TAK-071 20 mg capsule, orally, once on Day 1 to non-Japanese healthy participants. Dose of TAK-071 was based on the 24-hour post-dose safety and tolerability data from previous cohort.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SRD: Cohort 5: TAK-071 40 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TAK-071 40 mg capsule, orally, once on Day 1 to non-Japanese healthy participants. Dose of TAK-071 will be based on 24-hour safety, tolerability, and preliminary plasma PK data from Cohort 4.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SRD: Cohort 6: TAK-071 80 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TAK-071 80 mg capsules, orally, once on Day 1 to non-Japanese healthy participants. Dose of TAK-071 was based on 24-hour safety, tolerability, and preliminary plasma PK data from Cohort 5</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MRD: Placebo Cohorts 7-9</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>TAK-071 placebo-matching capsule, orally, once on Day 1 to non-Japanese healthy participants in the multiple-rising dose (MRD) period.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MRD: Cohort 7: TAK-071 3 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TAK-071 3 mg capsules, orally, once daily from Day 1 up to Day 21 to non-Japanese healthy participants. Dose of TAK-071 was based on 24-hour safety and tolerability from Cohort 4 and the 24-hour preliminary plasma PK and 12-hour CSF PK data from Cohort 3.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MRD: Cohort 8: TAK-071 9 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TAK-071 9 mg capsules, orally, once daily from Day 1 up to Day 21 to non-Japanese healthy participants. Dose of TAK-071 was based on safety, tolerability and available PK data arising from the ongoing SRD part and previous MRD cohort.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MRD: Cohort 9: TAK-071 15 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TAK-071 15 mg capsule, orally, once on Day 1, followed by a washout period of 7 days, then TAK-071 once daily for 21 days to non-Japanese healthy participants. Dose of TAK-071 will be based on safety, tolerability and available PK data arising from the ongoing SRD part and previous MRD cohort.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MRD: TAK-071 Placebo Cohorts 10-12+Donepezil</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>TAK-071 placebo-matching capsule, orally, once daily along with donepezil 5 mg, tablets, orally, once daily from Day 1 up to Day 21 to non-Japanese healthy participants who were pre-treated with donepezil 5 mg, tablet, once daily for 3 weeks prior to administration of TAK-071.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MRD: Cohort 10: TAK-071 3 mg+Donepezil 5 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TAK-071 3 mg capsules, orally, once daily along with donepezil 5 mg, tablets, orally, once daily from Day 1 up to Day 21 to non-Japanese healthy participants who were pre-treated with donepezil 5 mg, tablet, once daily for 3 weeks prior to administration of TAK-071. Dose of TAK-071 was same as the dose used in MRD Cohort 7.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MRD: Cohort 11: TAK-071 9 mg + Donepezil 5 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TAK-071 9 mg capsules, orally, once daily along with donepezil 5 mg, tablets, orally, once daily from Day 1 up to Day 21 to non-Japanese healthy participants who were pre-treated with donepezil 5 mg, tablet, once daily for 3 weeks prior to administration of TAK-071. Dose of TAK-071 was same as the dose used in MRD Cohort 8.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MRD: Cohort 12: TAK-071 15 mg+Donepezil 5 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TAK-071 15 mg capsule, orally, once daily along with donepezil 5 mg, tablets, orally, once daily from Day 1 up to Day 21 to non-Japanese healthy participants who were pre-treated with donepezil 5 mg, tablet, once daily for 3 weeks prior to administration of TAK-071. Dose of TAK-071 was same as the dose used in MRD Cohort 9.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MRD: Placebo Cohorts 13-15</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TAK-071 placebo-matching capsule, orally, once on Day 1 to Japanese healthy participants.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MRD: Cohort 13: TAK-071 3 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TAK-071 3 mg capsule, orally, once on Day 1, followed by a washout period of 7 days, then TAK-071 once daily for 21 days to Japanese healthy participants. Dose of TAK-071 was same as the dose used in MRD Cohort 7.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MRD: Cohort 14: TAK-071 9 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TAK-071 9 mg capsule or matching placebo, orally, once on Day 1, followed by a washout period of 7 days, then TAK-071 once daily for 21 days to Japanese healthy participants. Dose of TAK-071 was same as the dose used in MRD Cohort 8.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MRD: Cohort 15: TAK-071 15 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TAK-071 15 mg capsule, orally, once on Day 1, followed by a washout period of 7 days, then TAK-071 once daily for 21 days to Japanese healthy participants. Dose of TAK-071 was same as the dose used in MRD Cohort 9.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 16</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Bioavailability (BA)/Food Effect: Cohort 17 Sequence ABC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A: TAK-071 10 mg capsule, orally once on Day 1 in the fasted state in Period 1, followed by B: TAK-071 10 mg tablet, orally, once on Day 1 in the fasted state in Period 2, followed by C: TAK-071 10 mg tablet, orally, once on Day 1 in the fed state in Period 3 in non-Japanese healthy participants. There was a 21-day washout after each period.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BA/Food Effect: Cohort 17 Sequence BCA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>B: TAK-071 10 mg tablet, orally, once on Day 1 in the fasted state in Period 1, followed by C: TAK-071 10 mg tablet, orally, once on Day 1 in the Fed state in Period 2, followed by A: TAK-071 10 mg capsule, orally once on Day 1 in the fasted state Period 3 in non-Japanese healthy participants. There was a 21-day washout after each period.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BA/Food Effect: Cohort 17 Sequence CAB</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>C: TAK-071 10 mg tablet, orally, once on Day 1 in the fed state in Period 1, followed by A: TAK-071 10 mg capsule, orally once on Day 1 in the fasted state in Period 2, followed by B: TAK-20 10 mg tablet, orally, once on Day 1 in the fasted state in Period 3 in non-Japanese healthy participants. There was a 21-day washout after each period.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SRD: Cohort 18: TAK-071 120 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TAK-071 120 mg capsule, orally, once on Day 1 to non-Japanese healthy participants. Dose of TAK-071 was based on 24-hour safety, tolerability, and preliminary plasma PK data from Cohort 6.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SRD: Cohort 19: TAK-071 160 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TAK-071 160 mg capsule, orally, once on Day 1 to non-Japanese healthy participants. Dose of TAK-071 was based on 24-hour safety, tolerability, and preliminary plasma PK data from Cohort 18.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SRD: TAK-071 Placebo+Donepezil Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>TAK-071 placebo-matching capsule, orally, once on Day 1 followed by donepezil placebo-matching tablet, orally on Day 2 to non-Japanese healthy participants.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SRD: TAK-071 Placebo+Donepezil</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>TAK-071 placebo-matching capsule, orally, once on Day 1 followed by donepezil 10 mg tablet, orally, on Day 2 to non-Japanese healthy participants.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SRD: Cohort 20: TAK-071 40 mg+Donepezil</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TAK-071 40 mg capsule, orally, once on Day 1 followed by donepezil 10 mg, tablets, orally, once on Day 2 to non-Japanese healthy participants. Dose of TAK-071 was based on 24-hour safety, tolerability, and preliminary plasma PK data from Cohort 19.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SRD: Cohort 21: TAK-071 60 mg+Donepezil</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TAK-071 60 mg capsule, orally, once on Day 1 followed by donepezil 10 mg, tablets, orally, once on Day 2 to non-Japanese healthy participants. Dose of TAK-071 was based on 24-hour safety and tolerability data from Cohort 20.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SRD: Cohort 22: TAK-071 80 mg+Donepizil</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TAK-071 80 mg capsule, orally, once on Day 1, followed by donepezil 10 mg, tablets, orally, once on Day 2 to non-Japanese healthy participants. Dose of TAK-071 was based on 24-hour safety and tolerability data from Cohort 21.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TAK-071</intervention_name>
    <description>TAK-071 capsules</description>
    <arm_group_label>BA/Food Effect: Cohort 17 Sequence BCA</arm_group_label>
    <arm_group_label>BA/Food Effect: Cohort 17 Sequence CAB</arm_group_label>
    <arm_group_label>Bioavailability (BA)/Food Effect: Cohort 17 Sequence ABC</arm_group_label>
    <arm_group_label>Cohort 16</arm_group_label>
    <arm_group_label>MRD: Cohort 10: TAK-071 3 mg+Donepezil 5 mg</arm_group_label>
    <arm_group_label>MRD: Cohort 11: TAK-071 9 mg + Donepezil 5 mg</arm_group_label>
    <arm_group_label>MRD: Cohort 12: TAK-071 15 mg+Donepezil 5 mg</arm_group_label>
    <arm_group_label>MRD: Cohort 13: TAK-071 3 mg</arm_group_label>
    <arm_group_label>MRD: Cohort 14: TAK-071 9 mg</arm_group_label>
    <arm_group_label>MRD: Cohort 15: TAK-071 15 mg</arm_group_label>
    <arm_group_label>MRD: Cohort 7: TAK-071 3 mg</arm_group_label>
    <arm_group_label>MRD: Cohort 8: TAK-071 9 mg</arm_group_label>
    <arm_group_label>MRD: Cohort 9: TAK-071 15 mg</arm_group_label>
    <arm_group_label>SRD: Cohort 18: TAK-071 120 mg</arm_group_label>
    <arm_group_label>SRD: Cohort 19: TAK-071 160 mg</arm_group_label>
    <arm_group_label>SRD: Cohort 1: TAK-071 1 mg</arm_group_label>
    <arm_group_label>SRD: Cohort 20: TAK-071 40 mg+Donepezil</arm_group_label>
    <arm_group_label>SRD: Cohort 21: TAK-071 60 mg+Donepezil</arm_group_label>
    <arm_group_label>SRD: Cohort 22: TAK-071 80 mg+Donepizil</arm_group_label>
    <arm_group_label>SRD: Cohort 2: TAK-071 3 mg</arm_group_label>
    <arm_group_label>SRD: Cohort 3: TAK-071 9 mg</arm_group_label>
    <arm_group_label>SRD: Cohort 4: TAK-071 20 mg</arm_group_label>
    <arm_group_label>SRD: Cohort 5: TAK-071 40 mg</arm_group_label>
    <arm_group_label>SRD: Cohort 6: TAK-071 80 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Donepezil</intervention_name>
    <description>Donepezil over-encapsulated tablet</description>
    <arm_group_label>MRD: Cohort 10: TAK-071 3 mg+Donepezil 5 mg</arm_group_label>
    <arm_group_label>MRD: Cohort 11: TAK-071 9 mg + Donepezil 5 mg</arm_group_label>
    <arm_group_label>MRD: Cohort 12: TAK-071 15 mg+Donepezil 5 mg</arm_group_label>
    <arm_group_label>MRD: TAK-071 Placebo Cohorts 10-12+Donepezil</arm_group_label>
    <arm_group_label>SRD: Cohort 20: TAK-071 40 mg+Donepezil</arm_group_label>
    <arm_group_label>SRD: Cohort 21: TAK-071 60 mg+Donepezil</arm_group_label>
    <arm_group_label>SRD: Cohort 22: TAK-071 80 mg+Donepizil</arm_group_label>
    <arm_group_label>SRD: TAK-071 Placebo+Donepezil</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TAK-071 Placebo</intervention_name>
    <description>TAK-071 placebo-matching capsules</description>
    <arm_group_label>MRD: Placebo Cohorts 13-15</arm_group_label>
    <arm_group_label>MRD: Placebo Cohorts 7-9</arm_group_label>
    <arm_group_label>MRD: TAK-071 Placebo Cohorts 10-12+Donepezil</arm_group_label>
    <arm_group_label>SRD: Placebo Cohorts 1-6, 18 and 19</arm_group_label>
    <arm_group_label>SRD: TAK-071 Placebo+Donepezil</arm_group_label>
    <arm_group_label>SRD: TAK-071 Placebo+Donepezil Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Donepezil Placebo</intervention_name>
    <description>Donepezil placebo-matching over-encapsulated tablet</description>
    <arm_group_label>SRD: TAK-071 Placebo+Donepezil Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Man or woman who weighs at least 50 kg and has a body mass index (BMI) from 18.0 to
             30.0 kg/m^2, inclusive, at Screening. Participants should be aged 18 to 55 years,
             inclusive (nonelderly at the time of informed consent and first study drug dose) for
             Cohorts 1 to 12, and 17 to 22; 20 to 55 years, inclusive, for Cohorts 13 to 15; and 55
             to 90 years, inclusive, for participants in Cohort 16.

          2. For Cohorts 13 to 15 only: First-generation Japanese, defined as having been born in
             Japan of Japanese parents and Japanese grandparents and living no more than 10 years
             outside of Japan, with no significant change in lifestyle, including diet, while
             living outside of Japan.

          3. Cohort 16 only: Healthy elderly or participants with MCI or mild AD, who must have
             Mini Mental State Examination (MMSE) score of 18 to 30, inclusive or 18 to 26
             inclusive, respectively, and no biomarker data to contradict this diagnosis.
             Participants with documented diagnosis of MCI or mild AD must be receiving ongoing
             donepezil therapy (10 mg) in the evening for a minimum of 21 days prior to Check-in
             (Day -1) or must consent to take donepezil dose titrated to at least 21 days of
             treatment with 10 mg QD prior to Check-in.

        Exclusion Criteria:

          1. Has clinically significant (Cohorts 1 to 15 and 17 to 22) or uncontrolled (Cohort 16)
             neurologic, cardiovascular, pulmonary, hepatic, renal, metabolic, gastrointestinal
             (GI), urologic, immunologic, endocrine, or psychiatric disease or other abnormality
             (other than the disease being studied), which may impact the ability of the
             participant to participate or potentially confound the study results.

          2. Has a history of type 1 diabetes (Cohorts 1 to 22) or type 2 diabetes (Cohorts 1 to
             15, 17 to 22) or hemoglobin A1c &gt;6.5% at Screening. Note: participants with controlled
             (hemoglobin A1c &lt;7.0% at Screening) type 2 diabetes in Cohort 16 may participate in
             the study.

          3. Has a risk of suicide or suicidal ideation with intent and plan according to the
             investigator's clinical judgment (affirmative answer to questions 4 and 5 of the
             ideation section of the Columbia-Suicide Severity Rating Scale) or has made a suicide
             attempt in the previous 6 months.

          4. Cohort 16 only: Any significant neurologic disease (other than suspected incipient or
             mild AD), such as Parkinson disease, stroke, transient ischemic attack, multi-infarct
             dementia, Huntington disease, head trauma with clinically significant cognitive
             sequelae, or chronic central nervous system infection, per investigator discretion.

          5. Has current or recent (within 6 months) GI disease that would be expected to influence
             the absorption of drugs (ie, a history of malabsorption, any surgical intervention
             known to impact absorption [eg, bariatric surgery or bowel resection], esophageal
             reflux, peptic ulcer disease, erosive esophagitis, or frequent [more than once per
             week] occurrence of heartburn).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director Clinical Science</last_name>
    <role>Study Director</role>
    <affiliation>Takeda</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Glendale</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>May 10, 2016</study_first_submitted>
  <study_first_submitted_qc>May 10, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 11, 2016</study_first_posted>
  <results_first_submitted>May 30, 2018</results_first_submitted>
  <results_first_submitted_qc>March 8, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">June 10, 2019</results_first_posted>
  <last_update_submitted>March 8, 2019</last_update_submitted>
  <last_update_submitted_qc>March 8, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">June 10, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Drug Therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
    <mesh_term>Cognitive Dysfunction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Donepezil</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>May 15, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/65/NCT02769065/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>August 8, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/65/NCT02769065/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants took part in the study at 1 investigative site in United States from 05 May 2016 to 08 June 2017.</recruitment_details>
      <pre_assignment_details>Healthy participants (non-Japanese and Japanese) and participants with mild cognitive impairment (MCI) or mild Alzheimer disease (AD) (non-Japanese) were enrolled in cohorts: TAK-071 single-rising-dose (SRD), multiple-rising dose (MRD), Food Effect Crossover or in combination with donepezil.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>SRD: Placebo Cohorts 1-6, 18 and 19</title>
          <description>TAK-071 placebo-matching capsules, orally, once on Day 1 to non-Japanese healthy participants in the single-rising dose (SRD) period.</description>
        </group>
        <group group_id="P2">
          <title>SRD: Cohort 1: TAK-071 1 mg</title>
          <description>TAK-071 1 mg, capsule, orally, once on Day 1 to non-Japanese healthy participants.</description>
        </group>
        <group group_id="P3">
          <title>SRD: Cohort 2: TAK-071 3 mg</title>
          <description>TAK-071 3 mg capsule, orally, once on Day 1 to non-Japanese healthy participants. Dose of TAK-071 was based on the 24-hour post-dose safety, tolerability and pharmacokinetic (PK) data from cohort 1.</description>
        </group>
        <group group_id="P4">
          <title>SRD: Cohort 3: TAK-071 9 mg</title>
          <description>TAK-071 9 mg capsule, orally, once on Day 1 to non-Japanese healthy participants. Dose of TAK-071 was based on 24-hour safety, tolerability, and preliminary plasma PK and 12-hour CSF PK data.</description>
        </group>
        <group group_id="P5">
          <title>SRD: Cohort 4: TAK-071 20 mg</title>
          <description>TAK-071 20 mg capsule, orally, once on Day 1 to non-Japanese healthy participants. Dose of TAK-071 was based on the 24-hour post-dose safety and tolerability data from previous cohort.</description>
        </group>
        <group group_id="P6">
          <title>SRD: Cohort 5: TAK-071 40 mg</title>
          <description>TAK-071 40 mg capsule, orally, once on Day 1 to non-Japanese healthy participants. Dose of TAK-071 will be based on 24-hour safety, tolerability, and preliminary plasma PK data from Cohort 4.</description>
        </group>
        <group group_id="P7">
          <title>SRD: Cohort 6: TAK-071 80 mg</title>
          <description>TAK-071 80 mg capsules, orally, once on Day 1 to non-Japanese healthy participants. Dose of TAK-071 was based on 24-hour safety, tolerability, and preliminary plasma PK data from Cohort 5</description>
        </group>
        <group group_id="P8">
          <title>MRD: Placebo Cohorts 7-9</title>
          <description>TAK-071 placebo-matching capsule, orally, once on Day 1 to non-Japanese healthy participants in the multiple-rising dose (MRD) period.</description>
        </group>
        <group group_id="P9">
          <title>MRD: Cohort 7: TAK-071 3 mg</title>
          <description>TAK-071 3 mg capsules, orally, once daily from Day 1 up to Day 21 to non-Japanese healthy participants. Dose of TAK-071 was based on 24-hour safety and tolerability from Cohort 4 and the 24-hour preliminary plasma PK and 12-hour CSF PK data from Cohort 3.</description>
        </group>
        <group group_id="P10">
          <title>MRD: Cohort 8: TAK-071 9 mg</title>
          <description>TAK-071 9 mg capsules, orally, once daily from Day 1 up to Day 21 to non-Japanese healthy participants. Dose of TAK-071 was based on safety, tolerability and available PK data arising from the ongoing SRD part and previous MRD cohort.</description>
        </group>
        <group group_id="P11">
          <title>MRD: Cohort 9: TAK-071 15 mg</title>
          <description>TAK-071 15 mg capsule, orally, once on Day 1, followed by a washout period of 7 days, then TAK-071 once daily for 21 days to non-Japanese healthy participants. Dose of TAK-071 will be based on safety, tolerability and available PK data arising from the ongoing SRD part and previous MRD cohort.</description>
        </group>
        <group group_id="P12">
          <title>MRD: TAK-071 Placebo Cohorts 10-12+Donepezil</title>
          <description>TAK-071 placebo-matching capsule, orally, once daily along with donepezil 5 mg, tablets, orally, once daily from Day 1 up to Day 21 to non-Japanese healthy participants who were pre-treated with donepezil 5 mg, tablet, once daily for 3 weeks prior to administration of TAK-071.</description>
        </group>
        <group group_id="P13">
          <title>MRD: Cohort 10: TAK-071 3 mg+Donepezil 5 mg</title>
          <description>TAK-071 3 mg capsules, orally, once daily along with donepezil 5 mg, tablets, orally, once daily from Day 1 up to Day 21 to non-Japanese healthy participants who were pre-treated with donepezil 5 mg, tablet, once daily for 3 weeks prior to administration of TAK-071. Dose of TAK-071 was same as the dose used in MRD Cohort 7.</description>
        </group>
        <group group_id="P14">
          <title>MRD: Cohort 11: TAK-071 9 mg + Donepezil 5 mg</title>
          <description>TAK-071 9 mg capsules, orally, once daily along with donepezil 5 mg, tablets, orally, once daily from Day 1 up to Day 21 to non-Japanese healthy participants who were pre-treated with donepezil 5 mg, tablet, once daily for 3 weeks prior to administration of TAK-071. Dose of TAK-071 was same as the dose used in MRD Cohort 8.</description>
        </group>
        <group group_id="P15">
          <title>MRD: Cohort 12: TAK-071 15 mg+Donepezil 5 mg</title>
          <description>TAK-071 15 mg capsule, orally, once daily along with donepezil 5 mg, tablets, orally, once daily from Day 1 up to Day 21 to non-Japanese healthy participants who were pre-treated with donepezil 5 mg, tablet, once daily for 3 weeks prior to administration of TAK-071. Dose of TAK-071 was same as the dose used in MRD Cohort 9.</description>
        </group>
        <group group_id="P16">
          <title>MRD: Placebo Cohorts 13-15</title>
          <description>TAK-071 placebo-matching capsule, orally, once on Day 1 to Japanese healthy participants.</description>
        </group>
        <group group_id="P17">
          <title>MRD: Cohort 13: TAK-071 3 mg</title>
          <description>TAK-071 3 mg capsule, orally, once on Day 1, followed by a washout period of 7 days, then TAK-071 once daily for 21 days to Japanese healthy participants. Dose of TAK-071 was same as the dose used in MRD Cohort 7.</description>
        </group>
        <group group_id="P18">
          <title>MRD: Cohort 14: TAK-071 9 mg</title>
          <description>TAK-071 9 mg capsule or matching placebo, orally, once on Day 1, followed by a washout period of 7 days, then TAK-071 once daily for 21 days to Japanese healthy participants. Dose of TAK-071 was same as the dose used in MRD Cohort 8.</description>
        </group>
        <group group_id="P19">
          <title>MRD: Cohort 15: TAK-071 15 mg</title>
          <description>TAK-071 15 mg capsule, orally, once on Day 1, followed by a washout period of 7 days, then TAK-071 once daily for 21 days to Japanese healthy participants. Dose of TAK-071 was same as the dose used in MRD Cohort 9.</description>
        </group>
        <group group_id="P20">
          <title>Cohort 16</title>
          <description>TAK-071 capsule, orally, once on Day 1 for 21 days, followed by a washout period of 21 days, or placebo matching tablets, orally, once on Day 1 for 21 days. Donepezil was delivered as 5 mg tablet, orally, once followed by 10 mg tablet, orally, once in run-in period.</description>
        </group>
        <group group_id="P21">
          <title>Bioavailability (BA)/Food Effect: Cohort 17 Sequence ABC</title>
          <description>A: TAK-071 10 mg capsule, orally once on Day 1 in the fasted state in Period 1, followed by B: TAK-071 10 mg tablet, orally, once on Day 1 in the fasted state in Period 2, followed by C: TAK-071 10 mg tablet, orally, once on Day 1 in the fed state in Period 3 in non-Japanese healthy participants. There was a 21-day washout after each period.</description>
        </group>
        <group group_id="P22">
          <title>BA/Food Effect: Cohort 17 Sequence BCA</title>
          <description>B: TAK-071 10 mg tablet, orally, once on Day 1 in the fasted state in Period 1, followed by C: TAK-071 10 mg tablet, orally, once on Day 1 in the Fed state in Period 2, followed by A: TAK-071 10 mg capsule, orally once on Day 1 in the fasted state Period 3 in non-Japanese healthy participants. There was a 21-day washout after each period.</description>
        </group>
        <group group_id="P23">
          <title>BA/Food Effect: Cohort 17 Sequence CAB</title>
          <description>C: TAK-071 10 mg tablet, orally, once on Day 1 in the fed state in Period 1, followed by A: TAK-071 10 mg capsule, orally once on Day 1 in the fasted state in Period 2, followed by B: TAK-20 10 mg tablet, orally, once on Day 1 in the fasted state in Period 3 in non-Japanese healthy participants. There was a 21-day washout after each period.</description>
        </group>
        <group group_id="P24">
          <title>SRD: Cohort 18: TAK-071 120 mg</title>
          <description>TAK-071 120 mg capsule, orally, once on Day 1 to non-Japanese healthy participants. Dose of TAK-071 was based on 24-hour safety, tolerability, and preliminary plasma PK data from Cohort 6.</description>
        </group>
        <group group_id="P25">
          <title>SRD: Cohort 19: TAK-071 160 mg</title>
          <description>TAK-071 160 mg capsule, orally, once on Day 1 to non-Japanese healthy participants. Dose of TAK-071 was based on 24-hour safety, tolerability, and preliminary plasma PK data from Cohort 18.</description>
        </group>
        <group group_id="P26">
          <title>SRD: TAK-071 Placebo+Donepezil Placebo</title>
          <description>TAK-071 placebo-matching capsule, orally, once on Day 1 followed by donepezil placebo-matching tablet, orally on Day 2 to non-Japanese healthy participants.</description>
        </group>
        <group group_id="P27">
          <title>SRD: TAK-071 Placebo+Donepezil</title>
          <description>TAK-071 placebo-matching capsule, orally, once on Day 1 followed by donepezil 10 mg tablet, orally, on Day 2 to non-Japanese healthy participants.</description>
        </group>
        <group group_id="P28">
          <title>SRD: Cohort 20: TAK-071 40 mg+Donepezil</title>
          <description>TAK-071 40 mg capsule, orally, once on Day 1 followed by donepezil 10 mg, tablets, orally, once on Day 2 to non-Japanese healthy participants. Dose of TAK-071 was based on 24-hour safety, tolerability, and preliminary plasma PK data from Cohort 19.</description>
        </group>
        <group group_id="P29">
          <title>SRD: Cohort 21: TAK-071 60 mg+Donepezil</title>
          <description>TAK-071 60 mg capsule, orally, once on Day 1 followed by donepezil 10 mg, tablets, orally, once on Day 2 to non-Japanese healthy participants. Dose of TAK-071 was based on 24-hour safety and tolerability data from Cohort 20.</description>
        </group>
        <group group_id="P30">
          <title>SRD: Cohort 22: TAK-071 80 mg+Donepezil</title>
          <description>TAK-071 80 mg capsule, orally, once on Day 1, followed by donepezil 10 mg, tablets, orally, once on Day 2 to non-Japanese healthy participants. Dose of TAK-071 was based on 24-hour safety and tolerability data from Cohort 21.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="6"/>
                <participants group_id="P6" count="6"/>
                <participants group_id="P7" count="7"/>
                <participants group_id="P8" count="6"/>
                <participants group_id="P9" count="6"/>
                <participants group_id="P10" count="6"/>
                <participants group_id="P11" count="6"/>
                <participants group_id="P12" count="6"/>
                <participants group_id="P13" count="6"/>
                <participants group_id="P14" count="6"/>
                <participants group_id="P15" count="6"/>
                <participants group_id="P16" count="3"/>
                <participants group_id="P17" count="5"/>
                <participants group_id="P18" count="5"/>
                <participants group_id="P19" count="5"/>
                <participants group_id="P20" count="0"/>
                <participants group_id="P21" count="4"/>
                <participants group_id="P22" count="4"/>
                <participants group_id="P23" count="4"/>
                <participants group_id="P24" count="6"/>
                <participants group_id="P25" count="6"/>
                <participants group_id="P26" count="9"/>
                <participants group_id="P27" count="9"/>
                <participants group_id="P28" count="5"/>
                <participants group_id="P29" count="6"/>
                <participants group_id="P30" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="6"/>
                <participants group_id="P6" count="6"/>
                <participants group_id="P7" count="6"/>
                <participants group_id="P8" count="6"/>
                <participants group_id="P9" count="6"/>
                <participants group_id="P10" count="6"/>
                <participants group_id="P11" count="5"/>
                <participants group_id="P12" count="6"/>
                <participants group_id="P13" count="6"/>
                <participants group_id="P14" count="6"/>
                <participants group_id="P15" count="6"/>
                <participants group_id="P16" count="3"/>
                <participants group_id="P17" count="5"/>
                <participants group_id="P18" count="5"/>
                <participants group_id="P19" count="5"/>
                <participants group_id="P20" count="0"/>
                <participants group_id="P21" count="4"/>
                <participants group_id="P22" count="4"/>
                <participants group_id="P23" count="4"/>
                <participants group_id="P24" count="6"/>
                <participants group_id="P25" count="6"/>
                <participants group_id="P26" count="9"/>
                <participants group_id="P27" count="9"/>
                <participants group_id="P28" count="5"/>
                <participants group_id="P29" count="6"/>
                <participants group_id="P30" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="1"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
                <participants group_id="P18" count="0"/>
                <participants group_id="P19" count="0"/>
                <participants group_id="P20" count="0"/>
                <participants group_id="P21" count="0"/>
                <participants group_id="P22" count="0"/>
                <participants group_id="P23" count="0"/>
                <participants group_id="P24" count="0"/>
                <participants group_id="P25" count="0"/>
                <participants group_id="P26" count="0"/>
                <participants group_id="P27" count="0"/>
                <participants group_id="P28" count="0"/>
                <participants group_id="P29" count="0"/>
                <participants group_id="P30" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Voluntary Withdrawal</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
                <participants group_id="P18" count="0"/>
                <participants group_id="P19" count="0"/>
                <participants group_id="P20" count="0"/>
                <participants group_id="P21" count="0"/>
                <participants group_id="P22" count="0"/>
                <participants group_id="P23" count="0"/>
                <participants group_id="P24" count="0"/>
                <participants group_id="P25" count="0"/>
                <participants group_id="P26" count="0"/>
                <participants group_id="P27" count="0"/>
                <participants group_id="P28" count="0"/>
                <participants group_id="P29" count="0"/>
                <participants group_id="P30" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Reason Not Specified</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
                <participants group_id="P18" count="0"/>
                <participants group_id="P19" count="0"/>
                <participants group_id="P20" count="0"/>
                <participants group_id="P21" count="0"/>
                <participants group_id="P22" count="0"/>
                <participants group_id="P23" count="0"/>
                <participants group_id="P24" count="0"/>
                <participants group_id="P25" count="0"/>
                <participants group_id="P26" count="0"/>
                <participants group_id="P27" count="0"/>
                <participants group_id="P28" count="0"/>
                <participants group_id="P29" count="0"/>
                <participants group_id="P30" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Pre-treatment Event/Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="1"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
                <participants group_id="P18" count="0"/>
                <participants group_id="P19" count="0"/>
                <participants group_id="P20" count="0"/>
                <participants group_id="P21" count="0"/>
                <participants group_id="P22" count="0"/>
                <participants group_id="P23" count="0"/>
                <participants group_id="P24" count="0"/>
                <participants group_id="P25" count="0"/>
                <participants group_id="P26" count="0"/>
                <participants group_id="P27" count="0"/>
                <participants group_id="P28" count="0"/>
                <participants group_id="P29" count="0"/>
                <participants group_id="P30" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Safety analysis set (SAS) included all participants who were enrolled and received at least 1 dose of the study drug.</population>
      <group_list>
        <group group_id="B1">
          <title>SRD: Placebo Cohorts 1-6, 18 and 19</title>
          <description>TAK-071 placebo-matching capsules, orally, once on Day 1 to non-Japanese healthy participants in the single-rising dose (SRD) period.</description>
        </group>
        <group group_id="B2">
          <title>SRD: Cohort 1: TAK-071 1 mg</title>
          <description>TAK-071 1 mg, capsule, orally, once on Day 1 to non-Japanese healthy participants.</description>
        </group>
        <group group_id="B3">
          <title>SRD: Cohort 2: TAK-071 3 mg</title>
          <description>TAK-071 3 mg capsule, orally, once on Day 1 to non-Japanese healthy participants. Dose of TAK-071 was based on the 24-hour post-dose safety, tolerability and pharmacokinetic (PK) data from cohort 1.</description>
        </group>
        <group group_id="B4">
          <title>SRD: Cohort 3: TAK-071 9 mg</title>
          <description>TAK-071 9 mg capsule, orally, once on Day 1 to non-Japanese healthy participants. Dose of TAK-071 was based on 24-hour safety, tolerability, and preliminary plasma PK and 12-hour CSF PK data.</description>
        </group>
        <group group_id="B5">
          <title>SRD: Cohort 4: TAK-071 20 mg</title>
          <description>TAK-071 20 mg capsule, orally, once on Day 1 to non-Japanese healthy participants. Dose of TAK-071 was based on the 24-hour post-dose safety and tolerability data from previous cohort.</description>
        </group>
        <group group_id="B6">
          <title>SRD: Cohort 5: TAK-071 40 mg</title>
          <description>TAK-071 40 mg capsule, orally, once on Day 1 to non-Japanese healthy participants. Dose of TAK-071 will be based on 24-hour safety, tolerability, and preliminary plasma PK data from Cohort 4.</description>
        </group>
        <group group_id="B7">
          <title>SRD: Cohort 6: TAK-071 80 mg</title>
          <description>TAK-071 80 mg capsules, orally, once on Day 1 to non-Japanese healthy participants. Dose of TAK-071 was based on 24-hour safety, tolerability, and preliminary plasma PK data from Cohort 5</description>
        </group>
        <group group_id="B8">
          <title>MRD: Placebo Cohorts 7-9</title>
          <description>TAK-071 placebo-matching capsule, orally, once on Day 1 to non-Japanese healthy participants in the multiple-rising dose (MRD) period.</description>
        </group>
        <group group_id="B9">
          <title>MRD: Cohort 7: TAK-071 3 mg</title>
          <description>TAK-071 3 mg capsules, orally, once daily from Day 1 up to Day 21 to non-Japanese healthy participants. Dose of TAK-071 was based on 24-hour safety and tolerability from Cohort 4 and the 24-hour preliminary plasma PK and 12-hour CSF PK data from Cohort 3.</description>
        </group>
        <group group_id="B10">
          <title>MRD: Cohort 8: TAK-071 9 mg</title>
          <description>TAK-071 9 mg capsules, orally, once daily from Day 1 up to Day 21 to non-Japanese healthy participants. Dose of TAK-071 was based on safety, tolerability and available PK data arising from the ongoing SRD part and previous MRD cohort.</description>
        </group>
        <group group_id="B11">
          <title>MRD: Cohort 9: TAK-071 15 mg</title>
          <description>TAK-071 15 mg capsule, orally, once on Day 1, followed by a washout period of 7 days, then TAK-071 once daily for 21 days to non-Japanese healthy participants. Dose of TAK-071 will be based on safety, tolerability and available PK data arising from the ongoing SRD part and previous MRD cohort.</description>
        </group>
        <group group_id="B12">
          <title>MRD: TAK-071 Placebo Cohorts 10-12+Donepezil</title>
          <description>TAK-071 placebo-matching capsule, orally, once daily along with donepezil 5 mg, tablets, orally, once daily from Day 1 up to Day 21 to non-Japanese healthy participants who were pre-treated with donepezil 5 mg, tablet, once daily for 3 weeks prior to administration of TAK-071.</description>
        </group>
        <group group_id="B13">
          <title>MRD: Cohort 10: TAK-071 3 mg+Donepezil 5 mg</title>
          <description>TAK-071 3 mg capsules, orally, once daily along with donepezil 5 mg, tablets, orally, once daily from Day 1 up to Day 21 to non-Japanese healthy participants who were pre-treated with donepezil 5 mg, tablet, once daily for 3 weeks prior to administration of TAK-071. Dose of TAK-071 was same as the dose used in MRD Cohort 7.</description>
        </group>
        <group group_id="B14">
          <title>MRD: Cohort 11: TAK-071 9 mg + Donepezil 5 mg</title>
          <description>TAK-071 9 mg capsules, orally, once daily along with donepezil 5 mg, tablets, orally, once daily from Day 1 up to Day 21 to non-Japanese healthy participants who were pre-treated with donepezil 5 mg, tablet, once daily for 3 weeks prior to administration of TAK-071. Dose of TAK-071 was same as the dose used in MRD Cohort 8.</description>
        </group>
        <group group_id="B15">
          <title>MRD: Cohort 12: TAK-071 15 mg+Donepezil 5 mg</title>
          <description>TAK-071 15 mg capsule, orally, once daily along with donepezil 5 mg, tablets, orally, once daily from Day 1 up to Day 21 to non-Japanese healthy participants who were pre-treated with donepezil 5 mg, tablet, once daily for 3 weeks prior to administration of TAK-071. Dose of TAK-071 was same as the dose used in MRD Cohort 9.</description>
        </group>
        <group group_id="B16">
          <title>MRD: Placebo Cohorts 13-15</title>
          <description>TAK-071 placebo-matching capsule, orally, once on Day 1 to Japanese healthy participants.</description>
        </group>
        <group group_id="B17">
          <title>MRD: Cohort 13: TAK-071 3 mg</title>
          <description>TAK-071 3 mg capsule, orally, once on Day 1, followed by a washout period of 7 days, then TAK-071 once daily for 21 days to Japanese healthy participants. Dose of TAK-071 was same as the dose used in MRD Cohort 7.</description>
        </group>
        <group group_id="B18">
          <title>MRD: Cohort 14: TAK-071 9 mg</title>
          <description>TAK-071 9 mg capsule or matching placebo, orally, once on Day 1, followed by a washout period of 7 days, then TAK-071 once daily for 21 days to Japanese healthy participants. Dose of TAK-071 was same as the dose used in MRD Cohort 8.</description>
        </group>
        <group group_id="B19">
          <title>MRD: Cohort 15: TAK-071 15 mg</title>
          <description>TAK-071 15 mg capsule, orally, once on Day 1, followed by a washout period of 7 days, then TAK-071 once daily for 21 days to Japanese healthy participants. Dose of TAK-071 was same as the dose used in MRD Cohort 9.</description>
        </group>
        <group group_id="B20">
          <title>Cohort 16</title>
          <description>TAK-071 capsule, orally, once on Day 1 for 21 days, followed by a washout period of 21 days, or placebo matching tablets, orally, once on Day 1 for 21 days. Donepezil was delivered as 5 mg tablet, orally, once followed by 10 mg tablet, orally, once in run-in period.</description>
        </group>
        <group group_id="B21">
          <title>Bioavailability (BA)/Food Effect: Cohort 17 Sequence ABC</title>
          <description>A: TAK-071 10 mg capsule, orally once on Day 1 in the fasted state in Period 1, followed by B: TAK-071 10 mg tablet, orally, once on Day 1 in the fasted state in Period 2, followed by C: TAK-071 10 mg tablet, orally, once on Day 1 in the fed state in Period 3 in non-Japanese healthy participants. There was a 21-day washout after each period.</description>
        </group>
        <group group_id="B22">
          <title>BA/Food Effect: Cohort 17 Sequence BCA</title>
          <description>B: TAK-071 10 mg tablet, orally, once on Day 1 in the fasted state in Period 1, followed by C: TAK-071 10 mg tablet, orally, once on Day 1 in the Fed state in Period 2, followed by A: TAK-071 10 mg capsule, orally once on Day 1 in the fasted state Period 3 in non-Japanese healthy participants. There was a 21-day washout after each period.</description>
        </group>
        <group group_id="B23">
          <title>BA/Food Effect: Cohort 17 Sequence CAB</title>
          <description>C: TAK-071 10 mg tablet, orally, once on Day 1 in the fed state in Period 1, followed by A: TAK-071 10 mg capsule, orally once on Day 1 in the fasted state in Period 2, followed by B: TAK-20 10 mg tablet, orally, once on Day 1 in the fasted state in Period 3 in non-Japanese healthy participants. There was a 21-day washout after each period.</description>
        </group>
        <group group_id="B24">
          <title>SRD: Cohort 18: TAK-071 120 mg</title>
          <description>TAK-071 120 mg capsule, orally, once on Day 1 to non-Japanese healthy participants. Dose of TAK-071 was based on 24-hour safety, tolerability, and preliminary plasma PK data from Cohort 6.</description>
        </group>
        <group group_id="B25">
          <title>SRD: Cohort 19: TAK-071 160 mg</title>
          <description>TAK-071 160 mg capsule, orally, once on Day 1 to non-Japanese healthy participants. Dose of TAK-071 was based on 24-hour safety, tolerability, and preliminary plasma PK data from Cohort 18.</description>
        </group>
        <group group_id="B26">
          <title>SRD: TAK-071 Placebo+Donepezil Placebo</title>
          <description>TAK-071 placebo-matching capsule, orally, once on Day 1 followed by donepezil placebo-matching tablet, orally on Day 2 to non-Japanese healthy participants.</description>
        </group>
        <group group_id="B27">
          <title>SRD: TAK-071 Placebo+Donepezil</title>
          <description>TAK-071 placebo-matching capsule, orally, once on Day 1 followed by donepezil 10 mg tablet, orally, on Day 2 to non-Japanese healthy participants.</description>
        </group>
        <group group_id="B28">
          <title>SRD: Cohort 20: TAK-071 40 mg+Donepezil</title>
          <description>TAK-071 40 mg capsule, orally, once on Day 1 followed by donepezil 10 mg, tablets, orally, once on Day 2 to non-Japanese healthy participants. Dose of TAK-071 was based on 24-hour safety, tolerability, and preliminary plasma PK data from Cohort 19.</description>
        </group>
        <group group_id="B29">
          <title>SRD: Cohort 21: TAK-071 60 mg+Donepezil</title>
          <description>TAK-071 60 mg capsule, orally, once on Day 1 followed by donepezil 10 mg, tablets, orally, once on Day 2 to non-Japanese healthy participants. Dose of TAK-071 was based on 24-hour safety and tolerability data from Cohort 20.</description>
        </group>
        <group group_id="B30">
          <title>SRD: Cohort 22: TAK-071 80 mg+Donepezil</title>
          <description>TAK-071 80 mg capsule, orally, once on Day 1, followed by donepezil 10 mg, tablets, orally, once on Day 2 to non-Japanese healthy participants. Dose of TAK-071 was based on 24-hour safety and tolerability data from Cohort 21.</description>
        </group>
        <group group_id="B31">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="16"/>
            <count group_id="B2" value="6"/>
            <count group_id="B3" value="6"/>
            <count group_id="B4" value="6"/>
            <count group_id="B5" value="6"/>
            <count group_id="B6" value="6"/>
            <count group_id="B7" value="6"/>
            <count group_id="B8" value="6"/>
            <count group_id="B9" value="6"/>
            <count group_id="B10" value="6"/>
            <count group_id="B11" value="6"/>
            <count group_id="B12" value="6"/>
            <count group_id="B13" value="6"/>
            <count group_id="B14" value="6"/>
            <count group_id="B15" value="6"/>
            <count group_id="B16" value="3"/>
            <count group_id="B17" value="5"/>
            <count group_id="B18" value="5"/>
            <count group_id="B19" value="5"/>
            <count group_id="B20" value="0"/>
            <count group_id="B21" value="4"/>
            <count group_id="B22" value="4"/>
            <count group_id="B23" value="4"/>
            <count group_id="B24" value="6"/>
            <count group_id="B25" value="6"/>
            <count group_id="B26" value="9"/>
            <count group_id="B27" value="9"/>
            <count group_id="B28" value="5"/>
            <count group_id="B29" value="6"/>
            <count group_id="B30" value="6"/>
            <count group_id="B31" value="177"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33.2" spread="6.46"/>
                    <measurement group_id="B2" value="34.7" spread="4.32"/>
                    <measurement group_id="B3" value="32.8" spread="9.43"/>
                    <measurement group_id="B4" value="39.5" spread="11.33"/>
                    <measurement group_id="B5" value="41.7" spread="9.33"/>
                    <measurement group_id="B6" value="36.3" spread="8.16"/>
                    <measurement group_id="B7" value="29.7" spread="8.12"/>
                    <measurement group_id="B8" value="37.7" spread="6.56"/>
                    <measurement group_id="B9" value="33.2" spread="7.78"/>
                    <measurement group_id="B10" value="31.2" spread="8.59"/>
                    <measurement group_id="B11" value="39.2" spread="6.71"/>
                    <measurement group_id="B12" value="38.7" spread="6.31"/>
                    <measurement group_id="B13" value="36.5" spread="6.53"/>
                    <measurement group_id="B14" value="35.3" spread="7.17"/>
                    <measurement group_id="B15" value="36.7" spread="9.54"/>
                    <measurement group_id="B16" value="37.7" spread="3.79"/>
                    <measurement group_id="B17" value="38.2" spread="10.99"/>
                    <measurement group_id="B18" value="34.8" spread="6.42"/>
                    <measurement group_id="B19" value="36.2" spread="8.67"/>
                    <measurement group_id="B21" value="32.3" spread="7.37"/>
                    <measurement group_id="B22" value="38.3" spread="8.88"/>
                    <measurement group_id="B23" value="30.0" spread="2.45"/>
                    <measurement group_id="B24" value="31.8" spread="10.26"/>
                    <measurement group_id="B25" value="31.7" spread="6.95"/>
                    <measurement group_id="B26" value="38.0" spread="9.18"/>
                    <measurement group_id="B27" value="36.8" spread="9.82"/>
                    <measurement group_id="B28" value="38.6" spread="13.20"/>
                    <measurement group_id="B29" value="32.2" spread="6.77"/>
                    <measurement group_id="B30" value="35.8" spread="9.47"/>
                    <measurement group_id="B31" value="36.4" spread="9.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="2"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="0"/>
                    <measurement group_id="B13" value="0"/>
                    <measurement group_id="B14" value="0"/>
                    <measurement group_id="B15" value="0"/>
                    <measurement group_id="B16" value="0"/>
                    <measurement group_id="B17" value="0"/>
                    <measurement group_id="B18" value="0"/>
                    <measurement group_id="B19" value="0"/>
                    <measurement group_id="B21" value="0"/>
                    <measurement group_id="B22" value="0"/>
                    <measurement group_id="B23" value="0"/>
                    <measurement group_id="B24" value="0"/>
                    <measurement group_id="B25" value="0"/>
                    <measurement group_id="B26" value="2"/>
                    <measurement group_id="B27" value="1"/>
                    <measurement group_id="B28" value="1"/>
                    <measurement group_id="B29" value="0"/>
                    <measurement group_id="B30" value="2"/>
                    <measurement group_id="B31" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="4"/>
                    <measurement group_id="B6" value="6"/>
                    <measurement group_id="B7" value="6"/>
                    <measurement group_id="B8" value="6"/>
                    <measurement group_id="B9" value="6"/>
                    <measurement group_id="B10" value="6"/>
                    <measurement group_id="B11" value="6"/>
                    <measurement group_id="B12" value="6"/>
                    <measurement group_id="B13" value="6"/>
                    <measurement group_id="B14" value="6"/>
                    <measurement group_id="B15" value="6"/>
                    <measurement group_id="B16" value="3"/>
                    <measurement group_id="B17" value="5"/>
                    <measurement group_id="B18" value="5"/>
                    <measurement group_id="B19" value="5"/>
                    <measurement group_id="B21" value="4"/>
                    <measurement group_id="B22" value="4"/>
                    <measurement group_id="B23" value="4"/>
                    <measurement group_id="B24" value="6"/>
                    <measurement group_id="B25" value="6"/>
                    <measurement group_id="B26" value="7"/>
                    <measurement group_id="B27" value="8"/>
                    <measurement group_id="B28" value="4"/>
                    <measurement group_id="B29" value="6"/>
                    <measurement group_id="B30" value="4"/>
                    <measurement group_id="B31" value="166"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="2"/>
                    <measurement group_id="B6" value="2"/>
                    <measurement group_id="B7" value="3"/>
                    <measurement group_id="B8" value="1"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="2"/>
                    <measurement group_id="B11" value="3"/>
                    <measurement group_id="B12" value="1"/>
                    <measurement group_id="B13" value="2"/>
                    <measurement group_id="B14" value="0"/>
                    <measurement group_id="B15" value="2"/>
                    <measurement group_id="B16" value="0"/>
                    <measurement group_id="B17" value="0"/>
                    <measurement group_id="B18" value="0"/>
                    <measurement group_id="B19" value="0"/>
                    <measurement group_id="B21" value="0"/>
                    <measurement group_id="B22" value="1"/>
                    <measurement group_id="B23" value="1"/>
                    <measurement group_id="B24" value="2"/>
                    <measurement group_id="B25" value="1"/>
                    <measurement group_id="B26" value="5"/>
                    <measurement group_id="B27" value="2"/>
                    <measurement group_id="B28" value="1"/>
                    <measurement group_id="B29" value="1"/>
                    <measurement group_id="B30" value="3"/>
                    <measurement group_id="B31" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="4"/>
                    <measurement group_id="B6" value="4"/>
                    <measurement group_id="B7" value="3"/>
                    <measurement group_id="B8" value="5"/>
                    <measurement group_id="B9" value="6"/>
                    <measurement group_id="B10" value="4"/>
                    <measurement group_id="B11" value="3"/>
                    <measurement group_id="B12" value="5"/>
                    <measurement group_id="B13" value="4"/>
                    <measurement group_id="B14" value="6"/>
                    <measurement group_id="B15" value="4"/>
                    <measurement group_id="B16" value="3"/>
                    <measurement group_id="B17" value="5"/>
                    <measurement group_id="B18" value="5"/>
                    <measurement group_id="B19" value="5"/>
                    <measurement group_id="B21" value="4"/>
                    <measurement group_id="B22" value="3"/>
                    <measurement group_id="B23" value="3"/>
                    <measurement group_id="B24" value="4"/>
                    <measurement group_id="B25" value="5"/>
                    <measurement group_id="B26" value="4"/>
                    <measurement group_id="B27" value="7"/>
                    <measurement group_id="B28" value="4"/>
                    <measurement group_id="B29" value="5"/>
                    <measurement group_id="B30" value="3"/>
                    <measurement group_id="B31" value="136"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="0"/>
                    <measurement group_id="B13" value="0"/>
                    <measurement group_id="B14" value="0"/>
                    <measurement group_id="B15" value="0"/>
                    <measurement group_id="B16" value="0"/>
                    <measurement group_id="B17" value="0"/>
                    <measurement group_id="B18" value="0"/>
                    <measurement group_id="B19" value="0"/>
                    <measurement group_id="B21" value="0"/>
                    <measurement group_id="B22" value="0"/>
                    <measurement group_id="B23" value="0"/>
                    <measurement group_id="B24" value="0"/>
                    <measurement group_id="B25" value="0"/>
                    <measurement group_id="B26" value="0"/>
                    <measurement group_id="B27" value="0"/>
                    <measurement group_id="B28" value="0"/>
                    <measurement group_id="B29" value="0"/>
                    <measurement group_id="B30" value="0"/>
                    <measurement group_id="B31" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="0"/>
                    <measurement group_id="B13" value="0"/>
                    <measurement group_id="B14" value="1"/>
                    <measurement group_id="B15" value="1"/>
                    <measurement group_id="B16" value="3"/>
                    <measurement group_id="B17" value="5"/>
                    <measurement group_id="B18" value="5"/>
                    <measurement group_id="B19" value="5"/>
                    <measurement group_id="B21" value="0"/>
                    <measurement group_id="B22" value="0"/>
                    <measurement group_id="B23" value="0"/>
                    <measurement group_id="B24" value="0"/>
                    <measurement group_id="B25" value="1"/>
                    <measurement group_id="B26" value="0"/>
                    <measurement group_id="B27" value="1"/>
                    <measurement group_id="B28" value="0"/>
                    <measurement group_id="B29" value="1"/>
                    <measurement group_id="B30" value="0"/>
                    <measurement group_id="B31" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="2"/>
                    <measurement group_id="B8" value="2"/>
                    <measurement group_id="B9" value="3"/>
                    <measurement group_id="B10" value="2"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="4"/>
                    <measurement group_id="B13" value="2"/>
                    <measurement group_id="B14" value="2"/>
                    <measurement group_id="B15" value="1"/>
                    <measurement group_id="B16" value="0"/>
                    <measurement group_id="B17" value="0"/>
                    <measurement group_id="B18" value="0"/>
                    <measurement group_id="B19" value="0"/>
                    <measurement group_id="B21" value="2"/>
                    <measurement group_id="B22" value="0"/>
                    <measurement group_id="B23" value="1"/>
                    <measurement group_id="B24" value="1"/>
                    <measurement group_id="B25" value="1"/>
                    <measurement group_id="B26" value="3"/>
                    <measurement group_id="B27" value="2"/>
                    <measurement group_id="B28" value="0"/>
                    <measurement group_id="B29" value="2"/>
                    <measurement group_id="B30" value="1"/>
                    <measurement group_id="B31" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="1"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="0"/>
                    <measurement group_id="B13" value="0"/>
                    <measurement group_id="B14" value="0"/>
                    <measurement group_id="B15" value="0"/>
                    <measurement group_id="B16" value="0"/>
                    <measurement group_id="B17" value="0"/>
                    <measurement group_id="B18" value="0"/>
                    <measurement group_id="B19" value="0"/>
                    <measurement group_id="B21" value="0"/>
                    <measurement group_id="B22" value="0"/>
                    <measurement group_id="B23" value="0"/>
                    <measurement group_id="B24" value="0"/>
                    <measurement group_id="B25" value="0"/>
                    <measurement group_id="B26" value="0"/>
                    <measurement group_id="B27" value="0"/>
                    <measurement group_id="B28" value="1"/>
                    <measurement group_id="B29" value="0"/>
                    <measurement group_id="B30" value="0"/>
                    <measurement group_id="B31" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="4"/>
                    <measurement group_id="B6" value="5"/>
                    <measurement group_id="B7" value="3"/>
                    <measurement group_id="B8" value="4"/>
                    <measurement group_id="B9" value="2"/>
                    <measurement group_id="B10" value="4"/>
                    <measurement group_id="B11" value="5"/>
                    <measurement group_id="B12" value="1"/>
                    <measurement group_id="B13" value="4"/>
                    <measurement group_id="B14" value="3"/>
                    <measurement group_id="B15" value="4"/>
                    <measurement group_id="B16" value="0"/>
                    <measurement group_id="B17" value="0"/>
                    <measurement group_id="B18" value="0"/>
                    <measurement group_id="B19" value="0"/>
                    <measurement group_id="B21" value="1"/>
                    <measurement group_id="B22" value="4"/>
                    <measurement group_id="B23" value="3"/>
                    <measurement group_id="B24" value="5"/>
                    <measurement group_id="B25" value="3"/>
                    <measurement group_id="B26" value="6"/>
                    <measurement group_id="B27" value="6"/>
                    <measurement group_id="B28" value="3"/>
                    <measurement group_id="B29" value="3"/>
                    <measurement group_id="B30" value="5"/>
                    <measurement group_id="B31" value="94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Multiracial</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="1"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="1"/>
                    <measurement group_id="B12" value="1"/>
                    <measurement group_id="B13" value="0"/>
                    <measurement group_id="B14" value="0"/>
                    <measurement group_id="B15" value="0"/>
                    <measurement group_id="B16" value="0"/>
                    <measurement group_id="B17" value="0"/>
                    <measurement group_id="B18" value="0"/>
                    <measurement group_id="B19" value="0"/>
                    <measurement group_id="B21" value="1"/>
                    <measurement group_id="B22" value="0"/>
                    <measurement group_id="B23" value="0"/>
                    <measurement group_id="B24" value="0"/>
                    <measurement group_id="B25" value="1"/>
                    <measurement group_id="B26" value="0"/>
                    <measurement group_id="B27" value="0"/>
                    <measurement group_id="B28" value="1"/>
                    <measurement group_id="B29" value="0"/>
                    <measurement group_id="B30" value="0"/>
                    <measurement group_id="B31" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="6"/>
                    <measurement group_id="B6" value="6"/>
                    <measurement group_id="B7" value="6"/>
                    <measurement group_id="B8" value="6"/>
                    <measurement group_id="B9" value="6"/>
                    <measurement group_id="B10" value="6"/>
                    <measurement group_id="B11" value="6"/>
                    <measurement group_id="B12" value="6"/>
                    <measurement group_id="B13" value="6"/>
                    <measurement group_id="B14" value="6"/>
                    <measurement group_id="B15" value="6"/>
                    <measurement group_id="B16" value="3"/>
                    <measurement group_id="B17" value="5"/>
                    <measurement group_id="B18" value="5"/>
                    <measurement group_id="B19" value="5"/>
                    <measurement group_id="B20" value="0"/>
                    <measurement group_id="B21" value="4"/>
                    <measurement group_id="B22" value="4"/>
                    <measurement group_id="B23" value="4"/>
                    <measurement group_id="B24" value="6"/>
                    <measurement group_id="B25" value="6"/>
                    <measurement group_id="B26" value="9"/>
                    <measurement group_id="B27" value="9"/>
                    <measurement group_id="B28" value="5"/>
                    <measurement group_id="B29" value="6"/>
                    <measurement group_id="B30" value="6"/>
                    <measurement group_id="B31" value="177"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Height</title>
          <units>cm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="175.8" spread="6.31"/>
                    <measurement group_id="B2" value="169.0" spread="5.97"/>
                    <measurement group_id="B3" value="175.0" spread="6.99"/>
                    <measurement group_id="B4" value="179.3" spread="8.14"/>
                    <measurement group_id="B5" value="172.3" spread="6.89"/>
                    <measurement group_id="B6" value="175.8" spread="7.31"/>
                    <measurement group_id="B7" value="179.8" spread="7.70"/>
                    <measurement group_id="B8" value="173.0" spread="9.63"/>
                    <measurement group_id="B9" value="178.8" spread="6.46"/>
                    <measurement group_id="B10" value="172.8" spread="5.12"/>
                    <measurement group_id="B11" value="174.7" spread="6.89"/>
                    <measurement group_id="B12" value="175.3" spread="6.53"/>
                    <measurement group_id="B13" value="177.0" spread="8.20"/>
                    <measurement group_id="B14" value="176.2" spread="4.54"/>
                    <measurement group_id="B15" value="168.0" spread="8.72"/>
                    <measurement group_id="B16" value="172.3" spread="2.08"/>
                    <measurement group_id="B17" value="171.2" spread="8.96"/>
                    <measurement group_id="B18" value="172.8" spread="6.10"/>
                    <measurement group_id="B19" value="178.2" spread="7.33"/>
                    <measurement group_id="B21" value="178.8" spread="5.06"/>
                    <measurement group_id="B22" value="175.8" spread="8.42"/>
                    <measurement group_id="B23" value="175.3" spread="5.80"/>
                    <measurement group_id="B24" value="173.0" spread="4.77"/>
                    <measurement group_id="B25" value="174.8" spread="5.56"/>
                    <measurement group_id="B26" value="175.2" spread="13.07"/>
                    <measurement group_id="B27" value="173.9" spread="7.61"/>
                    <measurement group_id="B28" value="178.4" spread="11.28"/>
                    <measurement group_id="B29" value="174.7" spread="5.47"/>
                    <measurement group_id="B30" value="170.8" spread="10.03"/>
                    <measurement group_id="B31" value="174.5" spread="9.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight</title>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="80.77" spread="7.563"/>
                    <measurement group_id="B2" value="71.80" spread="11.927"/>
                    <measurement group_id="B3" value="73.25" spread="12.314"/>
                    <measurement group_id="B4" value="85.35" spread="9.712"/>
                    <measurement group_id="B5" value="80.35" spread="7.076"/>
                    <measurement group_id="B6" value="82.58" spread="9.870"/>
                    <measurement group_id="B7" value="80.00" spread="10.942"/>
                    <measurement group_id="B8" value="78.05" spread="10.936"/>
                    <measurement group_id="B9" value="84.22" spread="11.284"/>
                    <measurement group_id="B10" value="76.73" spread="10.094"/>
                    <measurement group_id="B11" value="75.33" spread="14.062"/>
                    <measurement group_id="B12" value="81.93" spread="10.508"/>
                    <measurement group_id="B13" value="76.55" spread="8.147"/>
                    <measurement group_id="B14" value="76.23" spread="9.066"/>
                    <measurement group_id="B15" value="76.72" spread="9.972"/>
                    <measurement group_id="B16" value="69.63" spread="13.668"/>
                    <measurement group_id="B17" value="69.52" spread="7.253"/>
                    <measurement group_id="B18" value="67.72" spread="14.487"/>
                    <measurement group_id="B19" value="74.72" spread="12.583"/>
                    <measurement group_id="B21" value="79.73" spread="5.421"/>
                    <measurement group_id="B22" value="83.85" spread="11.356"/>
                    <measurement group_id="B23" value="75.53" spread="10.529"/>
                    <measurement group_id="B24" value="78.63" spread="12.980"/>
                    <measurement group_id="B25" value="78.42" spread="11.553"/>
                    <measurement group_id="B26" value="77.58" spread="12.727"/>
                    <measurement group_id="B27" value="77.66" spread="8.549"/>
                    <measurement group_id="B28" value="87.28" spread="11.637"/>
                    <measurement group_id="B29" value="72.25" spread="6.339"/>
                    <measurement group_id="B30" value="70.78" spread="10.039"/>
                    <measurement group_id="B31" value="77.09" spread="10.857"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index (BMI)</title>
          <description>Body Mass Index = weight (kg)/[height (m)^2]</description>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26.18" spread="2.349"/>
                    <measurement group_id="B2" value="24.99" spread="2.827"/>
                    <measurement group_id="B3" value="23.82" spread="3.090"/>
                    <measurement group_id="B4" value="26.50" spread="2.018"/>
                    <measurement group_id="B5" value="27.13" spread="2.766"/>
                    <measurement group_id="B6" value="26.65" spread="1.895"/>
                    <measurement group_id="B7" value="24.65" spread="1.895"/>
                    <measurement group_id="B8" value="26.04" spread="2.596"/>
                    <measurement group_id="B9" value="26.30" spread="2.966"/>
                    <measurement group_id="B10" value="25.71" spread="3.327"/>
                    <measurement group_id="B11" value="24.58" spread="3.503"/>
                    <measurement group_id="B12" value="26.59" spread="2.428"/>
                    <measurement group_id="B13" value="24.46" spread="2.344"/>
                    <measurement group_id="B14" value="24.52" spread="2.267"/>
                    <measurement group_id="B15" value="27.10" spread="2.066"/>
                    <measurement group_id="B16" value="23.38" spread="4.074"/>
                    <measurement group_id="B17" value="23.69" spread="1.113"/>
                    <measurement group_id="B18" value="22.56" spread="3.615"/>
                    <measurement group_id="B19" value="23.45" spread="3.032"/>
                    <measurement group_id="B21" value="24.95" spread="1.237"/>
                    <measurement group_id="B22" value="27.06" spread="2.221"/>
                    <measurement group_id="B23" value="24.66" spread="3.873"/>
                    <measurement group_id="B24" value="26.19" spread="3.611"/>
                    <measurement group_id="B25" value="25.60" spread="3.265"/>
                    <measurement group_id="B26" value="25.21" spread="2.721"/>
                    <measurement group_id="B27" value="25.66" spread="2.078"/>
                    <measurement group_id="B28" value="27.36" spread="1.767"/>
                    <measurement group_id="B29" value="23.73" spread="2.388"/>
                    <measurement group_id="B30" value="24.65" spread="1.432"/>
                    <measurement group_id="B31" value="25.30" spread="2.351"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Smoking Classification</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Never Smoked</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="6"/>
                    <measurement group_id="B6" value="5"/>
                    <measurement group_id="B7" value="6"/>
                    <measurement group_id="B8" value="5"/>
                    <measurement group_id="B9" value="5"/>
                    <measurement group_id="B10" value="5"/>
                    <measurement group_id="B11" value="4"/>
                    <measurement group_id="B12" value="5"/>
                    <measurement group_id="B13" value="3"/>
                    <measurement group_id="B14" value="5"/>
                    <measurement group_id="B15" value="6"/>
                    <measurement group_id="B16" value="2"/>
                    <measurement group_id="B17" value="5"/>
                    <measurement group_id="B18" value="3"/>
                    <measurement group_id="B19" value="5"/>
                    <measurement group_id="B21" value="4"/>
                    <measurement group_id="B22" value="4"/>
                    <measurement group_id="B23" value="4"/>
                    <measurement group_id="B24" value="6"/>
                    <measurement group_id="B25" value="4"/>
                    <measurement group_id="B26" value="8"/>
                    <measurement group_id="B27" value="8"/>
                    <measurement group_id="B28" value="3"/>
                    <measurement group_id="B29" value="6"/>
                    <measurement group_id="B30" value="6"/>
                    <measurement group_id="B31" value="154"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Current Smoker</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="0"/>
                    <measurement group_id="B13" value="0"/>
                    <measurement group_id="B14" value="0"/>
                    <measurement group_id="B15" value="0"/>
                    <measurement group_id="B16" value="0"/>
                    <measurement group_id="B17" value="0"/>
                    <measurement group_id="B18" value="0"/>
                    <measurement group_id="B19" value="0"/>
                    <measurement group_id="B21" value="0"/>
                    <measurement group_id="B22" value="0"/>
                    <measurement group_id="B23" value="0"/>
                    <measurement group_id="B24" value="0"/>
                    <measurement group_id="B25" value="0"/>
                    <measurement group_id="B26" value="0"/>
                    <measurement group_id="B27" value="0"/>
                    <measurement group_id="B28" value="0"/>
                    <measurement group_id="B29" value="0"/>
                    <measurement group_id="B30" value="0"/>
                    <measurement group_id="B31" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ex-smoker</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="1"/>
                    <measurement group_id="B9" value="1"/>
                    <measurement group_id="B10" value="1"/>
                    <measurement group_id="B11" value="2"/>
                    <measurement group_id="B12" value="1"/>
                    <measurement group_id="B13" value="3"/>
                    <measurement group_id="B14" value="1"/>
                    <measurement group_id="B15" value="0"/>
                    <measurement group_id="B16" value="1"/>
                    <measurement group_id="B17" value="0"/>
                    <measurement group_id="B18" value="2"/>
                    <measurement group_id="B19" value="0"/>
                    <measurement group_id="B21" value="0"/>
                    <measurement group_id="B22" value="0"/>
                    <measurement group_id="B23" value="0"/>
                    <measurement group_id="B24" value="0"/>
                    <measurement group_id="B25" value="2"/>
                    <measurement group_id="B26" value="1"/>
                    <measurement group_id="B27" value="1"/>
                    <measurement group_id="B28" value="2"/>
                    <measurement group_id="B29" value="0"/>
                    <measurement group_id="B30" value="0"/>
                    <measurement group_id="B31" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Alcohol Classification</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Never Drunk</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="6"/>
                    <measurement group_id="B6" value="4"/>
                    <measurement group_id="B7" value="6"/>
                    <measurement group_id="B8" value="6"/>
                    <measurement group_id="B9" value="5"/>
                    <measurement group_id="B10" value="6"/>
                    <measurement group_id="B11" value="4"/>
                    <measurement group_id="B12" value="5"/>
                    <measurement group_id="B13" value="6"/>
                    <measurement group_id="B14" value="3"/>
                    <measurement group_id="B15" value="5"/>
                    <measurement group_id="B16" value="2"/>
                    <measurement group_id="B17" value="4"/>
                    <measurement group_id="B18" value="5"/>
                    <measurement group_id="B19" value="4"/>
                    <measurement group_id="B21" value="4"/>
                    <measurement group_id="B22" value="4"/>
                    <measurement group_id="B23" value="3"/>
                    <measurement group_id="B24" value="6"/>
                    <measurement group_id="B25" value="4"/>
                    <measurement group_id="B26" value="8"/>
                    <measurement group_id="B27" value="8"/>
                    <measurement group_id="B28" value="5"/>
                    <measurement group_id="B29" value="6"/>
                    <measurement group_id="B30" value="6"/>
                    <measurement group_id="B31" value="154"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Current Drinker</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="2"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="1"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="2"/>
                    <measurement group_id="B12" value="1"/>
                    <measurement group_id="B13" value="0"/>
                    <measurement group_id="B14" value="3"/>
                    <measurement group_id="B15" value="1"/>
                    <measurement group_id="B16" value="1"/>
                    <measurement group_id="B17" value="1"/>
                    <measurement group_id="B18" value="0"/>
                    <measurement group_id="B19" value="1"/>
                    <measurement group_id="B21" value="0"/>
                    <measurement group_id="B22" value="0"/>
                    <measurement group_id="B23" value="1"/>
                    <measurement group_id="B24" value="0"/>
                    <measurement group_id="B25" value="2"/>
                    <measurement group_id="B26" value="1"/>
                    <measurement group_id="B27" value="1"/>
                    <measurement group_id="B28" value="0"/>
                    <measurement group_id="B29" value="0"/>
                    <measurement group_id="B30" value="0"/>
                    <measurement group_id="B31" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ex-drinker</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="0"/>
                    <measurement group_id="B13" value="0"/>
                    <measurement group_id="B14" value="0"/>
                    <measurement group_id="B15" value="0"/>
                    <measurement group_id="B16" value="0"/>
                    <measurement group_id="B17" value="0"/>
                    <measurement group_id="B18" value="0"/>
                    <measurement group_id="B19" value="0"/>
                    <measurement group_id="B21" value="0"/>
                    <measurement group_id="B22" value="0"/>
                    <measurement group_id="B23" value="0"/>
                    <measurement group_id="B24" value="0"/>
                    <measurement group_id="B25" value="0"/>
                    <measurement group_id="B26" value="0"/>
                    <measurement group_id="B27" value="0"/>
                    <measurement group_id="B28" value="0"/>
                    <measurement group_id="B29" value="0"/>
                    <measurement group_id="B30" value="0"/>
                    <measurement group_id="B31" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Xanthine/Caffeine Consumption</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="3"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="3"/>
                    <measurement group_id="B12" value="1"/>
                    <measurement group_id="B13" value="1"/>
                    <measurement group_id="B14" value="0"/>
                    <measurement group_id="B15" value="0"/>
                    <measurement group_id="B16" value="3"/>
                    <measurement group_id="B17" value="0"/>
                    <measurement group_id="B18" value="1"/>
                    <measurement group_id="B19" value="2"/>
                    <measurement group_id="B21" value="1"/>
                    <measurement group_id="B22" value="3"/>
                    <measurement group_id="B23" value="1"/>
                    <measurement group_id="B24" value="2"/>
                    <measurement group_id="B25" value="3"/>
                    <measurement group_id="B26" value="6"/>
                    <measurement group_id="B27" value="2"/>
                    <measurement group_id="B28" value="1"/>
                    <measurement group_id="B29" value="1"/>
                    <measurement group_id="B30" value="0"/>
                    <measurement group_id="B31" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="3"/>
                    <measurement group_id="B6" value="5"/>
                    <measurement group_id="B7" value="6"/>
                    <measurement group_id="B8" value="6"/>
                    <measurement group_id="B9" value="6"/>
                    <measurement group_id="B10" value="6"/>
                    <measurement group_id="B11" value="3"/>
                    <measurement group_id="B12" value="5"/>
                    <measurement group_id="B13" value="5"/>
                    <measurement group_id="B14" value="6"/>
                    <measurement group_id="B15" value="6"/>
                    <measurement group_id="B16" value="0"/>
                    <measurement group_id="B17" value="5"/>
                    <measurement group_id="B18" value="4"/>
                    <measurement group_id="B19" value="3"/>
                    <measurement group_id="B21" value="3"/>
                    <measurement group_id="B22" value="1"/>
                    <measurement group_id="B23" value="3"/>
                    <measurement group_id="B24" value="4"/>
                    <measurement group_id="B25" value="3"/>
                    <measurement group_id="B26" value="3"/>
                    <measurement group_id="B27" value="7"/>
                    <measurement group_id="B28" value="4"/>
                    <measurement group_id="B29" value="5"/>
                    <measurement group_id="B30" value="6"/>
                    <measurement group_id="B31" value="137"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Female Reproductive Status</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Postmenopausal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="0"/>
                    <measurement group_id="B13" value="0"/>
                    <measurement group_id="B14" value="0"/>
                    <measurement group_id="B15" value="0"/>
                    <measurement group_id="B16" value="0"/>
                    <measurement group_id="B17" value="0"/>
                    <measurement group_id="B18" value="0"/>
                    <measurement group_id="B19" value="0"/>
                    <measurement group_id="B21" value="0"/>
                    <measurement group_id="B22" value="0"/>
                    <measurement group_id="B23" value="0"/>
                    <measurement group_id="B24" value="0"/>
                    <measurement group_id="B25" value="0"/>
                    <measurement group_id="B26" value="2"/>
                    <measurement group_id="B27" value="1"/>
                    <measurement group_id="B28" value="1"/>
                    <measurement group_id="B29" value="0"/>
                    <measurement group_id="B30" value="1"/>
                    <measurement group_id="B31" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Surgically Sterile</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="0"/>
                    <measurement group_id="B13" value="0"/>
                    <measurement group_id="B14" value="0"/>
                    <measurement group_id="B15" value="0"/>
                    <measurement group_id="B16" value="0"/>
                    <measurement group_id="B17" value="0"/>
                    <measurement group_id="B18" value="0"/>
                    <measurement group_id="B19" value="0"/>
                    <measurement group_id="B21" value="0"/>
                    <measurement group_id="B22" value="0"/>
                    <measurement group_id="B23" value="0"/>
                    <measurement group_id="B24" value="0"/>
                    <measurement group_id="B25" value="0"/>
                    <measurement group_id="B26" value="0"/>
                    <measurement group_id="B27" value="0"/>
                    <measurement group_id="B28" value="0"/>
                    <measurement group_id="B29" value="0"/>
                    <measurement group_id="B30" value="1"/>
                    <measurement group_id="B31" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Female of Childbearing Potential</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="0"/>
                    <measurement group_id="B13" value="0"/>
                    <measurement group_id="B14" value="0"/>
                    <measurement group_id="B15" value="0"/>
                    <measurement group_id="B16" value="0"/>
                    <measurement group_id="B17" value="0"/>
                    <measurement group_id="B18" value="0"/>
                    <measurement group_id="B19" value="0"/>
                    <measurement group_id="B21" value="0"/>
                    <measurement group_id="B22" value="0"/>
                    <measurement group_id="B23" value="0"/>
                    <measurement group_id="B24" value="0"/>
                    <measurement group_id="B25" value="0"/>
                    <measurement group_id="B26" value="0"/>
                    <measurement group_id="B27" value="0"/>
                    <measurement group_id="B28" value="0"/>
                    <measurement group_id="B29" value="0"/>
                    <measurement group_id="B30" value="0"/>
                    <measurement group_id="B31" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>N/A (Subject is Male)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="4"/>
                    <measurement group_id="B6" value="6"/>
                    <measurement group_id="B7" value="6"/>
                    <measurement group_id="B8" value="6"/>
                    <measurement group_id="B9" value="6"/>
                    <measurement group_id="B10" value="6"/>
                    <measurement group_id="B11" value="6"/>
                    <measurement group_id="B12" value="6"/>
                    <measurement group_id="B13" value="6"/>
                    <measurement group_id="B14" value="6"/>
                    <measurement group_id="B15" value="6"/>
                    <measurement group_id="B16" value="3"/>
                    <measurement group_id="B17" value="5"/>
                    <measurement group_id="B18" value="5"/>
                    <measurement group_id="B19" value="5"/>
                    <measurement group_id="B21" value="4"/>
                    <measurement group_id="B22" value="4"/>
                    <measurement group_id="B23" value="4"/>
                    <measurement group_id="B24" value="6"/>
                    <measurement group_id="B25" value="6"/>
                    <measurement group_id="B26" value="7"/>
                    <measurement group_id="B27" value="8"/>
                    <measurement group_id="B28" value="4"/>
                    <measurement group_id="B29" value="6"/>
                    <measurement group_id="B30" value="4"/>
                    <measurement group_id="B31" value="166"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Who Experienced at Least One Treatment-Emergent Adverse Event (TEAE)</title>
        <description>An Adverse Event (AE) is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. A TEAE is defined as an adverse event with an onset that occurs or gets worse after receiving study drug.</description>
        <time_frame>Day 1 up to Day 41</time_frame>
        <population>Safety Analysis Set (SAS) included all randomized participants who received at least 1 dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>SRD: Placebo Cohorts 1-6, 18 and 19</title>
            <description>TAK-071 placebo-matching capsules, orally, once on Day 1 to non-Japanese healthy participants in the single-rising dose (SRD) period.</description>
          </group>
          <group group_id="O2">
            <title>SRD: Cohort 1: TAK-071 1 mg</title>
            <description>TAK-071 1 mg, capsule, orally, once on Day 1 to non-Japanese healthy participants.</description>
          </group>
          <group group_id="O3">
            <title>SRD: Cohort 2: TAK-071 3 mg</title>
            <description>TAK-071 3 mg capsule, orally, once on Day 1 to non-Japanese healthy participants. Dose of TAK-071 was based on the 24-hour post-dose safety, tolerability and pharmacokinetic (PK) data from cohort 1.</description>
          </group>
          <group group_id="O4">
            <title>SRD: Cohort 3: TAK-071 9 mg</title>
            <description>TAK-071 9 mg capsule, orally, once on Day 1 to non-Japanese healthy participants. Dose of TAK-071 was based on 24-hour safety, tolerability, and preliminary plasma PK and 12-hour CSF PK data.</description>
          </group>
          <group group_id="O5">
            <title>SRD: Cohort 4: TAK-071 20 mg</title>
            <description>TAK-071 20 mg capsule, orally, once on Day 1 to non-Japanese healthy participants. Dose of TAK-071 was based on the 24-hour post-dose safety and tolerability data from previous cohort.</description>
          </group>
          <group group_id="O6">
            <title>SRD: Cohort 5: TAK-071 40 mg</title>
            <description>TAK-071 40 mg capsule, orally, once on Day 1 to non-Japanese healthy participants. Dose of TAK-071 will be based on 24-hour safety, tolerability, and preliminary plasma PK data from Cohort 4.</description>
          </group>
          <group group_id="O7">
            <title>SRD: Cohort 6: TAK-071 80 mg</title>
            <description>TAK-071 80 mg capsules, orally, once on Day 1 to non-Japanese healthy participants. Dose of TAK-071 was based on 24-hour safety, tolerability, and preliminary plasma PK data from Cohort 5</description>
          </group>
          <group group_id="O8">
            <title>MRD: Placebo Cohorts 7-9</title>
            <description>TAK-071 placebo-matching capsule, orally, once on Day 1 to non-Japanese healthy participants in the multiple-rising dose (MRD) period.</description>
          </group>
          <group group_id="O9">
            <title>MRD: Cohort 7: TAK-071 3 mg</title>
            <description>TAK-071 3 mg capsules, orally, once daily from Day 1 up to Day 21 to non-Japanese healthy participants. Dose of TAK-071 was based on 24-hour safety and tolerability from Cohort 4 and the 24-hour preliminary plasma PK and 12-hour CSF PK data from Cohort 3.</description>
          </group>
          <group group_id="O10">
            <title>MRD: Cohort 8: TAK-071 9 mg</title>
            <description>TAK-071 9 mg capsules, orally, once daily from Day 1 up to Day 21 to non-Japanese healthy participants. Dose of TAK-071 was based on safety, tolerability and available PK data arising from the ongoing SRD part and previous MRD cohort.</description>
          </group>
          <group group_id="O11">
            <title>MRD: Cohort 9: TAK-071 15 mg</title>
            <description>TAK-071 15 mg capsule, orally, once on Day 1, followed by a washout period of 7 days, then TAK-071 once daily for 21 days to non-Japanese healthy participants. Dose of TAK-071 will be based on safety, tolerability and available PK data arising from the ongoing SRD part and previous MRD cohort.</description>
          </group>
          <group group_id="O12">
            <title>MRD: TAK-071 Placebo Cohorts 10-12+Donepezil</title>
            <description>TAK-071 placebo-matching capsule, orally, once daily along with donepezil 5 mg, tablets, orally, once daily from Day 1 up to Day 21 to non-Japanese healthy participants who were pre-treated with donepezil 5 mg, tablet, once daily for 3 weeks prior to administration of TAK-071.</description>
          </group>
          <group group_id="O13">
            <title>MRD: Cohort 10: TAK-071 3 mg+Donepezil 5 mg</title>
            <description>TAK-071 3 mg capsules, orally, once daily along with donepezil 5 mg, tablets, orally, once daily from Day 1 up to Day 21 to non-Japanese healthy participants who were pre-treated with donepezil 5 mg, tablet, once daily for 3 weeks prior to administration of TAK-071. Dose of TAK-071 was same as the dose used in MRD Cohort 7.</description>
          </group>
          <group group_id="O14">
            <title>MRD: Cohort 11: TAK-071 9 mg + Donepezil 5 mg</title>
            <description>TAK-071 9 mg capsules, orally, once daily along with donepezil 5 mg, tablets, orally, once daily from Day 1 up to Day 21 to non-Japanese healthy participants who were pre-treated with donepezil 5 mg, tablet, once daily for 3 weeks prior to administration of TAK-071. Dose of TAK-071 was same as the dose used in MRD Cohort 8.</description>
          </group>
          <group group_id="O15">
            <title>MRD: Cohort 12: TAK-071 15 mg+Donepezil 5 mg</title>
            <description>TAK-071 15 mg capsule, orally, once daily along with donepezil 5 mg, tablets, orally, once daily from Day 1 up to Day 21 to non-Japanese healthy participants who were pre-treated with donepezil 5 mg, tablet, once daily for 3 weeks prior to administration of TAK-071. Dose of TAK-071 was same as the dose used in MRD Cohort 9.</description>
          </group>
          <group group_id="O16">
            <title>MRD: Placebo Cohorts 13-15</title>
            <description>TAK-071 placebo-matching capsule, orally, once on Day 1 to Japanese healthy participants.</description>
          </group>
          <group group_id="O17">
            <title>MRD: Cohort 13: TAK-071 3 mg</title>
            <description>TAK-071 3 mg capsule, orally, once on Day 1, followed by a washout period of 7 days, then TAK-071 once daily for 21 days to Japanese healthy participants. Dose of TAK-071 was same as the dose used in MRD Cohort 7.</description>
          </group>
          <group group_id="O18">
            <title>MRD: Cohort 14: TAK-071 9 mg</title>
            <description>TAK-071 9 mg capsule or matching placebo, orally, once on Day 1, followed by a washout period of 7 days, then TAK-071 once daily for 21 days to Japanese healthy participants. Dose of TAK-071 was same as the dose used in MRD Cohort 8.</description>
          </group>
          <group group_id="O19">
            <title>MRD: Cohort 15: TAK-071 15 mg</title>
            <description>TAK-071 15 mg capsule, orally, once on Day 1, followed by a washout period of 7 days, then TAK-071 once daily for 21 days to Japanese healthy participants. Dose of TAK-071 was same as the dose used in MRD Cohort 9.</description>
          </group>
          <group group_id="O20">
            <title>Bioavailability (BA)/Food Effect: Cohort 17 Regimen A</title>
            <description>TAK-071 10 mg capsule, orally once on Day 1 in the fasted state in Period 1 or Period 2 or Period 3</description>
          </group>
          <group group_id="O21">
            <title>BA/Food Effect: Cohort 17 Regimen B</title>
            <description>TAK-071 10 mg tablet, orally, once on Day 1 in the fasted state in Period 1 or Period 2 or Period 3</description>
          </group>
          <group group_id="O22">
            <title>BA/Food Effect: Cohort 17 Regimen C</title>
            <description>TAK-071 10 mg tablet, orally, once on Day 1 in the fed state in Period 1 or Period 2 or Period 3</description>
          </group>
          <group group_id="O23">
            <title>SRD: Cohort 18: TAK-071 120 mg</title>
            <description>TAK-071 120 mg capsule, orally, once on Day 1 to non-Japanese healthy participants. Dose of TAK-071 was based on 24-hour safety, tolerability, and preliminary plasma PK data from Cohort 6.</description>
          </group>
          <group group_id="O24">
            <title>SRD: Cohort 19: TAK-071 160 mg</title>
            <description>TAK-071 160 mg capsule, orally, once on Day 1 to non-Japanese healthy participants. Dose of TAK-071 was based on 24-hour safety, tolerability, and preliminary plasma PK data from Cohort 18.</description>
          </group>
          <group group_id="O25">
            <title>SRD: TAK-071 Placebo+Donepezil Placebo</title>
            <description>TAK-071 placebo-matching capsule, orally, once on Day 1 followed by donepezil placebo-matching tablet, orally on Day 2 to non-Japanese healthy participants.</description>
          </group>
          <group group_id="O26">
            <title>SRD: TAK-071 Placebo+Donepezil</title>
            <description>TAK-071 placebo-matching capsule, orally, once on Day 1 followed by donepezil 10 mg tablet, orally, on Day 2 to non-Japanese healthy participants.</description>
          </group>
          <group group_id="O27">
            <title>SRD: Cohort 20: TAK-071 40 mg+Donepezil</title>
            <description>TAK-071 40 mg capsule, orally, once on Day 1 followed by donepezil 10 mg, tablets, orally, once on Day 2 to non-Japanese healthy participants. Dose of TAK-071 was based on 24-hour safety, tolerability, and preliminary plasma PK data from Cohort 19.</description>
          </group>
          <group group_id="O28">
            <title>SRD: Cohort 21: TAK-071 60 mg+Donepezil</title>
            <description>TAK-071 60 mg capsule, orally, once on Day 1 followed by donepezil 10 mg, tablets, orally, once on Day 2 to non-Japanese healthy participants. Dose of TAK-071 was based on 24-hour safety and tolerability data from Cohort 20.</description>
          </group>
          <group group_id="O29">
            <title>SRD: Cohort 22: TAK-071 80 mg+Donepezil</title>
            <description>TAK-071 80 mg capsule, orally, once on Day 1, followed by donepezil 10 mg, tablets, orally, once on Day 2 to non-Japanese healthy participants. Dose of TAK-071 was based on 24-hour safety and tolerability data from Cohort 21.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Experienced at Least One Treatment-Emergent Adverse Event (TEAE)</title>
          <description>An Adverse Event (AE) is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. A TEAE is defined as an adverse event with an onset that occurs or gets worse after receiving study drug.</description>
          <population>Safety Analysis Set (SAS) included all randomized participants who received at least 1 dose of study drug.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="6"/>
                <count group_id="O9" value="6"/>
                <count group_id="O10" value="6"/>
                <count group_id="O11" value="6"/>
                <count group_id="O12" value="6"/>
                <count group_id="O13" value="6"/>
                <count group_id="O14" value="6"/>
                <count group_id="O15" value="6"/>
                <count group_id="O16" value="3"/>
                <count group_id="O17" value="5"/>
                <count group_id="O18" value="5"/>
                <count group_id="O19" value="5"/>
                <count group_id="O20" value="12"/>
                <count group_id="O21" value="12"/>
                <count group_id="O22" value="12"/>
                <count group_id="O23" value="6"/>
                <count group_id="O24" value="6"/>
                <count group_id="O25" value="9"/>
                <count group_id="O26" value="9"/>
                <count group_id="O27" value="5"/>
                <count group_id="O28" value="6"/>
                <count group_id="O29" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.0"/>
                    <measurement group_id="O2" value="33.3"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="66.7"/>
                    <measurement group_id="O5" value="33.3"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="16.7"/>
                    <measurement group_id="O8" value="50.0"/>
                    <measurement group_id="O9" value="16.7"/>
                    <measurement group_id="O10" value="16.7"/>
                    <measurement group_id="O11" value="50.0"/>
                    <measurement group_id="O12" value="33.3"/>
                    <measurement group_id="O13" value="33.3"/>
                    <measurement group_id="O14" value="50.0"/>
                    <measurement group_id="O15" value="50.0"/>
                    <measurement group_id="O16" value="66.7"/>
                    <measurement group_id="O17" value="40.0"/>
                    <measurement group_id="O18" value="40.0"/>
                    <measurement group_id="O19" value="60.0"/>
                    <measurement group_id="O20" value="16.7"/>
                    <measurement group_id="O21" value="8.3"/>
                    <measurement group_id="O22" value="8.3"/>
                    <measurement group_id="O23" value="0"/>
                    <measurement group_id="O24" value="33.3"/>
                    <measurement group_id="O25" value="44.4"/>
                    <measurement group_id="O26" value="55.6"/>
                    <measurement group_id="O27" value="80.0"/>
                    <measurement group_id="O28" value="100"/>
                    <measurement group_id="O29" value="83.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Who Meet the Markedly Abnormal Criteria for Clinical Laboratory Tests at Least Once Post-dose</title>
        <description>Clinical laboratory tests included serum chemistry, hematology, coagulation and urinalysis. ULN=upper limit of normal range.</description>
        <time_frame>Day 1 up to Day 41</time_frame>
        <population>SAS included all randomized participants who received at least 1 dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>SRD: Placebo Cohorts 1-6, 18 and 19</title>
            <description>TAK-071 placebo-matching capsules, orally, once on Day 1 to non-Japanese healthy participants in the single-rising dose (SRD) period.</description>
          </group>
          <group group_id="O2">
            <title>SRD: Cohort 1: TAK-071 1 mg</title>
            <description>TAK-071 1 mg, capsule, orally, once on Day 1 to non-Japanese healthy participants.</description>
          </group>
          <group group_id="O3">
            <title>SRD: Cohort 2: TAK-071 3 mg</title>
            <description>TAK-071 3 mg capsule, orally, once on Day 1 to non-Japanese healthy participants. Dose of TAK-071 was based on the 24-hour post-dose safety, tolerability and pharmacokinetic (PK) data from cohort 1.</description>
          </group>
          <group group_id="O4">
            <title>SRD: Cohort 3: TAK-071 9 mg</title>
            <description>TAK-071 9 mg capsule, orally, once on Day 1 to non-Japanese healthy participants. Dose of TAK-071 was based on 24-hour safety, tolerability, and preliminary plasma PK and 12-hour CSF PK data.</description>
          </group>
          <group group_id="O5">
            <title>SRD: Cohort 4: TAK-071 20 mg</title>
            <description>TAK-071 20 mg capsule, orally, once on Day 1 to non-Japanese healthy participants. Dose of TAK-071 was based on the 24-hour post-dose safety and tolerability data from previous cohort.</description>
          </group>
          <group group_id="O6">
            <title>SRD: Cohort 5: TAK-071 40 mg</title>
            <description>TAK-071 40 mg capsule, orally, once on Day 1 to non-Japanese healthy participants. Dose of TAK-071 will be based on 24-hour safety, tolerability, and preliminary plasma PK data from Cohort 4.</description>
          </group>
          <group group_id="O7">
            <title>SRD: Cohort 6: TAK-071 80 mg</title>
            <description>TAK-071 80 mg capsules, orally, once on Day 1 to non-Japanese healthy participants. Dose of TAK-071 was based on 24-hour safety, tolerability, and preliminary plasma PK data from Cohort 5</description>
          </group>
          <group group_id="O8">
            <title>MRD: Placebo Cohorts 7-9</title>
            <description>TAK-071 placebo-matching capsule, orally, once on Day 1 to non-Japanese healthy participants in the multiple-rising dose (MRD) period.</description>
          </group>
          <group group_id="O9">
            <title>MRD: Cohort 7: TAK-071 3 mg</title>
            <description>TAK-071 3 mg capsules, orally, once daily from Day 1 up to Day 21 to non-Japanese healthy participants. Dose of TAK-071 was based on 24-hour safety and tolerability from Cohort 4 and the 24-hour preliminary plasma PK and 12-hour CSF PK data from Cohort 3.</description>
          </group>
          <group group_id="O10">
            <title>MRD: Cohort 8: TAK-071 9 mg</title>
            <description>TAK-071 9 mg capsules, orally, once daily from Day 1 up to Day 21 to non-Japanese healthy participants. Dose of TAK-071 was based on safety, tolerability and available PK data arising from the ongoing SRD part and previous MRD cohort.</description>
          </group>
          <group group_id="O11">
            <title>MRD: Cohort 9: TAK-071 15 mg</title>
            <description>TAK-071 15 mg capsule, orally, once on Day 1, followed by a washout period of 7 days, then TAK-071 once daily for 21 days to non-Japanese healthy participants. Dose of TAK-071 will be based on safety, tolerability and available PK data arising from the ongoing SRD part and previous MRD cohort.</description>
          </group>
          <group group_id="O12">
            <title>MRD: TAK-071 Placebo Cohorts 10-12+Donepezil</title>
            <description>TAK-071 placebo-matching capsule, orally, once daily along with donepezil 5 mg, tablets, orally, once daily from Day 1 up to Day 21 to non-Japanese healthy participants who were pre-treated with donepezil 5 mg, tablet, once daily for 3 weeks prior to administration of TAK-071.</description>
          </group>
          <group group_id="O13">
            <title>MRD: Cohort 10: TAK-071 3 mg+Donepezil 5 mg</title>
            <description>TAK-071 3 mg capsules, orally, once daily along with donepezil 5 mg, tablets, orally, once daily from Day 1 up to Day 21 to non-Japanese healthy participants who were pre-treated with donepezil 5 mg, tablet, once daily for 3 weeks prior to administration of TAK-071. Dose of TAK-071 was same as the dose used in MRD Cohort 7.</description>
          </group>
          <group group_id="O14">
            <title>MRD: Cohort 11: TAK-071 9 mg + Donepezil 5 mg</title>
            <description>TAK-071 9 mg capsules, orally, once daily along with donepezil 5 mg, tablets, orally, once daily from Day 1 up to Day 21 to non-Japanese healthy participants who were pre-treated with donepezil 5 mg, tablet, once daily for 3 weeks prior to administration of TAK-071. Dose of TAK-071 was same as the dose used in MRD Cohort 8.</description>
          </group>
          <group group_id="O15">
            <title>MRD: Cohort 12: TAK-071 15 mg+Donepezil 5 mg</title>
            <description>TAK-071 15 mg capsule, orally, once daily along with donepezil 5 mg, tablets, orally, once daily from Day 1 up to Day 21 to non-Japanese healthy participants who were pre-treated with donepezil 5 mg, tablet, once daily for 3 weeks prior to administration of TAK-071. Dose of TAK-071 was same as the dose used in MRD Cohort 9.</description>
          </group>
          <group group_id="O16">
            <title>MRD: Placebo Cohorts 13-15</title>
            <description>TAK-071 placebo-matching capsule, orally, once on Day 1 to Japanese healthy participants.</description>
          </group>
          <group group_id="O17">
            <title>MRD: Cohort 13: TAK-071 3 mg</title>
            <description>TAK-071 3 mg capsule, orally, once on Day 1, followed by a washout period of 7 days, then TAK-071 once daily for 21 days to Japanese healthy participants. Dose of TAK-071 was same as the dose used in MRD Cohort 7.</description>
          </group>
          <group group_id="O18">
            <title>MRD: Cohort 14: TAK-071 9 mg</title>
            <description>TAK-071 9 mg capsule or matching placebo, orally, once on Day 1, followed by a washout period of 7 days, then TAK-071 once daily for 21 days to Japanese healthy participants. Dose of TAK-071 was same as the dose used in MRD Cohort 8.</description>
          </group>
          <group group_id="O19">
            <title>MRD: Cohort 15: TAK-071 15 mg</title>
            <description>TAK-071 15 mg capsule, orally, once on Day 1, followed by a washout period of 7 days, then TAK-071 once daily for 21 days to Japanese healthy participants. Dose of TAK-071 was same as the dose used in MRD Cohort 9.</description>
          </group>
          <group group_id="O20">
            <title>Bioavailability (BA)/Food Effect: Cohort 17 Regimen A</title>
            <description>TAK-071 10 mg capsule, orally once on Day 1 in the fasted state in Period 1 or Period 2 or Period 3</description>
          </group>
          <group group_id="O21">
            <title>BA/Food Effect: Cohort 17 Regimen B</title>
            <description>TAK-071 10 mg tablet, orally, once on Day 1 in the fasted state in Period 1 or Period 2 or Period 3</description>
          </group>
          <group group_id="O22">
            <title>BA/Food Effect: Cohort 17 Regimen C</title>
            <description>TAK-071 10 mg tablet, orally, once on Day 1 in the fed state in Period 1 or Period 2 or Period 3</description>
          </group>
          <group group_id="O23">
            <title>SRD: Cohort 18: TAK-071 120 mg</title>
            <description>TAK-071 120 mg capsule, orally, once on Day 1 to non-Japanese healthy participants. Dose of TAK-071 was based on 24-hour safety, tolerability, and preliminary plasma PK data from Cohort 6.</description>
          </group>
          <group group_id="O24">
            <title>SRD: Cohort 19: TAK-071 160 mg</title>
            <description>TAK-071 160 mg capsule, orally, once on Day 1 to non-Japanese healthy participants. Dose of TAK-071 was based on 24-hour safety, tolerability, and preliminary plasma PK data from Cohort 18.</description>
          </group>
          <group group_id="O25">
            <title>SRD: TAK-071 Placebo+Donepezil Placebo</title>
            <description>TAK-071 placebo-matching capsule, orally, once on Day 1 followed by donepezil placebo-matching tablet, orally on Day 2 to non-Japanese healthy participants.</description>
          </group>
          <group group_id="O26">
            <title>SRD: TAK-071 Placebo+Donepezil</title>
            <description>TAK-071 placebo-matching capsule, orally, once on Day 1 followed by donepezil 10 mg tablet, orally, on Day 2 to non-Japanese healthy participants.</description>
          </group>
          <group group_id="O27">
            <title>SRD: Cohort 20: TAK-071 40 mg+Donepezil</title>
            <description>TAK-071 40 mg capsule, orally, once on Day 1 followed by donepezil 10 mg, tablets, orally, once on Day 2 to non-Japanese healthy participants. Dose of TAK-071 was based on 24-hour safety, tolerability, and preliminary plasma PK data from Cohort 19.</description>
          </group>
          <group group_id="O28">
            <title>SRD: Cohort 21: TAK-071 60 mg+Donepezil</title>
            <description>TAK-071 60 mg capsule, orally, once on Day 1 followed by donepezil 10 mg, tablets, orally, once on Day 2 to non-Japanese healthy participants. Dose of TAK-071 was based on 24-hour safety and tolerability data from Cohort 20.</description>
          </group>
          <group group_id="O29">
            <title>SRD: Cohort 22: TAK-071 80 mg+Donepezil</title>
            <description>TAK-071 80 mg capsule, orally, once on Day 1, followed by donepezil 10 mg, tablets, orally, once on Day 2 to non-Japanese healthy participants. Dose of TAK-071 was based on 24-hour safety and tolerability data from Cohort 21.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Meet the Markedly Abnormal Criteria for Clinical Laboratory Tests at Least Once Post-dose</title>
          <description>Clinical laboratory tests included serum chemistry, hematology, coagulation and urinalysis. ULN=upper limit of normal range.</description>
          <population>SAS included all randomized participants who received at least 1 dose of study drug.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="6"/>
                <count group_id="O9" value="6"/>
                <count group_id="O10" value="6"/>
                <count group_id="O11" value="6"/>
                <count group_id="O12" value="6"/>
                <count group_id="O13" value="6"/>
                <count group_id="O14" value="6"/>
                <count group_id="O15" value="6"/>
                <count group_id="O16" value="3"/>
                <count group_id="O17" value="5"/>
                <count group_id="O18" value="5"/>
                <count group_id="O19" value="5"/>
                <count group_id="O20" value="12"/>
                <count group_id="O21" value="12"/>
                <count group_id="O22" value="12"/>
                <count group_id="O23" value="6"/>
                <count group_id="O24" value="6"/>
                <count group_id="O25" value="9"/>
                <count group_id="O26" value="9"/>
                <count group_id="O27" value="5"/>
                <count group_id="O28" value="6"/>
                <count group_id="O29" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Bilirubin (&gt;2.0 mg/dL, &gt;34.2 umol/L)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="16.7"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="0"/>
                    <measurement group_id="O13" value="0"/>
                    <measurement group_id="O14" value="0"/>
                    <measurement group_id="O15" value="0"/>
                    <measurement group_id="O16" value="0"/>
                    <measurement group_id="O17" value="0"/>
                    <measurement group_id="O18" value="0"/>
                    <measurement group_id="O19" value="0"/>
                    <measurement group_id="O20" value="0"/>
                    <measurement group_id="O21" value="0"/>
                    <measurement group_id="O22" value="0"/>
                    <measurement group_id="O23" value="0"/>
                    <measurement group_id="O24" value="0"/>
                    <measurement group_id="O25" value="0"/>
                    <measurement group_id="O26" value="0"/>
                    <measurement group_id="O27" value="0"/>
                    <measurement group_id="O28" value="0"/>
                    <measurement group_id="O29" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Creatine Kinase (&gt;5*ULN)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.3"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="16.7"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="0"/>
                    <measurement group_id="O13" value="0"/>
                    <measurement group_id="O14" value="0"/>
                    <measurement group_id="O15" value="0"/>
                    <measurement group_id="O16" value="0"/>
                    <measurement group_id="O17" value="0"/>
                    <measurement group_id="O18" value="0"/>
                    <measurement group_id="O19" value="0"/>
                    <measurement group_id="O20" value="8.3"/>
                    <measurement group_id="O21" value="0"/>
                    <measurement group_id="O22" value="8.3"/>
                    <measurement group_id="O23" value="0"/>
                    <measurement group_id="O24" value="0"/>
                    <measurement group_id="O25" value="0"/>
                    <measurement group_id="O26" value="0"/>
                    <measurement group_id="O27" value="0"/>
                    <measurement group_id="O28" value="0"/>
                    <measurement group_id="O29" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Blood Urea Nitrogen (&gt;30 mg/dL, &gt;10.7 mmol/L)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="16.7"/>
                    <measurement group_id="O12" value="0"/>
                    <measurement group_id="O13" value="0"/>
                    <measurement group_id="O14" value="0"/>
                    <measurement group_id="O15" value="0"/>
                    <measurement group_id="O16" value="0"/>
                    <measurement group_id="O17" value="0"/>
                    <measurement group_id="O18" value="0"/>
                    <measurement group_id="O19" value="0"/>
                    <measurement group_id="O20" value="0"/>
                    <measurement group_id="O21" value="0"/>
                    <measurement group_id="O22" value="0"/>
                    <measurement group_id="O23" value="0"/>
                    <measurement group_id="O24" value="0"/>
                    <measurement group_id="O25" value="0"/>
                    <measurement group_id="O26" value="0"/>
                    <measurement group_id="O27" value="0"/>
                    <measurement group_id="O28" value="0"/>
                    <measurement group_id="O29" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Prothrombin Intl. Normalized Ratio (&gt;1.5*ULN)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="0"/>
                    <measurement group_id="O13" value="16.7"/>
                    <measurement group_id="O14" value="0"/>
                    <measurement group_id="O15" value="0"/>
                    <measurement group_id="O16" value="0"/>
                    <measurement group_id="O17" value="0"/>
                    <measurement group_id="O18" value="0"/>
                    <measurement group_id="O19" value="0"/>
                    <measurement group_id="O20" value="0"/>
                    <measurement group_id="O21" value="0"/>
                    <measurement group_id="O22" value="0"/>
                    <measurement group_id="O23" value="0"/>
                    <measurement group_id="O24" value="0"/>
                    <measurement group_id="O25" value="0"/>
                    <measurement group_id="O26" value="0"/>
                    <measurement group_id="O27" value="0"/>
                    <measurement group_id="O28" value="0"/>
                    <measurement group_id="O29" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Aspartate Aminotransferase (&gt;3*ULN)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="0"/>
                    <measurement group_id="O13" value="0"/>
                    <measurement group_id="O14" value="0"/>
                    <measurement group_id="O15" value="0"/>
                    <measurement group_id="O16" value="0"/>
                    <measurement group_id="O17" value="0"/>
                    <measurement group_id="O18" value="0"/>
                    <measurement group_id="O19" value="0"/>
                    <measurement group_id="O20" value="0"/>
                    <measurement group_id="O21" value="0"/>
                    <measurement group_id="O22" value="8.3"/>
                    <measurement group_id="O23" value="0"/>
                    <measurement group_id="O24" value="0"/>
                    <measurement group_id="O25" value="0"/>
                    <measurement group_id="O26" value="0"/>
                    <measurement group_id="O27" value="0"/>
                    <measurement group_id="O28" value="0"/>
                    <measurement group_id="O29" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Who Meet the Markedly Abnormal Criteria for Vital Sign Measurements at Least Once Post-dose</title>
        <description>Vital Sign measurements included systolic blood pressure (SBP), diastolic blood presssure (DBP), pulse, temperature, orthostatic SBP, orthostatic DBP and orthostatic pulse.</description>
        <time_frame>Day 1 up to Day 41</time_frame>
        <population>SAS included all randomized participants who received at least 1 dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>SRD: Placebo Cohorts 1-6, 18 and 19</title>
            <description>TAK-071 placebo-matching capsules, orally, once on Day 1 to non-Japanese healthy participants in the single-rising dose (SRD) period.</description>
          </group>
          <group group_id="O2">
            <title>SRD: Cohort 1: TAK-071 1 mg</title>
            <description>TAK-071 1 mg, capsule, orally, once on Day 1 to non-Japanese healthy participants.</description>
          </group>
          <group group_id="O3">
            <title>SRD: Cohort 2: TAK-071 3 mg</title>
            <description>TAK-071 3 mg capsule, orally, once on Day 1 to non-Japanese healthy participants. Dose of TAK-071 was based on the 24-hour post-dose safety, tolerability and pharmacokinetic (PK) data from cohort 1.</description>
          </group>
          <group group_id="O4">
            <title>SRD: Cohort 3: TAK-071 9 mg</title>
            <description>TAK-071 9 mg capsule, orally, once on Day 1 to non-Japanese healthy participants. Dose of TAK-071 was based on 24-hour safety, tolerability, and preliminary plasma PK and 12-hour CSF PK data.</description>
          </group>
          <group group_id="O5">
            <title>SRD: Cohort 4: TAK-071 20 mg</title>
            <description>TAK-071 20 mg capsule, orally, once on Day 1 to non-Japanese healthy participants. Dose of TAK-071 was based on the 24-hour post-dose safety and tolerability data from previous cohort.</description>
          </group>
          <group group_id="O6">
            <title>SRD: Cohort 5: TAK-071 40 mg</title>
            <description>TAK-071 40 mg capsule, orally, once on Day 1 to non-Japanese healthy participants. Dose of TAK-071 will be based on 24-hour safety, tolerability, and preliminary plasma PK data from Cohort 4.</description>
          </group>
          <group group_id="O7">
            <title>SRD: Cohort 6: TAK-071 80 mg</title>
            <description>TAK-071 80 mg capsules, orally, once on Day 1 to non-Japanese healthy participants. Dose of TAK-071 was based on 24-hour safety, tolerability, and preliminary plasma PK data from Cohort 5</description>
          </group>
          <group group_id="O8">
            <title>MRD: Placebo Cohorts 7-9</title>
            <description>TAK-071 placebo-matching capsule, orally, once on Day 1 to non-Japanese healthy participants in the multiple-rising dose (MRD) period.</description>
          </group>
          <group group_id="O9">
            <title>MRD: Cohort 7: TAK-071 3 mg</title>
            <description>TAK-071 3 mg capsules, orally, once daily from Day 1 up to Day 21 to non-Japanese healthy participants. Dose of TAK-071 was based on 24-hour safety and tolerability from Cohort 4 and the 24-hour preliminary plasma PK and 12-hour CSF PK data from Cohort 3.</description>
          </group>
          <group group_id="O10">
            <title>MRD: Cohort 8: TAK-071 9 mg</title>
            <description>TAK-071 9 mg capsules, orally, once daily from Day 1 up to Day 21 to non-Japanese healthy participants. Dose of TAK-071 was based on safety, tolerability and available PK data arising from the ongoing SRD part and previous MRD cohort.</description>
          </group>
          <group group_id="O11">
            <title>MRD: Cohort 9: TAK-071 15 mg</title>
            <description>TAK-071 15 mg capsule, orally, once on Day 1, followed by a washout period of 7 days, then TAK-071 once daily for 21 days to non-Japanese healthy participants. Dose of TAK-071 will be based on safety, tolerability and available PK data arising from the ongoing SRD part and previous MRD cohort.</description>
          </group>
          <group group_id="O12">
            <title>MRD: TAK-071 Placebo Cohorts 10-12+Donepezil</title>
            <description>TAK-071 placebo-matching capsule, orally, once daily along with donepezil 5 mg, tablets, orally, once daily from Day 1 up to Day 21 to non-Japanese healthy participants who were pre-treated with donepezil 5 mg, tablet, once daily for 3 weeks prior to administration of TAK-071.</description>
          </group>
          <group group_id="O13">
            <title>MRD: Cohort 10: TAK-071 3 mg+Donepezil 5 mg</title>
            <description>TAK-071 3 mg capsules, orally, once daily along with donepezil 5 mg, tablets, orally, once daily from Day 1 up to Day 21 to non-Japanese healthy participants who were pre-treated with donepezil 5 mg, tablet, once daily for 3 weeks prior to administration of TAK-071. Dose of TAK-071 was same as the dose used in MRD Cohort 7.</description>
          </group>
          <group group_id="O14">
            <title>MRD: Cohort 11: TAK-071 9 mg + Donepezil 5 mg</title>
            <description>TAK-071 9 mg capsules, orally, once daily along with donepezil 5 mg, tablets, orally, once daily from Day 1 up to Day 21 to non-Japanese healthy participants who were pre-treated with donepezil 5 mg, tablet, once daily for 3 weeks prior to administration of TAK-071. Dose of TAK-071 was same as the dose used in MRD Cohort 8.</description>
          </group>
          <group group_id="O15">
            <title>MRD: Cohort 12: TAK-071 15 mg+Donepezil 5 mg</title>
            <description>TAK-071 15 mg capsule, orally, once daily along with donepezil 5 mg, tablets, orally, once daily from Day 1 up to Day 21 to non-Japanese healthy participants who were pre-treated with donepezil 5 mg, tablet, once daily for 3 weeks prior to administration of TAK-071. Dose of TAK-071 was same as the dose used in MRD Cohort 9.</description>
          </group>
          <group group_id="O16">
            <title>MRD: Placebo Cohorts 13-15</title>
            <description>TAK-071 placebo-matching capsule, orally, once on Day 1 to Japanese healthy participants.</description>
          </group>
          <group group_id="O17">
            <title>MRD: Cohort 13: TAK-071 3 mg</title>
            <description>TAK-071 3 mg capsule, orally, once on Day 1, followed by a washout period of 7 days, then TAK-071 once daily for 21 days to Japanese healthy participants. Dose of TAK-071 was same as the dose used in MRD Cohort 7.</description>
          </group>
          <group group_id="O18">
            <title>MRD: Cohort 14: TAK-071 9 mg</title>
            <description>TAK-071 9 mg capsule or matching placebo, orally, once on Day 1, followed by a washout period of 7 days, then TAK-071 once daily for 21 days to Japanese healthy participants. Dose of TAK-071 was same as the dose used in MRD Cohort 8.</description>
          </group>
          <group group_id="O19">
            <title>MRD: Cohort 15: TAK-071 15 mg</title>
            <description>TAK-071 15 mg capsule, orally, once on Day 1, followed by a washout period of 7 days, then TAK-071 once daily for 21 days to Japanese healthy participants. Dose of TAK-071 was same as the dose used in MRD Cohort 9.</description>
          </group>
          <group group_id="O20">
            <title>Bioavailability (BA)/Food Effect: Cohort 17 Regimen A</title>
            <description>TAK-071 10 mg capsule, orally once on Day 1 in the fasted state in Period 1 or Period 2 or Period 3</description>
          </group>
          <group group_id="O21">
            <title>BA/Food Effect: Cohort 17 Regimen B</title>
            <description>TAK-071 10 mg tablet, orally, once on Day 1 in the fasted state in Period 1 or Period 2 or Period 3</description>
          </group>
          <group group_id="O22">
            <title>BA/Food Effect: Cohort 17 Regimen C</title>
            <description>TAK-071 10 mg tablet, orally, once on Day 1 in the fed state in Period 1 or Period 2 or Period 3</description>
          </group>
          <group group_id="O23">
            <title>SRD: Cohort 18: TAK-071 120 mg</title>
            <description>TAK-071 120 mg capsule, orally, once on Day 1 to non-Japanese healthy participants. Dose of TAK-071 was based on 24-hour safety, tolerability, and preliminary plasma PK data from Cohort 6.</description>
          </group>
          <group group_id="O24">
            <title>SRD: Cohort 19: TAK-071 160 mg</title>
            <description>TAK-071 160 mg capsule, orally, once on Day 1 to non-Japanese healthy participants. Dose of TAK-071 was based on 24-hour safety, tolerability, and preliminary plasma PK data from Cohort 18.</description>
          </group>
          <group group_id="O25">
            <title>SRD: TAK-071 Placebo+Donepezil Placebo</title>
            <description>TAK-071 placebo-matching capsule, orally, once on Day 1 followed by donepezil placebo-matching tablet, orally on Day 2 to non-Japanese healthy participants.</description>
          </group>
          <group group_id="O26">
            <title>SRD: TAK-071 Placebo+Donepezil</title>
            <description>TAK-071 placebo-matching capsule, orally, once on Day 1 followed by donepezil 10 mg tablet, orally, on Day 2 to non-Japanese healthy participants.</description>
          </group>
          <group group_id="O27">
            <title>SRD: Cohort 20: TAK-071 40 mg+Donepezil</title>
            <description>TAK-071 40 mg capsule, orally, once on Day 1 followed by donepezil 10 mg, tablets, orally, once on Day 2 to non-Japanese healthy participants. Dose of TAK-071 was based on 24-hour safety, tolerability, and preliminary plasma PK data from Cohort 19.</description>
          </group>
          <group group_id="O28">
            <title>SRD: Cohort 21: TAK-071 60 mg+Donepezil</title>
            <description>TAK-071 60 mg capsule, orally, once on Day 1 followed by donepezil 10 mg, tablets, orally, once on Day 2 to non-Japanese healthy participants. Dose of TAK-071 was based on 24-hour safety and tolerability data from Cohort 20.</description>
          </group>
          <group group_id="O29">
            <title>SRD: Cohort 22: TAK-071 80 mg+Donepezil</title>
            <description>TAK-071 80 mg capsule, orally, once on Day 1, followed by donepezil 10 mg, tablets, orally, once on Day 2 to non-Japanese healthy participants. Dose of TAK-071 was based on 24-hour safety and tolerability data from Cohort 21.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Meet the Markedly Abnormal Criteria for Vital Sign Measurements at Least Once Post-dose</title>
          <description>Vital Sign measurements included systolic blood pressure (SBP), diastolic blood presssure (DBP), pulse, temperature, orthostatic SBP, orthostatic DBP and orthostatic pulse.</description>
          <population>SAS included all randomized participants who received at least 1 dose of study drug.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="6"/>
                <count group_id="O9" value="6"/>
                <count group_id="O10" value="6"/>
                <count group_id="O11" value="6"/>
                <count group_id="O12" value="6"/>
                <count group_id="O13" value="6"/>
                <count group_id="O14" value="6"/>
                <count group_id="O15" value="6"/>
                <count group_id="O16" value="3"/>
                <count group_id="O17" value="5"/>
                <count group_id="O18" value="5"/>
                <count group_id="O19" value="5"/>
                <count group_id="O20" value="12"/>
                <count group_id="O21" value="12"/>
                <count group_id="O22" value="12"/>
                <count group_id="O23" value="6"/>
                <count group_id="O24" value="6"/>
                <count group_id="O25" value="9"/>
                <count group_id="O26" value="9"/>
                <count group_id="O27" value="5"/>
                <count group_id="O28" value="6"/>
                <count group_id="O29" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Systolic Blood Pressure (SBP), Supine, &lt;85 mmHg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="16.7"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="0"/>
                    <measurement group_id="O13" value="0"/>
                    <measurement group_id="O14" value="0"/>
                    <measurement group_id="O15" value="0"/>
                    <measurement group_id="O16" value="0"/>
                    <measurement group_id="O17" value="0"/>
                    <measurement group_id="O18" value="0"/>
                    <measurement group_id="O19" value="0"/>
                    <measurement group_id="O20" value="0"/>
                    <measurement group_id="O21" value="0"/>
                    <measurement group_id="O22" value="0"/>
                    <measurement group_id="O23" value="0"/>
                    <measurement group_id="O24" value="0"/>
                    <measurement group_id="O25" value="0"/>
                    <measurement group_id="O26" value="0"/>
                    <measurement group_id="O27" value="0"/>
                    <measurement group_id="O28" value="0"/>
                    <measurement group_id="O29" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP, Supine, &gt;180 mmHg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="0"/>
                    <measurement group_id="O13" value="0"/>
                    <measurement group_id="O14" value="0"/>
                    <measurement group_id="O15" value="0"/>
                    <measurement group_id="O16" value="0"/>
                    <measurement group_id="O17" value="0"/>
                    <measurement group_id="O18" value="0"/>
                    <measurement group_id="O19" value="0"/>
                    <measurement group_id="O20" value="0"/>
                    <measurement group_id="O21" value="0"/>
                    <measurement group_id="O22" value="0"/>
                    <measurement group_id="O23" value="0"/>
                    <measurement group_id="O24" value="0"/>
                    <measurement group_id="O25" value="0"/>
                    <measurement group_id="O26" value="0"/>
                    <measurement group_id="O27" value="0"/>
                    <measurement group_id="O28" value="0"/>
                    <measurement group_id="O29" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP, 5 minutes (min) Supine, &lt;85 mmHg,</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="16.7"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="0"/>
                    <measurement group_id="O13" value="0"/>
                    <measurement group_id="O14" value="16.7"/>
                    <measurement group_id="O15" value="0"/>
                    <measurement group_id="O16" value="0"/>
                    <measurement group_id="O17" value="0"/>
                    <measurement group_id="O18" value="0"/>
                    <measurement group_id="O19" value="0"/>
                    <measurement group_id="O20" value="0"/>
                    <measurement group_id="O21" value="0"/>
                    <measurement group_id="O22" value="8.3"/>
                    <measurement group_id="O23" value="0"/>
                    <measurement group_id="O24" value="0"/>
                    <measurement group_id="O25" value="0"/>
                    <measurement group_id="O26" value="0"/>
                    <measurement group_id="O27" value="0"/>
                    <measurement group_id="O28" value="0"/>
                    <measurement group_id="O29" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP, 5 min Supine, &gt;180 mmHg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="0"/>
                    <measurement group_id="O13" value="0"/>
                    <measurement group_id="O14" value="0"/>
                    <measurement group_id="O15" value="0"/>
                    <measurement group_id="O16" value="0"/>
                    <measurement group_id="O17" value="0"/>
                    <measurement group_id="O18" value="0"/>
                    <measurement group_id="O19" value="0"/>
                    <measurement group_id="O20" value="0"/>
                    <measurement group_id="O21" value="0"/>
                    <measurement group_id="O22" value="0"/>
                    <measurement group_id="O23" value="0"/>
                    <measurement group_id="O24" value="0"/>
                    <measurement group_id="O25" value="0"/>
                    <measurement group_id="O26" value="0"/>
                    <measurement group_id="O27" value="0"/>
                    <measurement group_id="O28" value="0"/>
                    <measurement group_id="O29" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP, 1 min Standing, &lt;85 mmHg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="16.7"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="16.7"/>
                    <measurement group_id="O10" value="16.7"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="0"/>
                    <measurement group_id="O13" value="16.7"/>
                    <measurement group_id="O14" value="0"/>
                    <measurement group_id="O15" value="0"/>
                    <measurement group_id="O16" value="0"/>
                    <measurement group_id="O17" value="0"/>
                    <measurement group_id="O18" value="0"/>
                    <measurement group_id="O19" value="20.0"/>
                    <measurement group_id="O20" value="8.3"/>
                    <measurement group_id="O21" value="8.3"/>
                    <measurement group_id="O22" value="0"/>
                    <measurement group_id="O23" value="16.7"/>
                    <measurement group_id="O24" value="0"/>
                    <measurement group_id="O25" value="0"/>
                    <measurement group_id="O26" value="11.1"/>
                    <measurement group_id="O27" value="0"/>
                    <measurement group_id="O28" value="0"/>
                    <measurement group_id="O29" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP, 1 min Standing, &gt;180 mmHg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="0"/>
                    <measurement group_id="O13" value="0"/>
                    <measurement group_id="O14" value="0"/>
                    <measurement group_id="O15" value="0"/>
                    <measurement group_id="O16" value="0"/>
                    <measurement group_id="O17" value="0"/>
                    <measurement group_id="O18" value="0"/>
                    <measurement group_id="O19" value="0"/>
                    <measurement group_id="O20" value="0"/>
                    <measurement group_id="O21" value="0"/>
                    <measurement group_id="O22" value="0"/>
                    <measurement group_id="O23" value="0"/>
                    <measurement group_id="O24" value="0"/>
                    <measurement group_id="O25" value="0"/>
                    <measurement group_id="O26" value="0"/>
                    <measurement group_id="O27" value="0"/>
                    <measurement group_id="O28" value="0"/>
                    <measurement group_id="O29" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP, 3 min Standing, &lt;85 mmHg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="16.7"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="16.7"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="0"/>
                    <measurement group_id="O13" value="16.7"/>
                    <measurement group_id="O14" value="33.3"/>
                    <measurement group_id="O15" value="0"/>
                    <measurement group_id="O16" value="0"/>
                    <measurement group_id="O17" value="0"/>
                    <measurement group_id="O18" value="0"/>
                    <measurement group_id="O19" value="20.0"/>
                    <measurement group_id="O20" value="8.3"/>
                    <measurement group_id="O21" value="8.3"/>
                    <measurement group_id="O22" value="0"/>
                    <measurement group_id="O23" value="0"/>
                    <measurement group_id="O24" value="16.7"/>
                    <measurement group_id="O25" value="0"/>
                    <measurement group_id="O26" value="11.1"/>
                    <measurement group_id="O27" value="0"/>
                    <measurement group_id="O28" value="0"/>
                    <measurement group_id="O29" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP, 3 min Standing, &gt;180 mmHg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="0"/>
                    <measurement group_id="O13" value="0"/>
                    <measurement group_id="O14" value="0"/>
                    <measurement group_id="O15" value="0"/>
                    <measurement group_id="O16" value="0"/>
                    <measurement group_id="O17" value="0"/>
                    <measurement group_id="O18" value="0"/>
                    <measurement group_id="O19" value="0"/>
                    <measurement group_id="O20" value="0"/>
                    <measurement group_id="O21" value="0"/>
                    <measurement group_id="O22" value="0"/>
                    <measurement group_id="O23" value="0"/>
                    <measurement group_id="O24" value="0"/>
                    <measurement group_id="O25" value="0"/>
                    <measurement group_id="O26" value="0"/>
                    <measurement group_id="O27" value="0"/>
                    <measurement group_id="O28" value="0"/>
                    <measurement group_id="O29" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diastolic Blood Pressure (DBP), Supine, &lt;50 mmHg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="16.7"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="0"/>
                    <measurement group_id="O13" value="0"/>
                    <measurement group_id="O14" value="0"/>
                    <measurement group_id="O15" value="0"/>
                    <measurement group_id="O16" value="0"/>
                    <measurement group_id="O17" value="0"/>
                    <measurement group_id="O18" value="0"/>
                    <measurement group_id="O19" value="0"/>
                    <measurement group_id="O20" value="0"/>
                    <measurement group_id="O21" value="0"/>
                    <measurement group_id="O22" value="0"/>
                    <measurement group_id="O23" value="0"/>
                    <measurement group_id="O24" value="0"/>
                    <measurement group_id="O25" value="0"/>
                    <measurement group_id="O26" value="0"/>
                    <measurement group_id="O27" value="0"/>
                    <measurement group_id="O28" value="0"/>
                    <measurement group_id="O29" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP, Supine, &gt;110 mmHg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="0"/>
                    <measurement group_id="O13" value="0"/>
                    <measurement group_id="O14" value="0"/>
                    <measurement group_id="O15" value="0"/>
                    <measurement group_id="O16" value="0"/>
                    <measurement group_id="O17" value="0"/>
                    <measurement group_id="O18" value="0"/>
                    <measurement group_id="O19" value="0"/>
                    <measurement group_id="O20" value="0"/>
                    <measurement group_id="O21" value="0"/>
                    <measurement group_id="O22" value="0"/>
                    <measurement group_id="O23" value="0"/>
                    <measurement group_id="O24" value="0"/>
                    <measurement group_id="O25" value="0"/>
                    <measurement group_id="O26" value="0"/>
                    <measurement group_id="O27" value="0"/>
                    <measurement group_id="O28" value="0"/>
                    <measurement group_id="O29" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP, 5 min supine, &lt;50 mmHg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="16.7"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="0"/>
                    <measurement group_id="O13" value="0"/>
                    <measurement group_id="O14" value="0"/>
                    <measurement group_id="O15" value="0"/>
                    <measurement group_id="O16" value="0"/>
                    <measurement group_id="O17" value="0"/>
                    <measurement group_id="O18" value="0"/>
                    <measurement group_id="O19" value="0"/>
                    <measurement group_id="O20" value="0"/>
                    <measurement group_id="O21" value="8.3"/>
                    <measurement group_id="O22" value="0"/>
                    <measurement group_id="O23" value="0"/>
                    <measurement group_id="O24" value="0"/>
                    <measurement group_id="O25" value="0"/>
                    <measurement group_id="O26" value="11.1"/>
                    <measurement group_id="O27" value="0"/>
                    <measurement group_id="O28" value="0"/>
                    <measurement group_id="O29" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP, 5 min Supine, &gt;110 mmHg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="0"/>
                    <measurement group_id="O13" value="0"/>
                    <measurement group_id="O14" value="0"/>
                    <measurement group_id="O15" value="0"/>
                    <measurement group_id="O16" value="0"/>
                    <measurement group_id="O17" value="0"/>
                    <measurement group_id="O18" value="0"/>
                    <measurement group_id="O19" value="0"/>
                    <measurement group_id="O20" value="0"/>
                    <measurement group_id="O21" value="0"/>
                    <measurement group_id="O22" value="0"/>
                    <measurement group_id="O23" value="0"/>
                    <measurement group_id="O24" value="0"/>
                    <measurement group_id="O25" value="0"/>
                    <measurement group_id="O26" value="0"/>
                    <measurement group_id="O27" value="0"/>
                    <measurement group_id="O28" value="0"/>
                    <measurement group_id="O29" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP, 1 min Standing, &lt;50 mmHg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="0"/>
                    <measurement group_id="O13" value="16.7"/>
                    <measurement group_id="O14" value="0"/>
                    <measurement group_id="O15" value="0"/>
                    <measurement group_id="O16" value="0"/>
                    <measurement group_id="O17" value="0"/>
                    <measurement group_id="O18" value="0"/>
                    <measurement group_id="O19" value="0"/>
                    <measurement group_id="O20" value="8.3"/>
                    <measurement group_id="O21" value="8.3"/>
                    <measurement group_id="O22" value="0"/>
                    <measurement group_id="O23" value="0"/>
                    <measurement group_id="O24" value="0"/>
                    <measurement group_id="O25" value="0"/>
                    <measurement group_id="O26" value="0"/>
                    <measurement group_id="O27" value="0"/>
                    <measurement group_id="O28" value="0"/>
                    <measurement group_id="O29" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP, 1 min Standing, &gt;110 mmHg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="0"/>
                    <measurement group_id="O13" value="0"/>
                    <measurement group_id="O14" value="0"/>
                    <measurement group_id="O15" value="16.7"/>
                    <measurement group_id="O16" value="0"/>
                    <measurement group_id="O17" value="0"/>
                    <measurement group_id="O18" value="0"/>
                    <measurement group_id="O19" value="20.0"/>
                    <measurement group_id="O20" value="0"/>
                    <measurement group_id="O21" value="0"/>
                    <measurement group_id="O22" value="0"/>
                    <measurement group_id="O23" value="0"/>
                    <measurement group_id="O24" value="0"/>
                    <measurement group_id="O25" value="0"/>
                    <measurement group_id="O26" value="0"/>
                    <measurement group_id="O27" value="0"/>
                    <measurement group_id="O28" value="0"/>
                    <measurement group_id="O29" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP, 3 min Standing, &lt;50 mmHg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="0"/>
                    <measurement group_id="O13" value="0"/>
                    <measurement group_id="O14" value="16.7"/>
                    <measurement group_id="O15" value="0"/>
                    <measurement group_id="O16" value="0"/>
                    <measurement group_id="O17" value="0"/>
                    <measurement group_id="O18" value="0"/>
                    <measurement group_id="O19" value="0"/>
                    <measurement group_id="O20" value="0"/>
                    <measurement group_id="O21" value="0"/>
                    <measurement group_id="O22" value="0"/>
                    <measurement group_id="O23" value="0"/>
                    <measurement group_id="O24" value="0"/>
                    <measurement group_id="O25" value="0"/>
                    <measurement group_id="O26" value="11.1"/>
                    <measurement group_id="O27" value="0"/>
                    <measurement group_id="O28" value="0"/>
                    <measurement group_id="O29" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP, 3 min Standing, &gt;110 mmHg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="0"/>
                    <measurement group_id="O13" value="0"/>
                    <measurement group_id="O14" value="0"/>
                    <measurement group_id="O15" value="16.7"/>
                    <measurement group_id="O16" value="0"/>
                    <measurement group_id="O17" value="0"/>
                    <measurement group_id="O18" value="20.0"/>
                    <measurement group_id="O19" value="0"/>
                    <measurement group_id="O20" value="0"/>
                    <measurement group_id="O21" value="0"/>
                    <measurement group_id="O22" value="0"/>
                    <measurement group_id="O23" value="0"/>
                    <measurement group_id="O24" value="0"/>
                    <measurement group_id="O25" value="0"/>
                    <measurement group_id="O26" value="0"/>
                    <measurement group_id="O27" value="0"/>
                    <measurement group_id="O28" value="0"/>
                    <measurement group_id="O29" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pulse, Supine, &lt;50 beats/min (bpm)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.3"/>
                    <measurement group_id="O2" value="33.3"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="16.7"/>
                    <measurement group_id="O7" value="16.7"/>
                    <measurement group_id="O8" value="16.7"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="16.7"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="0"/>
                    <measurement group_id="O13" value="33.3"/>
                    <measurement group_id="O14" value="50.0"/>
                    <measurement group_id="O15" value="50.0"/>
                    <measurement group_id="O16" value="0"/>
                    <measurement group_id="O17" value="0"/>
                    <measurement group_id="O18" value="0"/>
                    <measurement group_id="O19" value="0"/>
                    <measurement group_id="O20" value="16.7"/>
                    <measurement group_id="O21" value="16.7"/>
                    <measurement group_id="O22" value="0"/>
                    <measurement group_id="O23" value="0"/>
                    <measurement group_id="O24" value="0"/>
                    <measurement group_id="O25" value="0"/>
                    <measurement group_id="O26" value="0"/>
                    <measurement group_id="O27" value="0"/>
                    <measurement group_id="O28" value="0"/>
                    <measurement group_id="O29" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pulse, Supine, &gt;120 beats/min</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.3"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="0"/>
                    <measurement group_id="O13" value="0"/>
                    <measurement group_id="O14" value="0"/>
                    <measurement group_id="O15" value="0"/>
                    <measurement group_id="O16" value="0"/>
                    <measurement group_id="O17" value="0"/>
                    <measurement group_id="O18" value="0"/>
                    <measurement group_id="O19" value="0"/>
                    <measurement group_id="O20" value="0"/>
                    <measurement group_id="O21" value="0"/>
                    <measurement group_id="O22" value="0"/>
                    <measurement group_id="O23" value="0"/>
                    <measurement group_id="O24" value="0"/>
                    <measurement group_id="O25" value="0"/>
                    <measurement group_id="O26" value="0"/>
                    <measurement group_id="O27" value="0"/>
                    <measurement group_id="O28" value="0"/>
                    <measurement group_id="O29" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pulse, 5 min Supine, &lt;50 beats/min</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="16.7"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="33.3"/>
                    <measurement group_id="O6" value="16.7"/>
                    <measurement group_id="O7" value="16.7"/>
                    <measurement group_id="O8" value="33.3"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="33.3"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="16.7"/>
                    <measurement group_id="O13" value="33.3"/>
                    <measurement group_id="O14" value="16.7"/>
                    <measurement group_id="O15" value="16.7"/>
                    <measurement group_id="O16" value="33.3"/>
                    <measurement group_id="O17" value="60.0"/>
                    <measurement group_id="O18" value="40.0"/>
                    <measurement group_id="O19" value="20.0"/>
                    <measurement group_id="O20" value="33.3"/>
                    <measurement group_id="O21" value="41.7"/>
                    <measurement group_id="O22" value="25.0"/>
                    <measurement group_id="O23" value="66.7"/>
                    <measurement group_id="O24" value="0"/>
                    <measurement group_id="O25" value="44.4"/>
                    <measurement group_id="O26" value="22.2"/>
                    <measurement group_id="O27" value="40.0"/>
                    <measurement group_id="O28" value="33.3"/>
                    <measurement group_id="O29" value="16.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pulse, 5 min Supine, &gt;120 beats/min</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="0"/>
                    <measurement group_id="O13" value="0"/>
                    <measurement group_id="O14" value="0"/>
                    <measurement group_id="O15" value="0"/>
                    <measurement group_id="O16" value="0"/>
                    <measurement group_id="O17" value="0"/>
                    <measurement group_id="O18" value="0"/>
                    <measurement group_id="O19" value="20.0"/>
                    <measurement group_id="O20" value="0"/>
                    <measurement group_id="O21" value="0"/>
                    <measurement group_id="O22" value="0"/>
                    <measurement group_id="O23" value="0"/>
                    <measurement group_id="O24" value="0"/>
                    <measurement group_id="O25" value="0"/>
                    <measurement group_id="O26" value="0"/>
                    <measurement group_id="O27" value="0"/>
                    <measurement group_id="O28" value="0"/>
                    <measurement group_id="O29" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pulse, 1 min Standing, &lt;50 beats/min</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="16.7"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="0"/>
                    <measurement group_id="O13" value="0"/>
                    <measurement group_id="O14" value="0"/>
                    <measurement group_id="O15" value="0"/>
                    <measurement group_id="O16" value="0"/>
                    <measurement group_id="O17" value="0"/>
                    <measurement group_id="O18" value="20.0"/>
                    <measurement group_id="O19" value="0"/>
                    <measurement group_id="O20" value="0"/>
                    <measurement group_id="O21" value="0"/>
                    <measurement group_id="O22" value="0"/>
                    <measurement group_id="O23" value="0"/>
                    <measurement group_id="O24" value="0"/>
                    <measurement group_id="O25" value="0"/>
                    <measurement group_id="O26" value="0"/>
                    <measurement group_id="O27" value="0"/>
                    <measurement group_id="O28" value="0"/>
                    <measurement group_id="O29" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pulse, 1 min Standing, &gt;120 beats/min</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.3"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="16.7"/>
                    <measurement group_id="O13" value="16.7"/>
                    <measurement group_id="O14" value="0"/>
                    <measurement group_id="O15" value="0"/>
                    <measurement group_id="O16" value="0"/>
                    <measurement group_id="O17" value="0"/>
                    <measurement group_id="O18" value="20.0"/>
                    <measurement group_id="O19" value="40.0"/>
                    <measurement group_id="O20" value="0"/>
                    <measurement group_id="O21" value="0"/>
                    <measurement group_id="O22" value="0"/>
                    <measurement group_id="O23" value="0"/>
                    <measurement group_id="O24" value="16.7"/>
                    <measurement group_id="O25" value="11.1"/>
                    <measurement group_id="O26" value="0"/>
                    <measurement group_id="O27" value="20.0"/>
                    <measurement group_id="O28" value="0"/>
                    <measurement group_id="O29" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pulse, 3 min Standing, &lt;50 beats/min</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="0"/>
                    <measurement group_id="O13" value="0"/>
                    <measurement group_id="O14" value="0"/>
                    <measurement group_id="O15" value="0"/>
                    <measurement group_id="O16" value="0"/>
                    <measurement group_id="O17" value="0"/>
                    <measurement group_id="O18" value="20.0"/>
                    <measurement group_id="O19" value="0"/>
                    <measurement group_id="O20" value="0"/>
                    <measurement group_id="O21" value="0"/>
                    <measurement group_id="O22" value="0"/>
                    <measurement group_id="O23" value="0"/>
                    <measurement group_id="O24" value="0"/>
                    <measurement group_id="O25" value="0"/>
                    <measurement group_id="O26" value="0"/>
                    <measurement group_id="O27" value="0"/>
                    <measurement group_id="O28" value="0"/>
                    <measurement group_id="O29" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pulse, 3 min Standing, &gt;120 beats/min</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="0"/>
                    <measurement group_id="O13" value="16.7"/>
                    <measurement group_id="O14" value="0"/>
                    <measurement group_id="O15" value="0"/>
                    <measurement group_id="O16" value="0"/>
                    <measurement group_id="O17" value="0"/>
                    <measurement group_id="O18" value="0"/>
                    <measurement group_id="O19" value="40.0"/>
                    <measurement group_id="O20" value="0"/>
                    <measurement group_id="O21" value="0"/>
                    <measurement group_id="O22" value="0"/>
                    <measurement group_id="O23" value="0"/>
                    <measurement group_id="O24" value="0"/>
                    <measurement group_id="O25" value="0"/>
                    <measurement group_id="O26" value="0"/>
                    <measurement group_id="O27" value="20.0"/>
                    <measurement group_id="O28" value="0"/>
                    <measurement group_id="O29" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Temperature, &lt;35.6 Celsius (C)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="16.7"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="33.3"/>
                    <measurement group_id="O8" value="50.0"/>
                    <measurement group_id="O9" value="16.7"/>
                    <measurement group_id="O10" value="33.3"/>
                    <measurement group_id="O11" value="16.7"/>
                    <measurement group_id="O12" value="16.7"/>
                    <measurement group_id="O13" value="33.3"/>
                    <measurement group_id="O14" value="0"/>
                    <measurement group_id="O15" value="33.3"/>
                    <measurement group_id="O16" value="66.7"/>
                    <measurement group_id="O17" value="40.0"/>
                    <measurement group_id="O18" value="20.0"/>
                    <measurement group_id="O19" value="60.0"/>
                    <measurement group_id="O20" value="25.0"/>
                    <measurement group_id="O21" value="0"/>
                    <measurement group_id="O22" value="8.3"/>
                    <measurement group_id="O23" value="0"/>
                    <measurement group_id="O24" value="0"/>
                    <measurement group_id="O25" value="0"/>
                    <measurement group_id="O26" value="0"/>
                    <measurement group_id="O27" value="40.0"/>
                    <measurement group_id="O28" value="0"/>
                    <measurement group_id="O29" value="16.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Temperature, &gt;37.7 C</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="0"/>
                    <measurement group_id="O13" value="0"/>
                    <measurement group_id="O14" value="0"/>
                    <measurement group_id="O15" value="0"/>
                    <measurement group_id="O16" value="0"/>
                    <measurement group_id="O17" value="0"/>
                    <measurement group_id="O18" value="20.0"/>
                    <measurement group_id="O19" value="0"/>
                    <measurement group_id="O20" value="0"/>
                    <measurement group_id="O21" value="0"/>
                    <measurement group_id="O22" value="0"/>
                    <measurement group_id="O23" value="0"/>
                    <measurement group_id="O24" value="0"/>
                    <measurement group_id="O25" value="0"/>
                    <measurement group_id="O26" value="0"/>
                    <measurement group_id="O27" value="0"/>
                    <measurement group_id="O28" value="0"/>
                    <measurement group_id="O29" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Orthostatic SBP, 1 min Standing-Supine, &lt;=-20 mmHg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.5"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="16.7"/>
                    <measurement group_id="O6" value="16.7"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="16.7"/>
                    <measurement group_id="O9" value="16.7"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="50.0"/>
                    <measurement group_id="O13" value="50.0"/>
                    <measurement group_id="O14" value="50.0"/>
                    <measurement group_id="O15" value="16.7"/>
                    <measurement group_id="O16" value="0"/>
                    <measurement group_id="O17" value="20.0"/>
                    <measurement group_id="O18" value="40.0"/>
                    <measurement group_id="O19" value="60.0"/>
                    <measurement group_id="O20" value="16.7"/>
                    <measurement group_id="O21" value="0"/>
                    <measurement group_id="O22" value="8.3"/>
                    <measurement group_id="O23" value="33.3"/>
                    <measurement group_id="O24" value="16.7"/>
                    <measurement group_id="O25" value="22.2"/>
                    <measurement group_id="O26" value="0"/>
                    <measurement group_id="O27" value="40.0"/>
                    <measurement group_id="O28" value="0"/>
                    <measurement group_id="O29" value="16.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Orthostatic SBP, 3 min Standing-Supine, &lt;=-20 mmHg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.3"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="33.3"/>
                    <measurement group_id="O8" value="16.7"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="33.3"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="16.7"/>
                    <measurement group_id="O13" value="33.3"/>
                    <measurement group_id="O14" value="50.0"/>
                    <measurement group_id="O15" value="0"/>
                    <measurement group_id="O16" value="0"/>
                    <measurement group_id="O17" value="20.0"/>
                    <measurement group_id="O18" value="40.0"/>
                    <measurement group_id="O19" value="40.0"/>
                    <measurement group_id="O20" value="16.7"/>
                    <measurement group_id="O21" value="8.3"/>
                    <measurement group_id="O22" value="0"/>
                    <measurement group_id="O23" value="16.7"/>
                    <measurement group_id="O24" value="16.7"/>
                    <measurement group_id="O25" value="0"/>
                    <measurement group_id="O26" value="0"/>
                    <measurement group_id="O27" value="40.0"/>
                    <measurement group_id="O28" value="16.7"/>
                    <measurement group_id="O29" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Orthostatic DBP, 1 min Standing-Supine, &lt;=-10 mmHg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="16.7"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="0"/>
                    <measurement group_id="O13" value="16.7"/>
                    <measurement group_id="O14" value="0"/>
                    <measurement group_id="O15" value="16.7"/>
                    <measurement group_id="O16" value="0"/>
                    <measurement group_id="O17" value="0"/>
                    <measurement group_id="O18" value="0"/>
                    <measurement group_id="O19" value="20.0"/>
                    <measurement group_id="O20" value="8.3"/>
                    <measurement group_id="O21" value="0"/>
                    <measurement group_id="O22" value="0"/>
                    <measurement group_id="O23" value="16.7"/>
                    <measurement group_id="O24" value="0"/>
                    <measurement group_id="O25" value="0"/>
                    <measurement group_id="O26" value="0"/>
                    <measurement group_id="O27" value="20.0"/>
                    <measurement group_id="O28" value="0"/>
                    <measurement group_id="O29" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Orthostatic DBP, 3 min Standing-Supine, &lt;=-10 mmHg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="16.7"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="0"/>
                    <measurement group_id="O13" value="16.7"/>
                    <measurement group_id="O14" value="33.3"/>
                    <measurement group_id="O15" value="0"/>
                    <measurement group_id="O16" value="0"/>
                    <measurement group_id="O17" value="0"/>
                    <measurement group_id="O18" value="20.0"/>
                    <measurement group_id="O19" value="20.0"/>
                    <measurement group_id="O20" value="8.3"/>
                    <measurement group_id="O21" value="0"/>
                    <measurement group_id="O22" value="0"/>
                    <measurement group_id="O23" value="16.7"/>
                    <measurement group_id="O24" value="0"/>
                    <measurement group_id="O25" value="0"/>
                    <measurement group_id="O26" value="0"/>
                    <measurement group_id="O27" value="0"/>
                    <measurement group_id="O28" value="0"/>
                    <measurement group_id="O29" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Orthostatic Pulse, 1 min Standing-Supine &gt;10 bpm</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="100"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="100"/>
                    <measurement group_id="O6" value="100"/>
                    <measurement group_id="O7" value="100"/>
                    <measurement group_id="O8" value="66.7"/>
                    <measurement group_id="O9" value="100"/>
                    <measurement group_id="O10" value="100"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="100"/>
                    <measurement group_id="O13" value="100"/>
                    <measurement group_id="O14" value="100"/>
                    <measurement group_id="O15" value="100"/>
                    <measurement group_id="O16" value="100"/>
                    <measurement group_id="O17" value="100"/>
                    <measurement group_id="O18" value="100"/>
                    <measurement group_id="O19" value="100"/>
                    <measurement group_id="O20" value="100"/>
                    <measurement group_id="O21" value="100"/>
                    <measurement group_id="O22" value="100"/>
                    <measurement group_id="O23" value="100"/>
                    <measurement group_id="O24" value="100"/>
                    <measurement group_id="O25" value="88.9"/>
                    <measurement group_id="O26" value="100"/>
                    <measurement group_id="O27" value="100"/>
                    <measurement group_id="O28" value="100"/>
                    <measurement group_id="O29" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Orthostatic Pulse, 3 min Standing-Supine &gt;10 bpm</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="100"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="100"/>
                    <measurement group_id="O6" value="100"/>
                    <measurement group_id="O7" value="100"/>
                    <measurement group_id="O8" value="66.7"/>
                    <measurement group_id="O9" value="100"/>
                    <measurement group_id="O10" value="100"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="100"/>
                    <measurement group_id="O13" value="100"/>
                    <measurement group_id="O14" value="100"/>
                    <measurement group_id="O15" value="100"/>
                    <measurement group_id="O16" value="100"/>
                    <measurement group_id="O17" value="100"/>
                    <measurement group_id="O18" value="100"/>
                    <measurement group_id="O19" value="100"/>
                    <measurement group_id="O20" value="100"/>
                    <measurement group_id="O21" value="100"/>
                    <measurement group_id="O22" value="100"/>
                    <measurement group_id="O23" value="100"/>
                    <measurement group_id="O24" value="100"/>
                    <measurement group_id="O25" value="88.9"/>
                    <measurement group_id="O26" value="100"/>
                    <measurement group_id="O27" value="100"/>
                    <measurement group_id="O28" value="100"/>
                    <measurement group_id="O29" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Who Meet the Markedly Abnormal Criteria for 12-lead Electrocardiogram (ECG) Parameters at Least Once Post-dose</title>
        <description>A standard 12-lead electrocardiogram (ECG) was performed. The percentage of participants with markedly abnormal ECG findings during the study.</description>
        <time_frame>Day 1 up to Day 41</time_frame>
        <population>SAS included all randomized participants who received at least 1 dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>SRD: Placebo Cohorts 1-6, 18 and 19</title>
            <description>TAK-071 placebo-matching capsules, orally, once on Day 1 to non-Japanese healthy participants in the single-rising dose (SRD) period.</description>
          </group>
          <group group_id="O2">
            <title>SRD: Cohort 1: TAK-071 1 mg</title>
            <description>TAK-071 1 mg, capsule, orally, once on Day 1 to non-Japanese healthy participants.</description>
          </group>
          <group group_id="O3">
            <title>SRD: Cohort 2: TAK-071 3 mg</title>
            <description>TAK-071 3 mg capsule, orally, once on Day 1 to non-Japanese healthy participants. Dose of TAK-071 was based on the 24-hour post-dose safety, tolerability and pharmacokinetic (PK) data from cohort 1.</description>
          </group>
          <group group_id="O4">
            <title>SRD: Cohort 3: TAK-071 9 mg</title>
            <description>TAK-071 9 mg capsule, orally, once on Day 1 to non-Japanese healthy participants. Dose of TAK-071 was based on 24-hour safety, tolerability, and preliminary plasma PK and 12-hour CSF PK data.</description>
          </group>
          <group group_id="O5">
            <title>SRD: Cohort 4: TAK-071 20 mg</title>
            <description>TAK-071 20 mg capsule, orally, once on Day 1 to non-Japanese healthy participants. Dose of TAK-071 was based on the 24-hour post-dose safety and tolerability data from previous cohort.</description>
          </group>
          <group group_id="O6">
            <title>SRD: Cohort 5: TAK-071 40 mg</title>
            <description>TAK-071 40 mg capsule, orally, once on Day 1 to non-Japanese healthy participants. Dose of TAK-071 will be based on 24-hour safety, tolerability, and preliminary plasma PK data from Cohort 4.</description>
          </group>
          <group group_id="O7">
            <title>SRD: Cohort 6: TAK-071 80 mg</title>
            <description>TAK-071 80 mg capsules, orally, once on Day 1 to non-Japanese healthy participants. Dose of TAK-071 was based on 24-hour safety, tolerability, and preliminary plasma PK data from Cohort 5</description>
          </group>
          <group group_id="O8">
            <title>MRD: Placebo Cohorts 7-9</title>
            <description>TAK-071 placebo-matching capsule, orally, once on Day 1 to non-Japanese healthy participants in the multiple-rising dose (MRD) period.</description>
          </group>
          <group group_id="O9">
            <title>MRD: Cohort 7: TAK-071 3 mg</title>
            <description>TAK-071 3 mg capsules, orally, once daily from Day 1 up to Day 21 to non-Japanese healthy participants. Dose of TAK-071 was based on 24-hour safety and tolerability from Cohort 4 and the 24-hour preliminary plasma PK and 12-hour CSF PK data from Cohort 3.</description>
          </group>
          <group group_id="O10">
            <title>MRD: Cohort 8: TAK-071 9 mg</title>
            <description>TAK-071 9 mg capsules, orally, once daily from Day 1 up to Day 21 to non-Japanese healthy participants. Dose of TAK-071 was based on safety, tolerability and available PK data arising from the ongoing SRD part and previous MRD cohort.</description>
          </group>
          <group group_id="O11">
            <title>MRD: Cohort 9: TAK-071 15 mg</title>
            <description>TAK-071 15 mg capsule, orally, once on Day 1, followed by a washout period of 7 days, then TAK-071 once daily for 21 days to non-Japanese healthy participants. Dose of TAK-071 will be based on safety, tolerability and available PK data arising from the ongoing SRD part and previous MRD cohort.</description>
          </group>
          <group group_id="O12">
            <title>MRD: TAK-071 Placebo Cohorts 10-12+Donepezil</title>
            <description>TAK-071 placebo-matching capsule, orally, once daily along with donepezil 5 mg, tablets, orally, once daily from Day 1 up to Day 21 to non-Japanese healthy participants who were pre-treated with donepezil 5 mg, tablet, once daily for 3 weeks prior to administration of TAK-071.</description>
          </group>
          <group group_id="O13">
            <title>MRD: Cohort 10: TAK-071 3 mg+Donepezil 5 mg</title>
            <description>TAK-071 3 mg capsules, orally, once daily along with donepezil 5 mg, tablets, orally, once daily from Day 1 up to Day 21 to non-Japanese healthy participants who were pre-treated with donepezil 5 mg, tablet, once daily for 3 weeks prior to administration of TAK-071. Dose of TAK-071 was same as the dose used in MRD Cohort 7.</description>
          </group>
          <group group_id="O14">
            <title>MRD: Cohort 11: TAK-071 9 mg + Donepezil 5 mg</title>
            <description>TAK-071 9 mg capsules, orally, once daily along with donepezil 5 mg, tablets, orally, once daily from Day 1 up to Day 21 to non-Japanese healthy participants who were pre-treated with donepezil 5 mg, tablet, once daily for 3 weeks prior to administration of TAK-071. Dose of TAK-071 was same as the dose used in MRD Cohort 8.</description>
          </group>
          <group group_id="O15">
            <title>MRD: Cohort 12: TAK-071 15 mg+Donepezil 5 mg</title>
            <description>TAK-071 15 mg capsule, orally, once daily along with donepezil 5 mg, tablets, orally, once daily from Day 1 up to Day 21 to non-Japanese healthy participants who were pre-treated with donepezil 5 mg, tablet, once daily for 3 weeks prior to administration of TAK-071. Dose of TAK-071 was same as the dose used in MRD Cohort 9.</description>
          </group>
          <group group_id="O16">
            <title>MRD: Placebo Cohorts 13-15</title>
            <description>TAK-071 placebo-matching capsule, orally, once on Day 1 to Japanese healthy participants.</description>
          </group>
          <group group_id="O17">
            <title>MRD: Cohort 13: TAK-071 3 mg</title>
            <description>TAK-071 3 mg capsule, orally, once on Day 1, followed by a washout period of 7 days, then TAK-071 once daily for 21 days to Japanese healthy participants. Dose of TAK-071 was same as the dose used in MRD Cohort 7.</description>
          </group>
          <group group_id="O18">
            <title>MRD: Cohort 14: TAK-071 9 mg</title>
            <description>TAK-071 9 mg capsule or matching placebo, orally, once on Day 1, followed by a washout period of 7 days, then TAK-071 once daily for 21 days to Japanese healthy participants. Dose of TAK-071 was same as the dose used in MRD Cohort 8.</description>
          </group>
          <group group_id="O19">
            <title>MRD: Cohort 15: TAK-071 15 mg</title>
            <description>TAK-071 15 mg capsule, orally, once on Day 1, followed by a washout period of 7 days, then TAK-071 once daily for 21 days to Japanese healthy participants. Dose of TAK-071 was same as the dose used in MRD Cohort 9.</description>
          </group>
          <group group_id="O20">
            <title>Bioavailability (BA)/Food Effect: Cohort 17 Regimen A</title>
            <description>TAK-071 10 mg capsule, orally once on Day 1 in the fasted state in Period 1 or Period 2 or Period 3</description>
          </group>
          <group group_id="O21">
            <title>BA/Food Effect: Cohort 17 Regimen B</title>
            <description>TAK-071 10 mg tablet, orally, once on Day 1 in the fasted state in Period 1 or Period 2 or Period 3</description>
          </group>
          <group group_id="O22">
            <title>BA/Food Effect: Cohort 17 Regimen C</title>
            <description>TAK-071 10 mg tablet, orally, once on Day 1 in the fed state in Period 1 or Period 2 or Period 3</description>
          </group>
          <group group_id="O23">
            <title>SRD: Cohort 18: TAK-071 120 mg</title>
            <description>TAK-071 120 mg capsule, orally, once on Day 1 to non-Japanese healthy participants. Dose of TAK-071 was based on 24-hour safety, tolerability, and preliminary plasma PK data from Cohort 6.</description>
          </group>
          <group group_id="O24">
            <title>SRD: Cohort 19: TAK-071 160 mg</title>
            <description>TAK-071 160 mg capsule, orally, once on Day 1 to non-Japanese healthy participants. Dose of TAK-071 was based on 24-hour safety, tolerability, and preliminary plasma PK data from Cohort 18.</description>
          </group>
          <group group_id="O25">
            <title>SRD: TAK-071 Placebo+Donepezil Placebo</title>
            <description>TAK-071 placebo-matching capsule, orally, once on Day 1 followed by donepezil placebo-matching tablet, orally on Day 2 to non-Japanese healthy participants.</description>
          </group>
          <group group_id="O26">
            <title>SRD: TAK-071 Placebo+Donepezil</title>
            <description>TAK-071 placebo-matching capsule, orally, once on Day 1 followed by donepezil 10 mg tablet, orally, on Day 2 to non-Japanese healthy participants.</description>
          </group>
          <group group_id="O27">
            <title>SRD: Cohort 20: TAK-071 40 mg+Donepezil</title>
            <description>TAK-071 40 mg capsule, orally, once on Day 1 followed by donepezil 10 mg, tablets, orally, once on Day 2 to non-Japanese healthy participants. Dose of TAK-071 was based on 24-hour safety, tolerability, and preliminary plasma PK data from Cohort 19.</description>
          </group>
          <group group_id="O28">
            <title>SRD: Cohort 21: TAK-071 60 mg+Donepezil</title>
            <description>TAK-071 60 mg capsule, orally, once on Day 1 followed by donepezil 10 mg, tablets, orally, once on Day 2 to non-Japanese healthy participants. Dose of TAK-071 was based on 24-hour safety and tolerability data from Cohort 20.</description>
          </group>
          <group group_id="O29">
            <title>SRD: Cohort 22: TAK-071 80 mg+Donepezil</title>
            <description>TAK-071 80 mg capsule, orally, once on Day 1, followed by donepezil 10 mg, tablets, orally, once on Day 2 to non-Japanese healthy participants. Dose of TAK-071 was based on 24-hour safety and tolerability data from Cohort 21.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Meet the Markedly Abnormal Criteria for 12-lead Electrocardiogram (ECG) Parameters at Least Once Post-dose</title>
          <description>A standard 12-lead electrocardiogram (ECG) was performed. The percentage of participants with markedly abnormal ECG findings during the study.</description>
          <population>SAS included all randomized participants who received at least 1 dose of study drug.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="6"/>
                <count group_id="O9" value="6"/>
                <count group_id="O10" value="6"/>
                <count group_id="O11" value="6"/>
                <count group_id="O12" value="6"/>
                <count group_id="O13" value="6"/>
                <count group_id="O14" value="6"/>
                <count group_id="O15" value="6"/>
                <count group_id="O16" value="3"/>
                <count group_id="O17" value="5"/>
                <count group_id="O18" value="5"/>
                <count group_id="O19" value="5"/>
                <count group_id="O20" value="12"/>
                <count group_id="O21" value="12"/>
                <count group_id="O22" value="12"/>
                <count group_id="O23" value="6"/>
                <count group_id="O24" value="6"/>
                <count group_id="O25" value="9"/>
                <count group_id="O26" value="9"/>
                <count group_id="O27" value="5"/>
                <count group_id="O28" value="6"/>
                <count group_id="O29" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>ECG Mean Heart Rate (HR), &lt;50 beats/min</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.5"/>
                    <measurement group_id="O2" value="33.3"/>
                    <measurement group_id="O3" value="16.7"/>
                    <measurement group_id="O4" value="16.7"/>
                    <measurement group_id="O5" value="33.3"/>
                    <measurement group_id="O6" value="33.3"/>
                    <measurement group_id="O7" value="16.7"/>
                    <measurement group_id="O8" value="33.3"/>
                    <measurement group_id="O9" value="16.7"/>
                    <measurement group_id="O10" value="33.3"/>
                    <measurement group_id="O11" value="33.3"/>
                    <measurement group_id="O12" value="16.7"/>
                    <measurement group_id="O13" value="33.3"/>
                    <measurement group_id="O14" value="50.0"/>
                    <measurement group_id="O15" value="33.3"/>
                    <measurement group_id="O16" value="66.7"/>
                    <measurement group_id="O17" value="40.0"/>
                    <measurement group_id="O18" value="40.0"/>
                    <measurement group_id="O19" value="40.0"/>
                    <measurement group_id="O20" value="58.3"/>
                    <measurement group_id="O21" value="41.7"/>
                    <measurement group_id="O22" value="33.3"/>
                    <measurement group_id="O23" value="66.7"/>
                    <measurement group_id="O24" value="0"/>
                    <measurement group_id="O25" value="44.4"/>
                    <measurement group_id="O26" value="22.2"/>
                    <measurement group_id="O27" value="60.0"/>
                    <measurement group_id="O28" value="33.3"/>
                    <measurement group_id="O29" value="50.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ECG Mean HR, &gt;120 beats/min</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="0"/>
                    <measurement group_id="O13" value="0"/>
                    <measurement group_id="O14" value="0"/>
                    <measurement group_id="O15" value="0"/>
                    <measurement group_id="O16" value="0"/>
                    <measurement group_id="O17" value="0"/>
                    <measurement group_id="O18" value="0"/>
                    <measurement group_id="O19" value="20.0"/>
                    <measurement group_id="O20" value="0"/>
                    <measurement group_id="O21" value="0"/>
                    <measurement group_id="O22" value="0"/>
                    <measurement group_id="O23" value="0"/>
                    <measurement group_id="O24" value="0"/>
                    <measurement group_id="O25" value="0"/>
                    <measurement group_id="O26" value="0"/>
                    <measurement group_id="O27" value="0"/>
                    <measurement group_id="O28" value="0"/>
                    <measurement group_id="O29" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PR Interval, Aggregate, &lt;=80 millisecond (msec)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="0"/>
                    <measurement group_id="O13" value="0"/>
                    <measurement group_id="O14" value="0"/>
                    <measurement group_id="O15" value="0"/>
                    <measurement group_id="O16" value="0"/>
                    <measurement group_id="O17" value="0"/>
                    <measurement group_id="O18" value="0"/>
                    <measurement group_id="O19" value="0"/>
                    <measurement group_id="O20" value="0"/>
                    <measurement group_id="O21" value="0"/>
                    <measurement group_id="O22" value="0"/>
                    <measurement group_id="O23" value="0"/>
                    <measurement group_id="O24" value="0"/>
                    <measurement group_id="O25" value="0"/>
                    <measurement group_id="O26" value="0"/>
                    <measurement group_id="O27" value="0"/>
                    <measurement group_id="O28" value="0"/>
                    <measurement group_id="O29" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PR Interval, Aggregate, &gt;=200 msec</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.8"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="16.7"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="16.7"/>
                    <measurement group_id="O6" value="16.7"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="16.7"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="16.7"/>
                    <measurement group_id="O13" value="16.7"/>
                    <measurement group_id="O14" value="16.7"/>
                    <measurement group_id="O15" value="16.7"/>
                    <measurement group_id="O16" value="66.7"/>
                    <measurement group_id="O17" value="0"/>
                    <measurement group_id="O18" value="40.0"/>
                    <measurement group_id="O19" value="20.0"/>
                    <measurement group_id="O20" value="33.3"/>
                    <measurement group_id="O21" value="25.0"/>
                    <measurement group_id="O22" value="25.0"/>
                    <measurement group_id="O23" value="0"/>
                    <measurement group_id="O24" value="0"/>
                    <measurement group_id="O25" value="11.1"/>
                    <measurement group_id="O26" value="11.1"/>
                    <measurement group_id="O27" value="20.0"/>
                    <measurement group_id="O28" value="0"/>
                    <measurement group_id="O29" value="16.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QRS Duration, Aggregate, &lt;=80 msec</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.3"/>
                    <measurement group_id="O2" value="33.3"/>
                    <measurement group_id="O3" value="33.3"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="50.0"/>
                    <measurement group_id="O6" value="16.7"/>
                    <measurement group_id="O7" value="16.7"/>
                    <measurement group_id="O8" value="33.3"/>
                    <measurement group_id="O9" value="16.7"/>
                    <measurement group_id="O10" value="16.7"/>
                    <measurement group_id="O11" value="16.7"/>
                    <measurement group_id="O12" value="50.0"/>
                    <measurement group_id="O13" value="16.7"/>
                    <measurement group_id="O14" value="16.7"/>
                    <measurement group_id="O15" value="16.7"/>
                    <measurement group_id="O16" value="33.3"/>
                    <measurement group_id="O17" value="40.0"/>
                    <measurement group_id="O18" value="20.0"/>
                    <measurement group_id="O19" value="40.0"/>
                    <measurement group_id="O20" value="8.3"/>
                    <measurement group_id="O21" value="16.7"/>
                    <measurement group_id="O22" value="16.7"/>
                    <measurement group_id="O23" value="16.7"/>
                    <measurement group_id="O24" value="50.0"/>
                    <measurement group_id="O25" value="11.1"/>
                    <measurement group_id="O26" value="11.1"/>
                    <measurement group_id="O27" value="20.0"/>
                    <measurement group_id="O28" value="0"/>
                    <measurement group_id="O29" value="16.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QRS Duration, Aggregate, &gt;=180 msec</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="0"/>
                    <measurement group_id="O13" value="0"/>
                    <measurement group_id="O14" value="0"/>
                    <measurement group_id="O15" value="0"/>
                    <measurement group_id="O16" value="0"/>
                    <measurement group_id="O17" value="0"/>
                    <measurement group_id="O18" value="0"/>
                    <measurement group_id="O19" value="0"/>
                    <measurement group_id="O20" value="0"/>
                    <measurement group_id="O21" value="0"/>
                    <measurement group_id="O22" value="0"/>
                    <measurement group_id="O23" value="0"/>
                    <measurement group_id="O24" value="0"/>
                    <measurement group_id="O25" value="0"/>
                    <measurement group_id="O26" value="0"/>
                    <measurement group_id="O27" value="0"/>
                    <measurement group_id="O28" value="0"/>
                    <measurement group_id="O29" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QT Interval, Aggregate, &lt;=50 msec</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="0"/>
                    <measurement group_id="O13" value="0"/>
                    <measurement group_id="O14" value="0"/>
                    <measurement group_id="O15" value="0"/>
                    <measurement group_id="O16" value="0"/>
                    <measurement group_id="O17" value="0"/>
                    <measurement group_id="O18" value="0"/>
                    <measurement group_id="O19" value="0"/>
                    <measurement group_id="O20" value="0"/>
                    <measurement group_id="O21" value="0"/>
                    <measurement group_id="O22" value="0"/>
                    <measurement group_id="O23" value="0"/>
                    <measurement group_id="O24" value="0"/>
                    <measurement group_id="O25" value="0"/>
                    <measurement group_id="O26" value="0"/>
                    <measurement group_id="O27" value="0"/>
                    <measurement group_id="O28" value="0"/>
                    <measurement group_id="O29" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QT Interval, Aggregate, &gt;=460 msec</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.5"/>
                    <measurement group_id="O2" value="33.3"/>
                    <measurement group_id="O3" value="16.7"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="16.7"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="16.7"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="0"/>
                    <measurement group_id="O13" value="0"/>
                    <measurement group_id="O14" value="0"/>
                    <measurement group_id="O15" value="0"/>
                    <measurement group_id="O16" value="0"/>
                    <measurement group_id="O17" value="20.0"/>
                    <measurement group_id="O18" value="20.0"/>
                    <measurement group_id="O19" value="20.0"/>
                    <measurement group_id="O20" value="16.7"/>
                    <measurement group_id="O21" value="16.7"/>
                    <measurement group_id="O22" value="8.3"/>
                    <measurement group_id="O23" value="16.7"/>
                    <measurement group_id="O24" value="0"/>
                    <measurement group_id="O25" value="11.1"/>
                    <measurement group_id="O26" value="11.1"/>
                    <measurement group_id="O27" value="40.0"/>
                    <measurement group_id="O28" value="0"/>
                    <measurement group_id="O29" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QTcB Interval, Aggregate, &lt;=50 msec</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="0"/>
                    <measurement group_id="O13" value="0"/>
                    <measurement group_id="O14" value="0"/>
                    <measurement group_id="O15" value="0"/>
                    <measurement group_id="O16" value="0"/>
                    <measurement group_id="O17" value="0"/>
                    <measurement group_id="O18" value="0"/>
                    <measurement group_id="O19" value="0"/>
                    <measurement group_id="O20" value="0"/>
                    <measurement group_id="O21" value="0"/>
                    <measurement group_id="O22" value="0"/>
                    <measurement group_id="O23" value="0"/>
                    <measurement group_id="O24" value="0"/>
                    <measurement group_id="O25" value="0"/>
                    <measurement group_id="O26" value="0"/>
                    <measurement group_id="O27" value="0"/>
                    <measurement group_id="O28" value="0"/>
                    <measurement group_id="O29" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QTcB Interval, Aggregate ≥500 OR ≥30 and ≥450 msec</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="16.7"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="0"/>
                    <measurement group_id="O13" value="0"/>
                    <measurement group_id="O14" value="16.7"/>
                    <measurement group_id="O15" value="16.7"/>
                    <measurement group_id="O16" value="0"/>
                    <measurement group_id="O17" value="0"/>
                    <measurement group_id="O18" value="20.0"/>
                    <measurement group_id="O19" value="20.0"/>
                    <measurement group_id="O20" value="8.3"/>
                    <measurement group_id="O21" value="0"/>
                    <measurement group_id="O22" value="0"/>
                    <measurement group_id="O23" value="0"/>
                    <measurement group_id="O24" value="0"/>
                    <measurement group_id="O25" value="0"/>
                    <measurement group_id="O26" value="0"/>
                    <measurement group_id="O27" value="20.0"/>
                    <measurement group_id="O28" value="0"/>
                    <measurement group_id="O29" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QTcF Interval, Aggregate, &lt;=50 msec</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="0"/>
                    <measurement group_id="O13" value="0"/>
                    <measurement group_id="O14" value="0"/>
                    <measurement group_id="O15" value="0"/>
                    <measurement group_id="O16" value="0"/>
                    <measurement group_id="O17" value="0"/>
                    <measurement group_id="O18" value="0"/>
                    <measurement group_id="O19" value="0"/>
                    <measurement group_id="O20" value="0"/>
                    <measurement group_id="O21" value="0"/>
                    <measurement group_id="O22" value="0"/>
                    <measurement group_id="O23" value="0"/>
                    <measurement group_id="O24" value="0"/>
                    <measurement group_id="O25" value="0"/>
                    <measurement group_id="O26" value="0"/>
                    <measurement group_id="O27" value="0"/>
                    <measurement group_id="O28" value="0"/>
                    <measurement group_id="O29" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QTcF Interval, Aggregate ≥500 OR ≥30 and ≥450 msec</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="16.7"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="0"/>
                    <measurement group_id="O13" value="0"/>
                    <measurement group_id="O14" value="0"/>
                    <measurement group_id="O15" value="0"/>
                    <measurement group_id="O16" value="0"/>
                    <measurement group_id="O17" value="0"/>
                    <measurement group_id="O18" value="0"/>
                    <measurement group_id="O19" value="0"/>
                    <measurement group_id="O20" value="0"/>
                    <measurement group_id="O21" value="0"/>
                    <measurement group_id="O22" value="0"/>
                    <measurement group_id="O23" value="0"/>
                    <measurement group_id="O24" value="0"/>
                    <measurement group_id="O25" value="0"/>
                    <measurement group_id="O26" value="0"/>
                    <measurement group_id="O27" value="0"/>
                    <measurement group_id="O28" value="0"/>
                    <measurement group_id="O29" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RR Interval, Aggregate, &lt;=600 msec</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="0"/>
                    <measurement group_id="O13" value="0"/>
                    <measurement group_id="O14" value="0"/>
                    <measurement group_id="O15" value="16.7"/>
                    <measurement group_id="O16" value="0"/>
                    <measurement group_id="O17" value="0"/>
                    <measurement group_id="O18" value="0"/>
                    <measurement group_id="O19" value="20.0"/>
                    <measurement group_id="O20" value="0"/>
                    <measurement group_id="O21" value="0"/>
                    <measurement group_id="O22" value="0"/>
                    <measurement group_id="O23" value="0"/>
                    <measurement group_id="O24" value="0"/>
                    <measurement group_id="O25" value="0"/>
                    <measurement group_id="O26" value="0"/>
                    <measurement group_id="O27" value="0"/>
                    <measurement group_id="O28" value="0"/>
                    <measurement group_id="O29" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RR Interval, Aggregate, &gt;=1440 msec</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="16.7"/>
                    <measurement group_id="O3" value="16.7"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="16.7"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="0"/>
                    <measurement group_id="O13" value="0"/>
                    <measurement group_id="O14" value="0"/>
                    <measurement group_id="O15" value="0"/>
                    <measurement group_id="O16" value="0"/>
                    <measurement group_id="O17" value="20.0"/>
                    <measurement group_id="O18" value="20.0"/>
                    <measurement group_id="O19" value="0"/>
                    <measurement group_id="O20" value="0"/>
                    <measurement group_id="O21" value="0"/>
                    <measurement group_id="O22" value="0"/>
                    <measurement group_id="O23" value="16.7"/>
                    <measurement group_id="O24" value="0"/>
                    <measurement group_id="O25" value="11.1"/>
                    <measurement group_id="O26" value="11.1"/>
                    <measurement group_id="O27" value="0"/>
                    <measurement group_id="O28" value="0"/>
                    <measurement group_id="O29" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Tmax: Time of First Occurrence of Cmax for TAK-071 Single-Rising Dose (SRD) Non-Japanese Participants</title>
        <time_frame>Pre-dose on Day 1 and at multiple time points (up to 168 hours) post-dose</time_frame>
        <population>Pharmacokinetic (PK) set included all participants who received study drug and had at least 1 measurable plasma concentration or amount of drug in the urine.</population>
        <group_list>
          <group group_id="O1">
            <title>SRD: Cohort 1: TAK-071 1 mg</title>
            <description>TAK-071 1 mg, capsule, orally, once on Day 1 to non-Japanese healthy participants.</description>
          </group>
          <group group_id="O2">
            <title>SRD: Cohort 2: TAK-071 3 mg</title>
            <description>TAK-071 3 mg capsule, orally, once on Day 1 to non-Japanese healthy participants. Dose of TAK-071 was based on the 24-hour post-dose safety, tolerability and pharmacokinetic (PK) data from cohort 1.</description>
          </group>
          <group group_id="O3">
            <title>SRD: Cohort 3: TAK-071 9 mg</title>
            <description>TAK-071 9 mg capsule, orally, once on Day 1 to non-Japanese healthy participants. Dose of TAK-071 was based on 24-hour safety, tolerability, and preliminary plasma PK and 12-hour CSF PK data.</description>
          </group>
          <group group_id="O4">
            <title>SRD: Cohort 4: TAK-071 20 mg</title>
            <description>TAK-071 20 mg capsule, orally, once on Day 1 to non-Japanese healthy participants. Dose of TAK-071 was based on the 24-hour post-dose safety and tolerability data from previous cohort.</description>
          </group>
          <group group_id="O5">
            <title>SRD: Cohort 5: TAK-071 40 mg</title>
            <description>TAK-071 40 mg capsule, orally, once on Day 1 to non-Japanese healthy participants. Dose of TAK-071 will be based on 24-hour safety, tolerability, and preliminary plasma PK data from Cohort 4.</description>
          </group>
          <group group_id="O6">
            <title>SRD: Cohort 6: TAK-071 80 mg</title>
            <description>TAK-071 80 mg capsules, orally, once on Day 1 to non-Japanese healthy participants. Dose of TAK-071 was based on 24-hour safety, tolerability, and preliminary plasma PK data from Cohort 5</description>
          </group>
          <group group_id="O7">
            <title>SRD: Cohort 18: TAK-071 120 mg</title>
            <description>TAK-071 120 mg capsule, orally, once on Day 1 to non-Japanese healthy participants. Dose of TAK-071 was based on 24-hour safety, tolerability, and preliminary plasma PK data from Cohort 6.</description>
          </group>
          <group group_id="O8">
            <title>SRD: Cohort 19: TAK-071 160 mg</title>
            <description>TAK-071 160 mg capsule, orally, once on Day 1 to non-Japanese healthy participants. Dose of TAK-071 was based on 24-hour safety, tolerability, and preliminary plasma PK data from Cohort 18.</description>
          </group>
        </group_list>
        <measure>
          <title>Tmax: Time of First Occurrence of Cmax for TAK-071 Single-Rising Dose (SRD) Non-Japanese Participants</title>
          <population>Pharmacokinetic (PK) set included all participants who received study drug and had at least 1 measurable plasma concentration or amount of drug in the urine.</population>
          <units>hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.750" lower_limit="1.48" upper_limit="4.00"/>
                    <measurement group_id="O2" value="4.017" lower_limit="3.00" upper_limit="23.95"/>
                    <measurement group_id="O3" value="10.975" lower_limit="3.00" upper_limit="24.00"/>
                    <measurement group_id="O4" value="8.000" lower_limit="4.02" upper_limit="24.02"/>
                    <measurement group_id="O5" value="9.933" lower_limit="3.00" upper_limit="48.00"/>
                    <measurement group_id="O6" value="24.033" lower_limit="12.02" upper_limit="48.07"/>
                    <measurement group_id="O7" value="22.050" lower_limit="8.00" upper_limit="39.95"/>
                    <measurement group_id="O8" value="24.058" lower_limit="24.00" upper_limit="32.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Tmax: Time of First Occurrence of Cmax for TAK-071 Multiple-Rising Dose (MRD) Non-Japanese Participants [Day 1]</title>
        <time_frame>Pre-dose on Day 1 and multiple time points (up to 24 hours) post-dose</time_frame>
        <population>PK set included all participants who received study drug and had at least 1 measurable plasma concentration or amount of drug in the urine.</population>
        <group_list>
          <group group_id="O1">
            <title>MRD: Cohort 7: TAK-071 3 mg</title>
            <description>TAK-071 3 mg capsules, orally, once daily from Day 1 up to Day 21 to non-Japanese healthy participants. Dose of TAK-071 was based on 24-hour safety and tolerability from Cohort 4 and the 24-hour preliminary plasma PK and 12-hour CSF PK data from Cohort 3.</description>
          </group>
          <group group_id="O2">
            <title>MRD: Cohort 8: TAK-071 9 mg</title>
            <description>TAK-071 9 mg capsules, orally, once daily from Day 1 up to Day 21 to non-Japanese healthy participants. Dose of TAK-071 was based on safety, tolerability and available PK data arising from the ongoing SRD part and previous MRD cohort.</description>
          </group>
        </group_list>
        <measure>
          <title>Tmax: Time of First Occurrence of Cmax for TAK-071 Multiple-Rising Dose (MRD) Non-Japanese Participants [Day 1]</title>
          <population>PK set included all participants who received study drug and had at least 1 measurable plasma concentration or amount of drug in the urine.</population>
          <units>hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.500" lower_limit="2.00" upper_limit="10.00"/>
                    <measurement group_id="O2" value="7.000" lower_limit="3.00" upper_limit="12.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Tmax: Time of First Occurrence of Cmax for TAK-071 MRD Non-Japanese Participants [Day 21]</title>
        <time_frame>Pre-dose on Day 21 and multiple time points (up to 24 hours) post-dose</time_frame>
        <population>PK set included all participants who received study drug and had at least 1 measurable plasma concentration or amount of drug in the urine.</population>
        <group_list>
          <group group_id="O1">
            <title>MRD: Cohort 7: TAK-071 3 mg</title>
            <description>TAK-071 3 mg capsules, orally, once daily from Day 1 up to Day 21 to non-Japanese healthy participants. Dose of TAK-071 was based on 24-hour safety and tolerability from Cohort 4 and the 24-hour preliminary plasma PK and 12-hour CSF PK data from Cohort 3.</description>
          </group>
          <group group_id="O2">
            <title>MRD: Cohort 8: TAK-071 9 mg</title>
            <description>TAK-071 9 mg capsules, orally, once daily from Day 1 up to Day 21 to non-Japanese healthy participants. Dose of TAK-071 was based on safety, tolerability and available PK data arising from the ongoing SRD part and previous MRD cohort.</description>
          </group>
        </group_list>
        <measure>
          <title>Tmax: Time of First Occurrence of Cmax for TAK-071 MRD Non-Japanese Participants [Day 21]</title>
          <population>PK set included all participants who received study drug and had at least 1 measurable plasma concentration or amount of drug in the urine.</population>
          <units>hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.500" lower_limit="2.00" upper_limit="6.00"/>
                    <measurement group_id="O2" value="4.000" lower_limit="2.00" upper_limit="12.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Tmax: Time of First Occurrence of Cmax for TAK-071 MRD Non-Japanese Participants [Day 1]</title>
        <time_frame>Pre-dose on Day 1 and multiple time points (up to 96 hours) post-dose</time_frame>
        <population>PK set included all participants who received study drug and had at least 1 measurable plasma concentration or amount of drug in the urine.</population>
        <group_list>
          <group group_id="O1">
            <title>MRD: Cohort 9: TAK-071 15 mg</title>
            <description>TAK-071 15 mg capsule, orally, once on Day 1, followed by a washout period of 7 days, then TAK-071 once daily for 21 days to non-Japanese healthy participants. Dose of TAK-071 will be based on safety, tolerability and available PK data arising from the ongoing SRD part and previous MRD cohort.</description>
          </group>
        </group_list>
        <measure>
          <title>Tmax: Time of First Occurrence of Cmax for TAK-071 MRD Non-Japanese Participants [Day 1]</title>
          <population>PK set included all participants who received study drug and had at least 1 measurable plasma concentration or amount of drug in the urine.</population>
          <units>hours</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.058" lower_limit="3.05" upper_limit="24.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Tmax: Time of First Occurrence of Cmax for TAK-071 MRD Non-Japanese Participants [Day 8]</title>
        <time_frame>Pre-dose on Day 8 and multiple time points (up to 24 hour) post-dose</time_frame>
        <population>PK set included all participants who received study drug and had at least 1 measurable plasma concentration or amount of drug in the urine.</population>
        <group_list>
          <group group_id="O1">
            <title>MRD: Cohort 9: TAK-071 15 mg</title>
            <description>TAK-071 15 mg capsule, orally, once on Day 1, followed by a washout period of 7 days, then TAK-071 once daily for 21 days to non-Japanese healthy participants. Dose of TAK-071 will be based on safety, tolerability and available PK data arising from the ongoing SRD part and previous MRD cohort.</description>
          </group>
        </group_list>
        <measure>
          <title>Tmax: Time of First Occurrence of Cmax for TAK-071 MRD Non-Japanese Participants [Day 8]</title>
          <population>PK set included all participants who received study drug and had at least 1 measurable plasma concentration or amount of drug in the urine.</population>
          <units>hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.017" lower_limit="2.00" upper_limit="23.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Tmax: Time of First Occurrence of Cmax for TAK-071 MRD Non-Japanese Participants [Day 28]</title>
        <time_frame>Pre-dose on Day 28 and multiple time points (up to 36 hours) post-dose</time_frame>
        <population>PK set included all participants who received study drug and had at least 1 measurable plasma concentration or amount of drug in the urine.</population>
        <group_list>
          <group group_id="O1">
            <title>MRD: Cohort 9: TAK-071 15 mg</title>
            <description>TAK-071 15 mg capsule, orally, once on Day 1, followed by a washout period of 7 days, then TAK-071 once daily for 21 days to non-Japanese healthy participants. Dose of TAK-071 will be based on safety, tolerability and available PK data arising from the ongoing SRD part and previous MRD cohort.</description>
          </group>
        </group_list>
        <measure>
          <title>Tmax: Time of First Occurrence of Cmax for TAK-071 MRD Non-Japanese Participants [Day 28]</title>
          <population>PK set included all participants who received study drug and had at least 1 measurable plasma concentration or amount of drug in the urine.</population>
          <units>hours</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.000" lower_limit="1.00" upper_limit="12.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Tmax: Time of First Occurrence of Cmax for TAK-071 MRD Japanese Participants [Day 1]</title>
        <time_frame>Pre-dose on Day 1 and multiple time points (up to 96 hours) post-dose</time_frame>
        <population>PK set included all participants who received study drug and had at least 1 measurable plasma concentration or amount of drug in the urine.</population>
        <group_list>
          <group group_id="O1">
            <title>MRD: Cohort 13: TAK-071 3 mg</title>
            <description>TAK-071 3 mg capsule, orally, once on Day 1, followed by a washout period of 7 days, then TAK-071 once daily for 21 days to Japanese healthy participants. Dose of TAK-071 was same as the dose used in MRD Cohort 7.</description>
          </group>
          <group group_id="O2">
            <title>MRD: Cohort 14: TAK-071 9 mg</title>
            <description>TAK-071 9 mg capsule or matching placebo, orally, once on Day 1, followed by a washout period of 7 days, then TAK-071 once daily for 21 days to Japanese healthy participants. Dose of TAK-071 was same as the dose used in MRD Cohort 8.</description>
          </group>
          <group group_id="O3">
            <title>MRD: Cohort 15: TAK-071 15 mg</title>
            <description>TAK-071 15 mg capsule, orally, once on Day 1, followed by a washout period of 7 days, then TAK-071 once daily for 21 days to Japanese healthy participants. Dose of TAK-071 was same as the dose used in MRD Cohort 9.</description>
          </group>
        </group_list>
        <measure>
          <title>Tmax: Time of First Occurrence of Cmax for TAK-071 MRD Japanese Participants [Day 1]</title>
          <population>PK set included all participants who received study drug and had at least 1 measurable plasma concentration or amount of drug in the urine.</population>
          <units>hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.000" lower_limit="4.00" upper_limit="8.00"/>
                    <measurement group_id="O2" value="6.000" lower_limit="2.00" upper_limit="12.00"/>
                    <measurement group_id="O3" value="12.000" lower_limit="6.00" upper_limit="14.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Tmax: Time of First Occurrence of Cmax for TAK-071 MRD Japanese Participants [Day 8]</title>
        <time_frame>Pre-dose on Day 8 and multiple time points (up to 24 hours) post-dose</time_frame>
        <population>PK set included all participants who received study drug and had at least 1 measurable plasma concentration or amount of drug in the urine.</population>
        <group_list>
          <group group_id="O1">
            <title>MRD: Cohort 13: TAK-071 3 mg</title>
            <description>TAK-071 3 mg capsule, orally, once on Day 1, followed by a washout period of 7 days, then TAK-071 once daily for 21 days to Japanese healthy participants. Dose of TAK-071 was same as the dose used in MRD Cohort 7.</description>
          </group>
          <group group_id="O2">
            <title>MRD: Cohort 14: TAK-071 9 mg</title>
            <description>TAK-071 9 mg capsule or matching placebo, orally, once on Day 1, followed by a washout period of 7 days, then TAK-071 once daily for 21 days to Japanese healthy participants. Dose of TAK-071 was same as the dose used in MRD Cohort 8.</description>
          </group>
          <group group_id="O3">
            <title>MRD: Cohort 15: TAK-071 15 mg</title>
            <description>TAK-071 15 mg capsule, orally, once on Day 1, followed by a washout period of 7 days, then TAK-071 once daily for 21 days to Japanese healthy participants. Dose of TAK-071 was same as the dose used in MRD Cohort 9.</description>
          </group>
        </group_list>
        <measure>
          <title>Tmax: Time of First Occurrence of Cmax for TAK-071 MRD Japanese Participants [Day 8]</title>
          <population>PK set included all participants who received study drug and had at least 1 measurable plasma concentration or amount of drug in the urine.</population>
          <units>hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.000" lower_limit="3.00" upper_limit="6.00"/>
                    <measurement group_id="O2" value="6.000" lower_limit="6.00" upper_limit="23.75"/>
                    <measurement group_id="O3" value="8.000" lower_limit="3.00" upper_limit="23.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Tmax: Time of First Occurrence of Cmax for TAK-071 MRD Japanese Participants [Day 28]</title>
        <time_frame>Pre-dose on Day 28 and multiple time points (up to 24 hours) post-dose</time_frame>
        <population>PK set included all participants who received study drug and had at least 1 measurable plasma concentration or amount of drug in the urine.</population>
        <group_list>
          <group group_id="O1">
            <title>MRD: Cohort 13: TAK-071 3 mg</title>
            <description>TAK-071 3 mg capsule, orally, once on Day 1, followed by a washout period of 7 days, then TAK-071 once daily for 21 days to Japanese healthy participants. Dose of TAK-071 was same as the dose used in MRD Cohort 7.</description>
          </group>
          <group group_id="O2">
            <title>MRD: Cohort 14: TAK-071 9 mg</title>
            <description>TAK-071 9 mg capsule or matching placebo, orally, once on Day 1, followed by a washout period of 7 days, then TAK-071 once daily for 21 days to Japanese healthy participants. Dose of TAK-071 was same as the dose used in MRD Cohort 8.</description>
          </group>
          <group group_id="O3">
            <title>MRD: Cohort 15: TAK-071 15 mg</title>
            <description>TAK-071 15 mg capsule, orally, once on Day 1, followed by a washout period of 7 days, then TAK-071 once daily for 21 days to Japanese healthy participants. Dose of TAK-071 was same as the dose used in MRD Cohort 9.</description>
          </group>
        </group_list>
        <measure>
          <title>Tmax: Time of First Occurrence of Cmax for TAK-071 MRD Japanese Participants [Day 28]</title>
          <population>PK set included all participants who received study drug and had at least 1 measurable plasma concentration or amount of drug in the urine.</population>
          <units>hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.000" lower_limit="3.00" upper_limit="4.00"/>
                    <measurement group_id="O2" value="3.000" lower_limit="1.50" upper_limit="6.05"/>
                    <measurement group_id="O3" value="3.000" lower_limit="1.50" upper_limit="6.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Tmax: Time of First Occurrence of Cmax for TAK-071 MRD Non-Japanese Participants [Day 1]</title>
        <time_frame>Pre-dose on Day 1 and multiple time points (up to 24 hours) post-dose</time_frame>
        <population>PK set included all participants who received study drug and had at least 1 measurable plasma concentration or amount of drug in the urine.</population>
        <group_list>
          <group group_id="O1">
            <title>MRD: Cohort 10: TAK-071 3 mg+Donepezil 5 mg</title>
            <description>TAK-071 3 mg capsules, orally, once daily along with donepezil 5 mg, tablets, orally, once daily from Day 1 up to Day 21 to non-Japanese healthy participants who were pre-treated with donepezil 5 mg, tablet, once daily for 3 weeks prior to administration of TAK-071. Dose of TAK-071 was same as the dose used in MRD Cohort 7.</description>
          </group>
          <group group_id="O2">
            <title>MRD: Cohort 11: TAK-071 9 mg + Donepezil 5 mg</title>
            <description>TAK-071 9 mg capsules, orally, once daily along with donepezil 5 mg, tablets, orally, once daily from Day 1 up to Day 21 to non-Japanese healthy participants who were pre-treated with donepezil 5 mg, tablet, once daily for 3 weeks prior to administration of TAK-071. Dose of TAK-071 was same as the dose used in MRD Cohort 8.</description>
          </group>
          <group group_id="O3">
            <title>MRD: Cohort 12: TAK-071 15 mg+Donepezil 5 mg</title>
            <description>TAK-071 15 mg capsule, orally, once daily along with donepezil 5 mg, tablets, orally, once daily from Day 1 up to Day 21 to non-Japanese healthy participants who were pre-treated with donepezil 5 mg, tablet, once daily for 3 weeks prior to administration of TAK-071. Dose of TAK-071 was same as the dose used in MRD Cohort 9.</description>
          </group>
        </group_list>
        <measure>
          <title>Tmax: Time of First Occurrence of Cmax for TAK-071 MRD Non-Japanese Participants [Day 1]</title>
          <population>PK set included all participants who received study drug and had at least 1 measurable plasma concentration or amount of drug in the urine.</population>
          <units>hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.508" lower_limit="2.00" upper_limit="8.00"/>
                    <measurement group_id="O2" value="4.992" lower_limit="3.00" upper_limit="10.00"/>
                    <measurement group_id="O3" value="7.000" lower_limit="3.00" upper_limit="14.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Tmax: Time of First Occurrence of Cmax for TAK-071 MRD Non-Japanese Participants [Day 21]</title>
        <time_frame>Pre-dose on Day 21 and multiple time points (up to 24 hours) post-dose</time_frame>
        <population>PK set included all participants who received study drug and had at least 1 measurable plasma concentration or amount of drug in the urine.</population>
        <group_list>
          <group group_id="O1">
            <title>MRD: Cohort 10: TAK-071 3 mg+Donepezil 5 mg</title>
            <description>TAK-071 3 mg capsules, orally, once daily along with donepezil 5 mg, tablets, orally, once daily from Day 1 up to Day 21 to non-Japanese healthy participants who were pre-treated with donepezil 5 mg, tablet, once daily for 3 weeks prior to administration of TAK-071. Dose of TAK-071 was same as the dose used in MRD Cohort 7.</description>
          </group>
          <group group_id="O2">
            <title>MRD: Cohort 11: TAK-071 9 mg + Donepezil 5 mg</title>
            <description>TAK-071 9 mg capsules, orally, once daily along with donepezil 5 mg, tablets, orally, once daily from Day 1 up to Day 21 to non-Japanese healthy participants who were pre-treated with donepezil 5 mg, tablet, once daily for 3 weeks prior to administration of TAK-071. Dose of TAK-071 was same as the dose used in MRD Cohort 8.</description>
          </group>
          <group group_id="O3">
            <title>MRD: Cohort 12: TAK-071 15 mg+Donepezil 5 mg</title>
            <description>TAK-071 15 mg capsule, orally, once daily along with donepezil 5 mg, tablets, orally, once daily from Day 1 up to Day 21 to non-Japanese healthy participants who were pre-treated with donepezil 5 mg, tablet, once daily for 3 weeks prior to administration of TAK-071. Dose of TAK-071 was same as the dose used in MRD Cohort 9.</description>
          </group>
        </group_list>
        <measure>
          <title>Tmax: Time of First Occurrence of Cmax for TAK-071 MRD Non-Japanese Participants [Day 21]</title>
          <population>PK set included all participants who received study drug and had at least 1 measurable plasma concentration or amount of drug in the urine.</population>
          <units>hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.500" lower_limit="2.00" upper_limit="6.00"/>
                    <measurement group_id="O2" value="3.008" lower_limit="2.00" upper_limit="4.00"/>
                    <measurement group_id="O3" value="3.500" lower_limit="1.50" upper_limit="6.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Tmax: Time of First Occurrence of Cmax for TAK-071 Relative Bioavailability and Food Effect</title>
        <time_frame>Pre-dose on Day 21 and multiple time points (up to 168 hours) post-dose</time_frame>
        <population>PK set included all participants who received study drug and had at least 1 measurable plasma concentration or amount of drug in the urine.</population>
        <group_list>
          <group group_id="O1">
            <title>Bioavailability (BA)/Food Effect: Cohort 17 Regimen A</title>
            <description>TAK-071 10 mg capsule, orally once on Day 1 in the fasted state in Period 1 or Period 2 or Period 3</description>
          </group>
          <group group_id="O2">
            <title>BA/Food Effect: Cohort 17 Regimen B</title>
            <description>TAK-071 10 mg tablet, orally, once on Day 1 in the fasted state in Period 1 or Period 2 or Period 3</description>
          </group>
          <group group_id="O3">
            <title>BA/Food Effect: Cohort 17 Regimen C</title>
            <description>TAK-071 10 mg tablet, orally, once on Day 1 in the fed state in Period 1 or Period 2 or Period 3</description>
          </group>
        </group_list>
        <measure>
          <title>Tmax: Time of First Occurrence of Cmax for TAK-071 Relative Bioavailability and Food Effect</title>
          <population>PK set included all participants who received study drug and had at least 1 measurable plasma concentration or amount of drug in the urine.</population>
          <units>hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.983" lower_limit="3.00" upper_limit="32.00"/>
                    <measurement group_id="O2" value="2.000" lower_limit="1.00" upper_limit="8.00"/>
                    <measurement group_id="O3" value="6.000" lower_limit="1.00" upper_limit="24.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Tmax: Time of First Occurrence of Cmax for TAK-071 SRD Non-Japanese Participants TAK-071+Donepezil</title>
        <time_frame>Pre-dose on Day 1 and at multiple time points (up to 168 hours) post-dose</time_frame>
        <population>PK set included all participants who received study drug and had at least 1 measurable plasma concentration or amount of drug in the urine.</population>
        <group_list>
          <group group_id="O1">
            <title>SRD: Cohort 20: TAK-071 40 mg+Donepezil</title>
            <description>TAK-071 40 mg capsule, orally, once on Day 1 followed by donepezil 10 mg, tablets, orally, once on Day 2 to non-Japanese healthy participants. Dose of TAK-071 was based on 24-hour safety, tolerability, and preliminary plasma PK data from Cohort 19.</description>
          </group>
          <group group_id="O2">
            <title>SRD: Cohort 21: TAK-071 60 mg+Donepezil</title>
            <description>TAK-071 60 mg capsule, orally, once on Day 1 followed by donepezil 10 mg, tablets, orally, once on Day 2 to non-Japanese healthy participants. Dose of TAK-071 was based on 24-hour safety and tolerability data from Cohort 20.</description>
          </group>
          <group group_id="O3">
            <title>SRD: Cohort 22: TAK-071 80 mg+Donepezil</title>
            <description>TAK-071 80 mg capsule, orally, once on Day 1, followed by donepezil 10 mg, tablets, orally, once on Day 2 to non-Japanese healthy participants. Dose of TAK-071 was based on 24-hour safety and tolerability data from Cohort 21.</description>
          </group>
        </group_list>
        <measure>
          <title>Tmax: Time of First Occurrence of Cmax for TAK-071 SRD Non-Japanese Participants TAK-071+Donepezil</title>
          <population>PK set included all participants who received study drug and had at least 1 measurable plasma concentration or amount of drug in the urine.</population>
          <units>hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.000" lower_limit="12.05" upper_limit="30.17"/>
                    <measurement group_id="O2" value="26.000" lower_limit="4.02" upper_limit="27.00"/>
                    <measurement group_id="O3" value="30.000" lower_limit="28.00" upper_limit="32.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Cmax: Maximum Observed Plasma Concentration for TAK-071 Single-Rising Dose (SRD) Non-Japanese Participants</title>
        <time_frame>Pre-dose on Day 1 and at multiple time points (up to 168 hours) post-dose</time_frame>
        <population>PK set included all participants who received study drug and had at least 1 measurable plasma concentration or amount of drug in the urine.</population>
        <group_list>
          <group group_id="O1">
            <title>SRD: Cohort 1: TAK-071 1 mg</title>
            <description>TAK-071 1 mg, capsule, orally, once on Day 1 to non-Japanese healthy participants.</description>
          </group>
          <group group_id="O2">
            <title>SRD: Cohort 2: TAK-071 3 mg</title>
            <description>TAK-071 3 mg capsule, orally, once on Day 1 to non-Japanese healthy participants. Dose of TAK-071 was based on the 24-hour post-dose safety, tolerability and pharmacokinetic (PK) data from cohort 1.</description>
          </group>
          <group group_id="O3">
            <title>SRD: Cohort 3: TAK-071 9 mg</title>
            <description>TAK-071 9 mg capsule, orally, once on Day 1 to non-Japanese healthy participants. Dose of TAK-071 was based on 24-hour safety, tolerability, and preliminary plasma PK and 12-hour CSF PK data.</description>
          </group>
          <group group_id="O4">
            <title>SRD: Cohort 4: TAK-071 20 mg</title>
            <description>TAK-071 20 mg capsule, orally, once on Day 1 to non-Japanese healthy participants. Dose of TAK-071 was based on the 24-hour post-dose safety and tolerability data from previous cohort.</description>
          </group>
          <group group_id="O5">
            <title>SRD: Cohort 5: TAK-071 40 mg</title>
            <description>TAK-071 40 mg capsule, orally, once on Day 1 to non-Japanese healthy participants. Dose of TAK-071 will be based on 24-hour safety, tolerability, and preliminary plasma PK data from Cohort 4.</description>
          </group>
          <group group_id="O6">
            <title>SRD: Cohort 6: TAK-071 80 mg</title>
            <description>TAK-071 80 mg capsules, orally, once on Day 1 to non-Japanese healthy participants. Dose of TAK-071 was based on 24-hour safety, tolerability, and preliminary plasma PK data from Cohort 5</description>
          </group>
          <group group_id="O7">
            <title>SRD: Cohort 18: TAK-071 120 mg</title>
            <description>TAK-071 120 mg capsule, orally, once on Day 1 to non-Japanese healthy participants. Dose of TAK-071 was based on 24-hour safety, tolerability, and preliminary plasma PK data from Cohort 6.</description>
          </group>
          <group group_id="O8">
            <title>SRD: Cohort 19: TAK-071 160 mg</title>
            <description>TAK-071 160 mg capsule, orally, once on Day 1 to non-Japanese healthy participants. Dose of TAK-071 was based on 24-hour safety, tolerability, and preliminary plasma PK data from Cohort 18.</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax: Maximum Observed Plasma Concentration for TAK-071 Single-Rising Dose (SRD) Non-Japanese Participants</title>
          <population>PK set included all participants who received study drug and had at least 1 measurable plasma concentration or amount of drug in the urine.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.65" spread="5.8589"/>
                    <measurement group_id="O2" value="65.82" spread="5.4268"/>
                    <measurement group_id="O3" value="162.2" spread="36.548"/>
                    <measurement group_id="O4" value="328.0" spread="72.200"/>
                    <measurement group_id="O5" value="485.7" spread="240.47"/>
                    <measurement group_id="O6" value="901.7" spread="210.05"/>
                    <measurement group_id="O7" value="1292" spread="315.30"/>
                    <measurement group_id="O8" value="1387" spread="312.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Cmax: Maximum Observed Plasma Concentration for TAK-071 Multiple-Rising Dose (MRD) Non-Japanese Participants [Day 1]</title>
        <time_frame>Pre-dose on Day 1 and multiple time points (up to 24 hours) post-dose</time_frame>
        <population>PK set included all participants who received study drug and had at least 1 measurable plasma concentration or amount of drug in the urine.</population>
        <group_list>
          <group group_id="O1">
            <title>MRD: Cohort 7: TAK-071 3 mg</title>
            <description>TAK-071 3 mg capsules, orally, once daily from Day 1 up to Day 21 to non-Japanese healthy participants. Dose of TAK-071 was based on 24-hour safety and tolerability from Cohort 4 and the 24-hour preliminary plasma PK and 12-hour CSF PK data from Cohort 3.</description>
          </group>
          <group group_id="O2">
            <title>MRD: Cohort 8: TAK-071 9 mg</title>
            <description>TAK-071 9 mg capsules, orally, once daily from Day 1 up to Day 21 to non-Japanese healthy participants. Dose of TAK-071 was based on safety, tolerability and available PK data arising from the ongoing SRD part and previous MRD cohort.</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax: Maximum Observed Plasma Concentration for TAK-071 Multiple-Rising Dose (MRD) Non-Japanese Participants [Day 1]</title>
          <population>PK set included all participants who received study drug and had at least 1 measurable plasma concentration or amount of drug in the urine.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74.33" spread="18.186"/>
                    <measurement group_id="O2" value="196.2" spread="54.668"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Cmax: Maximum Observed Plasma Concentration for TAK-071 MRD Non-Japanese Participants [Day 21]</title>
        <time_frame>Pre-dose on Day 21 and multiple time points (up to 24 hours) post-dose</time_frame>
        <population>PK set included all participants who received study drug and had at least 1 measurable plasma concentration or amount of drug in the urine.</population>
        <group_list>
          <group group_id="O1">
            <title>MRD: Cohort 7: TAK-071 3 mg</title>
            <description>TAK-071 3 mg capsules, orally, once daily from Day 1 up to Day 21 to non-Japanese healthy participants. Dose of TAK-071 was based on 24-hour safety and tolerability from Cohort 4 and the 24-hour preliminary plasma PK and 12-hour CSF PK data from Cohort 3.</description>
          </group>
          <group group_id="O2">
            <title>MRD: Cohort 8: TAK-071 9 mg</title>
            <description>TAK-071 9 mg capsules, orally, once daily from Day 1 up to Day 21 to non-Japanese healthy participants. Dose of TAK-071 was based on safety, tolerability and available PK data arising from the ongoing SRD part and previous MRD cohort.</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax: Maximum Observed Plasma Concentration for TAK-071 MRD Non-Japanese Participants [Day 21]</title>
          <population>PK set included all participants who received study drug and had at least 1 measurable plasma concentration or amount of drug in the urine.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="244.5" spread="66.163"/>
                    <measurement group_id="O2" value="646.5" spread="95.032"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Cmax: Maximum Observed Plasma Concentration for TAK-071 MRD Non-Japanese Participants [Day 1]</title>
        <time_frame>Pre-dose on Day 1 and multiple time points (up to 96 hours) post-dose</time_frame>
        <population>PK set included all participants who received study drug and had at least 1 measurable plasma concentration or amount of drug in the urine.</population>
        <group_list>
          <group group_id="O1">
            <title>MRD: Cohort 9: TAK-071 15 mg</title>
            <description>TAK-071 15 mg capsule, orally, once on Day 1, followed by a washout period of 7 days, then TAK-071 once daily for 21 days to non-Japanese healthy participants. Dose of TAK-071 will be based on safety, tolerability and available PK data arising from the ongoing SRD part and previous MRD cohort.</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax: Maximum Observed Plasma Concentration for TAK-071 MRD Non-Japanese Participants [Day 1]</title>
          <population>PK set included all participants who received study drug and had at least 1 measurable plasma concentration or amount of drug in the urine.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="264.8" spread="70.516"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Cmax: Maximum Observed Plasma Concentration for TAK-071 MRD Non-Japanese Participants [Day 8]</title>
        <time_frame>Pre-dose on Day 8 and multiple time points (up to 24 hour) post-dose</time_frame>
        <population>PK set included all participants who received study drug and had at least 1 measurable plasma concentration or amount of drug in the urine.</population>
        <group_list>
          <group group_id="O1">
            <title>MRD: Cohort 9: TAK-071 15 mg</title>
            <description>TAK-071 15 mg capsule, orally, once on Day 1, followed by a washout period of 7 days, then TAK-071 once daily for 21 days to non-Japanese healthy participants. Dose of TAK-071 will be based on safety, tolerability and available PK data arising from the ongoing SRD part and previous MRD cohort.</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax: Maximum Observed Plasma Concentration for TAK-071 MRD Non-Japanese Participants [Day 8]</title>
          <population>PK set included all participants who received study drug and had at least 1 measurable plasma concentration or amount of drug in the urine.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="294.2" spread="57.007"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Cmax: Maximum Observed Plasma Concentration for TAK-071 MRD Non-Japanese Participants [Day 28]</title>
        <time_frame>Pre-dose on Day 28 and multiple time points (up to 36 hours) post-dose</time_frame>
        <population>PK set included all participants who received study drug and had at least 1 measurable plasma concentration or amount of drug in the urine.</population>
        <group_list>
          <group group_id="O1">
            <title>MRD: Cohort 9: TAK-071 15 mg</title>
            <description>TAK-071 15 mg capsule, orally, once on Day 1, followed by a washout period of 7 days, then TAK-071 once daily for 21 days to non-Japanese healthy participants. Dose of TAK-071 will be based on safety, tolerability and available PK data arising from the ongoing SRD part and previous MRD cohort.</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax: Maximum Observed Plasma Concentration for TAK-071 MRD Non-Japanese Participants [Day 28]</title>
          <population>PK set included all participants who received study drug and had at least 1 measurable plasma concentration or amount of drug in the urine.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="936.4" spread="173.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Cmax: Maximum Observed Plasma Concentration for TAK-071 MRD Japanese Participants [Day 1]</title>
        <time_frame>Pre-dose on Day 1 and multiple time points (up to 96 hours) post-dose</time_frame>
        <population>PK set included all participants who received study drug and had at least 1 measurable plasma concentration or amount of drug in the urine.</population>
        <group_list>
          <group group_id="O1">
            <title>MRD: Cohort 13: TAK-071 3 mg</title>
            <description>TAK-071 3 mg capsule, orally, once on Day 1, followed by a washout period of 7 days, then TAK-071 once daily for 21 days to Japanese healthy participants. Dose of TAK-071 was same as the dose used in MRD Cohort 7.</description>
          </group>
          <group group_id="O2">
            <title>MRD: Cohort 14: TAK-071 9 mg</title>
            <description>TAK-071 9 mg capsule or matching placebo, orally, once on Day 1, followed by a washout period of 7 days, then TAK-071 once daily for 21 days to Japanese healthy participants. Dose of TAK-071 was same as the dose used in MRD Cohort 8.</description>
          </group>
          <group group_id="O3">
            <title>MRD: Cohort 15: TAK-071 15 mg</title>
            <description>TAK-071 15 mg capsule, orally, once on Day 1, followed by a washout period of 7 days, then TAK-071 once daily for 21 days to Japanese healthy participants. Dose of TAK-071 was same as the dose used in MRD Cohort 9.</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax: Maximum Observed Plasma Concentration for TAK-071 MRD Japanese Participants [Day 1]</title>
          <population>PK set included all participants who received study drug and had at least 1 measurable plasma concentration or amount of drug in the urine.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78.98" spread="10.736"/>
                    <measurement group_id="O2" value="208.4" spread="47.773"/>
                    <measurement group_id="O3" value="278.0" spread="63.828"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Cmax: Maximum Observed Plasma Concentration for TAK-071 MRD Japanese Participants [Day 8]</title>
        <time_frame>Pre-dose on Day 8 and multiple time points (up to 24 hours) post-dose</time_frame>
        <population>PK set included all participants who received study drug and had at least 1 measurable plasma concentration or amount of drug in the urine.</population>
        <group_list>
          <group group_id="O1">
            <title>MRD: Cohort 13: TAK-071 3 mg</title>
            <description>TAK-071 3 mg capsule, orally, once on Day 1, followed by a washout period of 7 days, then TAK-071 once daily for 21 days to Japanese healthy participants. Dose of TAK-071 was same as the dose used in MRD Cohort 7.</description>
          </group>
          <group group_id="O2">
            <title>MRD: Cohort 14: TAK-071 9 mg</title>
            <description>TAK-071 9 mg capsule or matching placebo, orally, once on Day 1, followed by a washout period of 7 days, then TAK-071 once daily for 21 days to Japanese healthy participants. Dose of TAK-071 was same as the dose used in MRD Cohort 8.</description>
          </group>
          <group group_id="O3">
            <title>MRD: Cohort 15: TAK-071 15 mg</title>
            <description>TAK-071 15 mg capsule, orally, once on Day 1, followed by a washout period of 7 days, then TAK-071 once daily for 21 days to Japanese healthy participants. Dose of TAK-071 was same as the dose used in MRD Cohort 9.</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax: Maximum Observed Plasma Concentration for TAK-071 MRD Japanese Participants [Day 8]</title>
          <population>PK set included all participants who received study drug and had at least 1 measurable plasma concentration or amount of drug in the urine.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81.16" spread="17.379"/>
                    <measurement group_id="O2" value="235.4" spread="37.740"/>
                    <measurement group_id="O3" value="329.6" spread="99.889"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Cmax: Maximum Observed Plasma Concentration for TAK-071 MRD Japanese Participants [Day 28]</title>
        <time_frame>Pre-dose on Day 28 and multiple time points (up to 24 hours) post-dose</time_frame>
        <population>PK set included all participants who received study drug and had at least 1 measurable plasma concentration or amount of drug in the urine.</population>
        <group_list>
          <group group_id="O1">
            <title>MRD: Cohort 13: TAK-071 3 mg</title>
            <description>TAK-071 3 mg capsule, orally, once on Day 1, followed by a washout period of 7 days, then TAK-071 once daily for 21 days to Japanese healthy participants. Dose of TAK-071 was same as the dose used in MRD Cohort 7.</description>
          </group>
          <group group_id="O2">
            <title>MRD: Cohort 14: TAK-071 9 mg</title>
            <description>TAK-071 9 mg capsule or matching placebo, orally, once on Day 1, followed by a washout period of 7 days, then TAK-071 once daily for 21 days to Japanese healthy participants. Dose of TAK-071 was same as the dose used in MRD Cohort 8.</description>
          </group>
          <group group_id="O3">
            <title>MRD: Cohort 15: TAK-071 15 mg</title>
            <description>TAK-071 15 mg capsule, orally, once on Day 1, followed by a washout period of 7 days, then TAK-071 once daily for 21 days to Japanese healthy participants. Dose of TAK-071 was same as the dose used in MRD Cohort 9.</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax: Maximum Observed Plasma Concentration for TAK-071 MRD Japanese Participants [Day 28]</title>
          <population>PK set included all participants who received study drug and had at least 1 measurable plasma concentration or amount of drug in the urine.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="235.6" spread="49.242"/>
                    <measurement group_id="O2" value="680.2" spread="181.99"/>
                    <measurement group_id="O3" value="895.2" spread="420.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Cmax: Maximum Observed Plasma Concentration for TAK-071 MRD Non-Japanese Participants [Day 1]</title>
        <time_frame>Pre-dose on Day 1 and multiple time points (up to 24 hours) post-dose</time_frame>
        <population>PK set included all participants who received study drug and had at least 1 measurable plasma concentration or amount of drug in the urine.</population>
        <group_list>
          <group group_id="O1">
            <title>MRD: Cohort 10: TAK-071 3 mg+Donepezil 5 mg</title>
            <description>TAK-071 3 mg capsules, orally, once daily along with donepezil 5 mg, tablets, orally, once daily from Day 1 up to Day 21 to non-Japanese healthy participants who were pre-treated with donepezil 5 mg, tablet, once daily for 3 weeks prior to administration of TAK-071. Dose of TAK-071 was same as the dose used in MRD Cohort 7.</description>
          </group>
          <group group_id="O2">
            <title>MRD: Cohort 11: TAK-071 9 mg + Donepezil 5 mg</title>
            <description>TAK-071 9 mg capsules, orally, once daily along with donepezil 5 mg, tablets, orally, once daily from Day 1 up to Day 21 to non-Japanese healthy participants who were pre-treated with donepezil 5 mg, tablet, once daily for 3 weeks prior to administration of TAK-071. Dose of TAK-071 was same as the dose used in MRD Cohort 8.</description>
          </group>
          <group group_id="O3">
            <title>MRD: Cohort 12: TAK-071 15 mg+Donepezil 5 mg</title>
            <description>TAK-071 15 mg capsule, orally, once daily along with donepezil 5 mg, tablets, orally, once daily from Day 1 up to Day 21 to non-Japanese healthy participants who were pre-treated with donepezil 5 mg, tablet, once daily for 3 weeks prior to administration of TAK-071. Dose of TAK-071 was same as the dose used in MRD Cohort 9.</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax: Maximum Observed Plasma Concentration for TAK-071 MRD Non-Japanese Participants [Day 1]</title>
          <population>PK set included all participants who received study drug and had at least 1 measurable plasma concentration or amount of drug in the urine.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79.12" spread="12.954"/>
                    <measurement group_id="O2" value="194.2" spread="17.325"/>
                    <measurement group_id="O3" value="303.7" spread="32.371"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Cmax: Maximum Observed Plasma Concentration for TAK-071 MRD Non-Japanese Participants [Day 21]</title>
        <time_frame>Pre-dose on Day 21 and multiple time points (up to 24 hours) post-dose</time_frame>
        <population>PK set included all participants who received study drug and had at least 1 measurable plasma concentration or amount of drug in the urine.</population>
        <group_list>
          <group group_id="O1">
            <title>MRD: Cohort 10: TAK-071 3 mg+Donepezil 5 mg</title>
            <description>TAK-071 3 mg capsules, orally, once daily along with donepezil 5 mg, tablets, orally, once daily from Day 1 up to Day 21 to non-Japanese healthy participants who were pre-treated with donepezil 5 mg, tablet, once daily for 3 weeks prior to administration of TAK-071. Dose of TAK-071 was same as the dose used in MRD Cohort 7.</description>
          </group>
          <group group_id="O2">
            <title>MRD: Cohort 11: TAK-071 9 mg + Donepezil 5 mg</title>
            <description>TAK-071 9 mg capsules, orally, once daily along with donepezil 5 mg, tablets, orally, once daily from Day 1 up to Day 21 to non-Japanese healthy participants who were pre-treated with donepezil 5 mg, tablet, once daily for 3 weeks prior to administration of TAK-071. Dose of TAK-071 was same as the dose used in MRD Cohort 8.</description>
          </group>
          <group group_id="O3">
            <title>MRD: Cohort 12: TAK-071 15 mg+Donepezil 5 mg</title>
            <description>TAK-071 15 mg capsule, orally, once daily along with donepezil 5 mg, tablets, orally, once daily from Day 1 up to Day 21 to non-Japanese healthy participants who were pre-treated with donepezil 5 mg, tablet, once daily for 3 weeks prior to administration of TAK-071. Dose of TAK-071 was same as the dose used in MRD Cohort 9.</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax: Maximum Observed Plasma Concentration for TAK-071 MRD Non-Japanese Participants [Day 21]</title>
          <population>PK set included all participants who received study drug and had at least 1 measurable plasma concentration or amount of drug in the urine.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="232.8" spread="69.277"/>
                    <measurement group_id="O2" value="678.0" spread="67.620"/>
                    <measurement group_id="O3" value="970.7" spread="228.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Cmax: Maximum Observed Plasma Concentration for TAK-071 Relative Bioavailability and Food Effect</title>
        <time_frame>Pre-dose on Day 1 and multiple time points (up to 168 hours) post-dose</time_frame>
        <population>PK set included all participants who received study drug and had at least 1 measurable plasma concentration or amount of drug in the urine.</population>
        <group_list>
          <group group_id="O1">
            <title>Bioavailability (BA)/Food Effect: Cohort 17 Regimen A</title>
            <description>TAK-071 10 mg capsule, orally once on Day 1 in the fasted state in Period 1 or Period 2 or Period 3</description>
          </group>
          <group group_id="O2">
            <title>BA/Food Effect: Cohort 17 Regimen B</title>
            <description>TAK-071 10 mg tablet, orally, once on Day 1 in the fasted state in Period 1 or Period 2 or Period 3</description>
          </group>
          <group group_id="O3">
            <title>BA/Food Effect: Cohort 17 Regimen C</title>
            <description>TAK-071 10 mg tablet, orally, once on Day 1 in the fed state in Period 1 or Period 2 or Period 3</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax: Maximum Observed Plasma Concentration for TAK-071 Relative Bioavailability and Food Effect</title>
          <population>PK set included all participants who received study drug and had at least 1 measurable plasma concentration or amount of drug in the urine.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="219.7" spread="46.986"/>
                    <measurement group_id="O2" value="251.0" spread="41.946"/>
                    <measurement group_id="O3" value="242.5" spread="41.513"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Cmax: Maximum Observed Plasma Concentration for TAK-071 SRD Non-Japanese Participants TAK-071+Donepezil</title>
        <time_frame>Pre-dose on Day 1 and at multiple time points (up to 168 hours) post-dose</time_frame>
        <population>PK set included all participants who received study drug and had at least 1 measurable plasma concentration or amount of drug in the urine.</population>
        <group_list>
          <group group_id="O1">
            <title>SRD: Cohort 20: TAK-071 40 mg+Donepezil</title>
            <description>TAK-071 40 mg capsule, orally, once on Day 1 followed by donepezil 10 mg, tablets, orally, once on Day 2 to non-Japanese healthy participants. Dose of TAK-071 was based on 24-hour safety, tolerability, and preliminary plasma PK data from Cohort 19.</description>
          </group>
          <group group_id="O2">
            <title>SRD: Cohort 21: TAK-071 60 mg+Donepezil</title>
            <description>TAK-071 60 mg capsule, orally, once on Day 1 followed by donepezil 10 mg, tablets, orally, once on Day 2 to non-Japanese healthy participants. Dose of TAK-071 was based on 24-hour safety and tolerability data from Cohort 20.</description>
          </group>
          <group group_id="O3">
            <title>SRD: Cohort 22: TAK-071 80 mg+Donepezil</title>
            <description>TAK-071 80 mg capsule, orally, once on Day 1, followed by donepezil 10 mg, tablets, orally, once on Day 2 to non-Japanese healthy participants. Dose of TAK-071 was based on 24-hour safety and tolerability data from Cohort 21.</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax: Maximum Observed Plasma Concentration for TAK-071 SRD Non-Japanese Participants TAK-071+Donepezil</title>
          <population>PK set included all participants who received study drug and had at least 1 measurable plasma concentration or amount of drug in the urine.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1110" spread="85.440"/>
                    <measurement group_id="O2" value="725.8" spread="186.03"/>
                    <measurement group_id="O3" value="532.2" spread="28.508"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUC(0-24): Area Under the Plasma Concentration-Time Curve From Time 0 to 24 Hours for TAK-071 Single-Rising Dose (SRD) Non-Japanese Participants</title>
        <time_frame>Pre-dose on Day 1 and at multiple time points (up to 168 hours) post-dose</time_frame>
        <population>PK set included all participants who received study drug and had at least 1 measurable plasma concentration or amount of drug in the urine.</population>
        <group_list>
          <group group_id="O1">
            <title>SRD: Cohort 1: TAK-071 1 mg</title>
            <description>TAK-071 1 mg, capsule, orally, once on Day 1 to non-Japanese healthy participants.</description>
          </group>
          <group group_id="O2">
            <title>SRD: Cohort 2: TAK-071 3 mg</title>
            <description>TAK-071 3 mg capsule, orally, once on Day 1 to non-Japanese healthy participants. Dose of TAK-071 was based on the 24-hour post-dose safety, tolerability and pharmacokinetic (PK) data from cohort 1.</description>
          </group>
          <group group_id="O3">
            <title>SRD: Cohort 3: TAK-071 9 mg</title>
            <description>TAK-071 9 mg capsule, orally, once on Day 1 to non-Japanese healthy participants. Dose of TAK-071 was based on 24-hour safety, tolerability, and preliminary plasma PK and 12-hour CSF PK data.</description>
          </group>
          <group group_id="O4">
            <title>SRD: Cohort 4: TAK-071 20 mg</title>
            <description>TAK-071 20 mg capsule, orally, once on Day 1 to non-Japanese healthy participants. Dose of TAK-071 was based on the 24-hour post-dose safety and tolerability data from previous cohort.</description>
          </group>
          <group group_id="O5">
            <title>SRD: Cohort 5: TAK-071 40 mg</title>
            <description>TAK-071 40 mg capsule, orally, once on Day 1 to non-Japanese healthy participants. Dose of TAK-071 will be based on 24-hour safety, tolerability, and preliminary plasma PK data from Cohort 4.</description>
          </group>
          <group group_id="O6">
            <title>SRD: Cohort 6: TAK-071 80 mg</title>
            <description>TAK-071 80 mg capsules, orally, once on Day 1 to non-Japanese healthy participants. Dose of TAK-071 was based on 24-hour safety, tolerability, and preliminary plasma PK data from Cohort 5</description>
          </group>
          <group group_id="O7">
            <title>SRD: Cohort 18: TAK-071 120 mg</title>
            <description>TAK-071 120 mg capsule, orally, once on Day 1 to non-Japanese healthy participants. Dose of TAK-071 was based on 24-hour safety, tolerability, and preliminary plasma PK data from Cohort 6.</description>
          </group>
          <group group_id="O8">
            <title>SRD: Cohort 19: TAK-071 160 mg</title>
            <description>TAK-071 160 mg capsule, orally, once on Day 1 to non-Japanese healthy participants. Dose of TAK-071 was based on 24-hour safety, tolerability, and preliminary plasma PK data from Cohort 18.</description>
          </group>
        </group_list>
        <measure>
          <title>AUC(0-24): Area Under the Plasma Concentration-Time Curve From Time 0 to 24 Hours for TAK-071 Single-Rising Dose (SRD) Non-Japanese Participants</title>
          <population>PK set included all participants who received study drug and had at least 1 measurable plasma concentration or amount of drug in the urine.</population>
          <units>h*ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="459.3" spread="111.88"/>
                    <measurement group_id="O2" value="1197" spread="92.810"/>
                    <measurement group_id="O3" value="3257" spread="634.89"/>
                    <measurement group_id="O4" value="6383" spread="1162.4"/>
                    <measurement group_id="O5" value="8905" spread="4529.9"/>
                    <measurement group_id="O6" value="16300" spread="3468.9"/>
                    <measurement group_id="O7" value="22350" spread="7203.2"/>
                    <measurement group_id="O8" value="25660" spread="8297.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUC(0-24): Area Under the Plasma Concentration-Time Curve From Time 0 to 24 Hours for TAK-071 Multiple-Rising Dose (MRD) Non-Japanese Participants [Day 1]</title>
        <time_frame>Pre-dose on Day 1 and multiple time points (up to 24 hours) post-dose</time_frame>
        <population>PK set included all participants who received study drug and had at least 1 measurable plasma concentration or amount of drug in the urine.</population>
        <group_list>
          <group group_id="O1">
            <title>MRD: Cohort 7: TAK-071 3 mg</title>
            <description>TAK-071 3 mg capsules, orally, once daily from Day 1 up to Day 21 to non-Japanese healthy participants. Dose of TAK-071 was based on 24-hour safety and tolerability from Cohort 4 and the 24-hour preliminary plasma PK and 12-hour CSF PK data from Cohort 3.</description>
          </group>
          <group group_id="O2">
            <title>MRD: Cohort 8: TAK-071 9 mg</title>
            <description>TAK-071 9 mg capsules, orally, once daily from Day 1 up to Day 21 to non-Japanese healthy participants. Dose of TAK-071 was based on safety, tolerability and available PK data arising from the ongoing SRD part and previous MRD cohort.</description>
          </group>
        </group_list>
        <measure>
          <title>AUC(0-24): Area Under the Plasma Concentration-Time Curve From Time 0 to 24 Hours for TAK-071 Multiple-Rising Dose (MRD) Non-Japanese Participants [Day 1]</title>
          <population>PK set included all participants who received study drug and had at least 1 measurable plasma concentration or amount of drug in the urine.</population>
          <units>h*ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1347" spread="302.98"/>
                    <measurement group_id="O2" value="3550" spread="765.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUC(0-24): Area Under the Plasma Concentration-Time Curve From Time 0 to 24 Hours for TAK-071 MRD Non-Japanese Participants [Day 21]</title>
        <time_frame>Pre-dose on Day 21 and multiple time points (up to 24 hours) post-dose</time_frame>
        <population>PK set included all participants who received study drug and had at least 1 measurable plasma concentration or amount of drug in the urine.</population>
        <group_list>
          <group group_id="O1">
            <title>MRD: Cohort 7: TAK-071 3 mg</title>
            <description>TAK-071 3 mg capsules, orally, once daily from Day 1 up to Day 21 to non-Japanese healthy participants. Dose of TAK-071 was based on 24-hour safety and tolerability from Cohort 4 and the 24-hour preliminary plasma PK and 12-hour CSF PK data from Cohort 3.</description>
          </group>
          <group group_id="O2">
            <title>MRD: Cohort 8: TAK-071 9 mg</title>
            <description>TAK-071 9 mg capsules, orally, once daily from Day 1 up to Day 21 to non-Japanese healthy participants. Dose of TAK-071 was based on safety, tolerability and available PK data arising from the ongoing SRD part and previous MRD cohort.</description>
          </group>
        </group_list>
        <measure>
          <title>AUC(0-24): Area Under the Plasma Concentration-Time Curve From Time 0 to 24 Hours for TAK-071 MRD Non-Japanese Participants [Day 21]</title>
          <population>PK set included all participants who received study drug and had at least 1 measurable plasma concentration or amount of drug in the urine.</population>
          <units>h*ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4783" spread="1258.0"/>
                    <measurement group_id="O2" value="12520" spread="2132.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUC(0-24): Area Under the Plasma Concentration-Time Curve From Time 0 to 24 Hours for TAK-071 MRD Non-Japanese Participants [Day 1]</title>
        <time_frame>Pre-dose on Day 1 and multiple time points (up to 96 hours) post-dose</time_frame>
        <population>PK set included all participants who received study drug and had at least 1 measurable plasma concentration or amount of drug in the urine.</population>
        <group_list>
          <group group_id="O1">
            <title>MRD: Cohort 9: TAK-071 15 mg</title>
            <description>TAK-071 15 mg capsule, orally, once on Day 1, followed by a washout period of 7 days, then TAK-071 once daily for 21 days to non-Japanese healthy participants. Dose of TAK-071 will be based on safety, tolerability and available PK data arising from the ongoing SRD part and previous MRD cohort.</description>
          </group>
        </group_list>
        <measure>
          <title>AUC(0-24): Area Under the Plasma Concentration-Time Curve From Time 0 to 24 Hours for TAK-071 MRD Non-Japanese Participants [Day 1]</title>
          <population>PK set included all participants who received study drug and had at least 1 measurable plasma concentration or amount of drug in the urine.</population>
          <units>h*ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5332" spread="1688.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUC(0-24): Area Under the Plasma Concentration-Time Curve From Time 0 to 24 Hours for TAK-071 MRD Non-Japanese Participants [Day 8]</title>
        <time_frame>Pre-dose on Day 8 and multiple time points (up to 24 hour) post-dose</time_frame>
        <population>PK set included all participants who received study drug and had at least 1 measurable plasma concentration or amount of drug in the urine.</population>
        <group_list>
          <group group_id="O1">
            <title>MRD: Cohort 9: TAK-071 15 mg</title>
            <description>TAK-071 15 mg capsule, orally, once on Day 1, followed by a washout period of 7 days, then TAK-071 once daily for 21 days to non-Japanese healthy participants. Dose of TAK-071 will be based on safety, tolerability and available PK data arising from the ongoing SRD part and previous MRD cohort.</description>
          </group>
        </group_list>
        <measure>
          <title>AUC(0-24): Area Under the Plasma Concentration-Time Curve From Time 0 to 24 Hours for TAK-071 MRD Non-Japanese Participants [Day 8]</title>
          <population>PK set included all participants who received study drug and had at least 1 measurable plasma concentration or amount of drug in the urine.</population>
          <units>h*ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5831" spread="998.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUC(0-24): Area Under the Plasma Concentration-Time Curve From Time 0 to 24 Hours for TAK-071 MRD Non-Japanese Participants [Day 28]</title>
        <time_frame>Pre-dose on Day 28 and multiple time points (up to 36 hours) post-dose</time_frame>
        <population>PK set included all participants who received study drug and had at least 1 measurable plasma concentration or amount of drug in the urine.</population>
        <group_list>
          <group group_id="O1">
            <title>MRD: Cohort 9: TAK-071 15 mg</title>
            <description>TAK-071 15 mg capsule, orally, once on Day 1, followed by a washout period of 7 days, then TAK-071 once daily for 21 days to non-Japanese healthy participants. Dose of TAK-071 will be based on safety, tolerability and available PK data arising from the ongoing SRD part and previous MRD cohort.</description>
          </group>
        </group_list>
        <measure>
          <title>AUC(0-24): Area Under the Plasma Concentration-Time Curve From Time 0 to 24 Hours for TAK-071 MRD Non-Japanese Participants [Day 28]</title>
          <population>PK set included all participants who received study drug and had at least 1 measurable plasma concentration or amount of drug in the urine.</population>
          <units>h*ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19920" spread="4563.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUC(0-24): Area Under the Plasma Concentration-Time Curve From Time 0 to 24 Hours for TAK-071 MRD Japanese Participants [Day 1]</title>
        <time_frame>Pre-dose on Day 1 and multiple time points (up to 96 hours) post-dose</time_frame>
        <population>PK set included all participants who received study drug and had at least 1 measurable plasma concentration or amount of drug in the urine.</population>
        <group_list>
          <group group_id="O1">
            <title>MRD: Cohort 13: TAK-071 3 mg</title>
            <description>TAK-071 3 mg capsule, orally, once on Day 1, followed by a washout period of 7 days, then TAK-071 once daily for 21 days to Japanese healthy participants. Dose of TAK-071 was same as the dose used in MRD Cohort 7.</description>
          </group>
          <group group_id="O2">
            <title>MRD: Cohort 14: TAK-071 9 mg</title>
            <description>TAK-071 9 mg capsule or matching placebo, orally, once on Day 1, followed by a washout period of 7 days, then TAK-071 once daily for 21 days to Japanese healthy participants. Dose of TAK-071 was same as the dose used in MRD Cohort 8.</description>
          </group>
          <group group_id="O3">
            <title>MRD: Cohort 15: TAK-071 15 mg</title>
            <description>TAK-071 15 mg capsule, orally, once on Day 1, followed by a washout period of 7 days, then TAK-071 once daily for 21 days to Japanese healthy participants. Dose of TAK-071 was same as the dose used in MRD Cohort 9.</description>
          </group>
        </group_list>
        <measure>
          <title>AUC(0-24): Area Under the Plasma Concentration-Time Curve From Time 0 to 24 Hours for TAK-071 MRD Japanese Participants [Day 1]</title>
          <population>PK set included all participants who received study drug and had at least 1 measurable plasma concentration or amount of drug in the urine.</population>
          <units>h*ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1485" spread="271.95"/>
                    <measurement group_id="O2" value="4201" spread="822.67"/>
                    <measurement group_id="O3" value="5581" spread="1141.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUC(0-24): Area Under the Plasma Concentration-Time Curve From Time 0 to 24 Hours for TAK-071 MRD Japanese Participants [Day 8]</title>
        <time_frame>Pre-dose on Day 8 and multiple time points (up to 24 hours) post-dose</time_frame>
        <population>PK set included all participants who received study drug and had at least 1 measurable plasma concentration or amount of drug in the urine.</population>
        <group_list>
          <group group_id="O1">
            <title>MRD: Cohort 13: TAK-071 3 mg</title>
            <description>TAK-071 3 mg capsule, orally, once on Day 1, followed by a washout period of 7 days, then TAK-071 once daily for 21 days to Japanese healthy participants. Dose of TAK-071 was same as the dose used in MRD Cohort 7.</description>
          </group>
          <group group_id="O2">
            <title>MRD: Cohort 14: TAK-071 9 mg</title>
            <description>TAK-071 9 mg capsule or matching placebo, orally, once on Day 1, followed by a washout period of 7 days, then TAK-071 once daily for 21 days to Japanese healthy participants. Dose of TAK-071 was same as the dose used in MRD Cohort 8.</description>
          </group>
          <group group_id="O3">
            <title>MRD: Cohort 15: TAK-071 15 mg</title>
            <description>TAK-071 15 mg capsule, orally, once on Day 1, followed by a washout period of 7 days, then TAK-071 once daily for 21 days to Japanese healthy participants. Dose of TAK-071 was same as the dose used in MRD Cohort 9.</description>
          </group>
        </group_list>
        <measure>
          <title>AUC(0-24): Area Under the Plasma Concentration-Time Curve From Time 0 to 24 Hours for TAK-071 MRD Japanese Participants [Day 8]</title>
          <population>PK set included all participants who received study drug and had at least 1 measurable plasma concentration or amount of drug in the urine.</population>
          <units>h*ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1529" spread="344.00"/>
                    <measurement group_id="O2" value="4634" spread="787.02"/>
                    <measurement group_id="O3" value="6110" spread="1217.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUC(0-24): Area Under the Plasma Concentration-Time Curve From Time 0 to 24 Hours for TAK-071 MRD Japanese Participants [Day 28]</title>
        <time_frame>Pre-dose on Day 28 and multiple time points (up to 24 hours) post-dose</time_frame>
        <population>PK set included all participants who received study drug and had at least 1 measurable plasma concentration or amount of drug in the urine.</population>
        <group_list>
          <group group_id="O1">
            <title>MRD: Cohort 13: TAK-071 3 mg</title>
            <description>TAK-071 3 mg capsule, orally, once on Day 1, followed by a washout period of 7 days, then TAK-071 once daily for 21 days to Japanese healthy participants. Dose of TAK-071 was same as the dose used in MRD Cohort 7.</description>
          </group>
          <group group_id="O2">
            <title>MRD: Cohort 14: TAK-071 9 mg</title>
            <description>TAK-071 9 mg capsule or matching placebo, orally, once on Day 1, followed by a washout period of 7 days, then TAK-071 once daily for 21 days to Japanese healthy participants. Dose of TAK-071 was same as the dose used in MRD Cohort 8.</description>
          </group>
          <group group_id="O3">
            <title>MRD: Cohort 15: TAK-071 15 mg</title>
            <description>TAK-071 15 mg capsule, orally, once on Day 1, followed by a washout period of 7 days, then TAK-071 once daily for 21 days to Japanese healthy participants. Dose of TAK-071 was same as the dose used in MRD Cohort 9.</description>
          </group>
        </group_list>
        <measure>
          <title>AUC(0-24): Area Under the Plasma Concentration-Time Curve From Time 0 to 24 Hours for TAK-071 MRD Japanese Participants [Day 28]</title>
          <population>PK set included all participants who received study drug and had at least 1 measurable plasma concentration or amount of drug in the urine.</population>
          <units>h*ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4439" spread="1135.6"/>
                    <measurement group_id="O2" value="13450" spread="3024.3"/>
                    <measurement group_id="O3" value="17120" spread="8088.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUC(0-24): Area Under the Plasma Concentration-Time Curve From Time 0 to 24 Hours for TAK-071 MRD Non-Japanese Participants [Day 1]</title>
        <time_frame>Pre-dose on Day 1 and multiple time points (up to 24 hours) post-dose</time_frame>
        <population>PK set included all participants who received study drug and had at least 1 measurable plasma concentration or amount of drug in the urine.</population>
        <group_list>
          <group group_id="O1">
            <title>MRD: Cohort 10: TAK-071 3 mg+Donepezil 5 mg</title>
            <description>TAK-071 3 mg capsules, orally, once daily along with donepezil 5 mg, tablets, orally, once daily from Day 1 up to Day 21 to non-Japanese healthy participants who were pre-treated with donepezil 5 mg, tablet, once daily for 3 weeks prior to administration of TAK-071. Dose of TAK-071 was same as the dose used in MRD Cohort 7.</description>
          </group>
          <group group_id="O2">
            <title>MRD: Cohort 11: TAK-071 9 mg + Donepezil 5 mg</title>
            <description>TAK-071 9 mg capsules, orally, once daily along with donepezil 5 mg, tablets, orally, once daily from Day 1 up to Day 21 to non-Japanese healthy participants who were pre-treated with donepezil 5 mg, tablet, once daily for 3 weeks prior to administration of TAK-071. Dose of TAK-071 was same as the dose used in MRD Cohort 8.</description>
          </group>
          <group group_id="O3">
            <title>MRD: Cohort 12: TAK-071 15 mg+Donepezil 5 mg</title>
            <description>TAK-071 15 mg capsule, orally, once daily along with donepezil 5 mg, tablets, orally, once daily from Day 1 up to Day 21 to non-Japanese healthy participants who were pre-treated with donepezil 5 mg, tablet, once daily for 3 weeks prior to administration of TAK-071. Dose of TAK-071 was same as the dose used in MRD Cohort 9.</description>
          </group>
        </group_list>
        <measure>
          <title>AUC(0-24): Area Under the Plasma Concentration-Time Curve From Time 0 to 24 Hours for TAK-071 MRD Non-Japanese Participants [Day 1]</title>
          <population>PK set included all participants who received study drug and had at least 1 measurable plasma concentration or amount of drug in the urine.</population>
          <units>h*ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1442" spread="251.62"/>
                    <measurement group_id="O2" value="3636" spread="286.83"/>
                    <measurement group_id="O3" value="5832" spread="921.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUC(0-24): Area Under the Plasma Concentration-Time Curve From Time 0 to 24 Hours for TAK-071 MRD Non-Japanese Participants [Day 21]</title>
        <time_frame>Pre-dose on Day 21 and multiple time points (up to 24 hours) post-dose</time_frame>
        <population>PK set included all participants who received study drug and had at least 1 measurable plasma concentration or amount of drug in the urine.</population>
        <group_list>
          <group group_id="O1">
            <title>MRD: Cohort 10: TAK-071 3 mg+Donepezil 5 mg</title>
            <description>TAK-071 3 mg capsules, orally, once daily along with donepezil 5 mg, tablets, orally, once daily from Day 1 up to Day 21 to non-Japanese healthy participants who were pre-treated with donepezil 5 mg, tablet, once daily for 3 weeks prior to administration of TAK-071. Dose of TAK-071 was same as the dose used in MRD Cohort 7.</description>
          </group>
          <group group_id="O2">
            <title>MRD: Cohort 11: TAK-071 9 mg + Donepezil 5 mg</title>
            <description>TAK-071 9 mg capsules, orally, once daily along with donepezil 5 mg, tablets, orally, once daily from Day 1 up to Day 21 to non-Japanese healthy participants who were pre-treated with donepezil 5 mg, tablet, once daily for 3 weeks prior to administration of TAK-071. Dose of TAK-071 was same as the dose used in MRD Cohort 8.</description>
          </group>
          <group group_id="O3">
            <title>MRD: Cohort 12: TAK-071 15 mg+Donepezil 5 mg</title>
            <description>TAK-071 15 mg capsule, orally, once daily along with donepezil 5 mg, tablets, orally, once daily from Day 1 up to Day 21 to non-Japanese healthy participants who were pre-treated with donepezil 5 mg, tablet, once daily for 3 weeks prior to administration of TAK-071. Dose of TAK-071 was same as the dose used in MRD Cohort 9.</description>
          </group>
        </group_list>
        <measure>
          <title>AUC(0-24): Area Under the Plasma Concentration-Time Curve From Time 0 to 24 Hours for TAK-071 MRD Non-Japanese Participants [Day 21]</title>
          <population>PK set included all participants who received study drug and had at least 1 measurable plasma concentration or amount of drug in the urine.</population>
          <units>h*ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4467" spread="1461.6"/>
                    <measurement group_id="O2" value="13570" spread="1647.0"/>
                    <measurement group_id="O3" value="19210" spread="4669.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUC∞: Area Under the Plasma Concentration-Time Curve From Time 0 to Infinity for TAK-071 Relative Bioavailability and Food Effect</title>
        <time_frame>Pre-dose on Day 21 and multiple time points (up to 168 hours) post-dose</time_frame>
        <population>PK set included all participants who received study drug and had at least 1 measurable plasma concentration or amount of drug in the urine.</population>
        <group_list>
          <group group_id="O1">
            <title>Bioavailability (BA)/Food Effect: Cohort 17 Regimen A</title>
            <description>TAK-071 10 mg capsule, orally once on Day 1 in the fasted state in Period 1 or Period 2 or Period 3</description>
          </group>
          <group group_id="O2">
            <title>BA/Food Effect: Cohort 17 Regimen B</title>
            <description>TAK-071 10 mg tablet, orally, once on Day 1 in the fasted state in Period 1 or Period 2 or Period 3</description>
          </group>
          <group group_id="O3">
            <title>BA/Food Effect: Cohort 17 Regimen C</title>
            <description>TAK-071 10 mg tablet, orally, once on Day 1 in the fed state in Period 1 or Period 2 or Period 3</description>
          </group>
        </group_list>
        <measure>
          <title>AUC∞: Area Under the Plasma Concentration-Time Curve From Time 0 to Infinity for TAK-071 Relative Bioavailability and Food Effect</title>
          <population>PK set included all participants who received study drug and had at least 1 measurable plasma concentration or amount of drug in the urine.</population>
          <units>h*ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16010" spread="4812.0"/>
                    <measurement group_id="O2" value="15190" spread="4576.6"/>
                    <measurement group_id="O3" value="16610" spread="5003.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUC(0-24): Area Under the Plasma Concentration-Time Curve From Time 0 to 24 Hours for TAK-071 SRD Non-Japanese Participants TAK-071+Donepezil</title>
        <time_frame>Pre-dose on Day 1 and at multiple time points (up to 168 hours) post-dose</time_frame>
        <population>PK set included all participants who received study drug and had at least 1 measurable plasma concentration or amount of drug in the urine.</population>
        <group_list>
          <group group_id="O1">
            <title>SRD: Cohort 20: TAK-071 40 mg+Donepezil</title>
            <description>TAK-071 40 mg capsule, orally, once on Day 1 followed by donepezil 10 mg, tablets, orally, once on Day 2 to non-Japanese healthy participants. Dose of TAK-071 was based on 24-hour safety, tolerability, and preliminary plasma PK data from Cohort 19.</description>
          </group>
          <group group_id="O2">
            <title>SRD: Cohort 21: TAK-071 60 mg+Donepezil</title>
            <description>TAK-071 60 mg capsule, orally, once on Day 1 followed by donepezil 10 mg, tablets, orally, once on Day 2 to non-Japanese healthy participants. Dose of TAK-071 was based on 24-hour safety and tolerability data from Cohort 20.</description>
          </group>
          <group group_id="O3">
            <title>SRD: Cohort 22: TAK-071 80 mg+Donepezil</title>
            <description>TAK-071 80 mg capsule, orally, once on Day 1, followed by donepezil 10 mg, tablets, orally, once on Day 2 to non-Japanese healthy participants. Dose of TAK-071 was based on 24-hour safety and tolerability data from Cohort 21.</description>
          </group>
        </group_list>
        <measure>
          <title>AUC(0-24): Area Under the Plasma Concentration-Time Curve From Time 0 to 24 Hours for TAK-071 SRD Non-Japanese Participants TAK-071+Donepezil</title>
          <population>PK set included all participants who received study drug and had at least 1 measurable plasma concentration or amount of drug in the urine.</population>
          <units>h*ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18370" spread="2361.9"/>
                    <measurement group_id="O2" value="12810" spread="2177.9"/>
                    <measurement group_id="O3" value="9440" spread="1353.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUC∞: Area Under the Concentration-Time Curve From Time 0 to Infinity, Calculated Using the Observed Value of the Last Quantifiable Concentration for TAK-071 SRD Non-Japanese Participants</title>
        <time_frame>Pre-dose on Day 1 and at multiple time points [up to 168 hours] post-dose</time_frame>
        <population>PK set included all participants who received study drug and had at least 1 measurable plasma concentration or amount of drug in the urine.</population>
        <group_list>
          <group group_id="O1">
            <title>SRD: Cohort 1: TAK-071 1 mg</title>
            <description>TAK-071 1 mg, capsule, orally, once on Day 1 to non-Japanese healthy participants.</description>
          </group>
          <group group_id="O2">
            <title>SRD: Cohort 2: TAK-071 3 mg</title>
            <description>TAK-071 3 mg capsule, orally, once on Day 1 to non-Japanese healthy participants. Dose of TAK-071 was based on the 24-hour post-dose safety, tolerability and pharmacokinetic (PK) data from cohort 1.</description>
          </group>
          <group group_id="O3">
            <title>SRD: Cohort 3: TAK-071 9 mg</title>
            <description>TAK-071 9 mg capsule, orally, once on Day 1 to non-Japanese healthy participants. Dose of TAK-071 was based on 24-hour safety, tolerability, and preliminary plasma PK and 12-hour CSF PK data.</description>
          </group>
          <group group_id="O4">
            <title>SRD: Cohort 4: TAK-071 20 mg</title>
            <description>TAK-071 20 mg capsule, orally, once on Day 1 to non-Japanese healthy participants. Dose of TAK-071 was based on the 24-hour post-dose safety and tolerability data from previous cohort.</description>
          </group>
          <group group_id="O5">
            <title>SRD: Cohort 5: TAK-071 40 mg</title>
            <description>TAK-071 40 mg capsule, orally, once on Day 1 to non-Japanese healthy participants. Dose of TAK-071 will be based on 24-hour safety, tolerability, and preliminary plasma PK data from Cohort 4.</description>
          </group>
          <group group_id="O6">
            <title>SRD: Cohort 6: TAK-071 80 mg</title>
            <description>TAK-071 80 mg capsules, orally, once on Day 1 to non-Japanese healthy participants. Dose of TAK-071 was based on 24-hour safety, tolerability, and preliminary plasma PK data from Cohort 5</description>
          </group>
          <group group_id="O7">
            <title>SRD: Cohort 18: TAK-071 120 mg</title>
            <description>TAK-071 120 mg capsule, orally, once on Day 1 to non-Japanese healthy participants. Dose of TAK-071 was based on 24-hour safety, tolerability, and preliminary plasma PK data from Cohort 6.</description>
          </group>
          <group group_id="O8">
            <title>SRD: Cohort 19: TAK-071 160 mg</title>
            <description>TAK-071 160 mg capsule, orally, once on Day 1 to non-Japanese healthy participants. Dose of TAK-071 was based on 24-hour safety, tolerability, and preliminary plasma PK data from Cohort 18.</description>
          </group>
        </group_list>
        <measure>
          <title>AUC∞: Area Under the Concentration-Time Curve From Time 0 to Infinity, Calculated Using the Observed Value of the Last Quantifiable Concentration for TAK-071 SRD Non-Japanese Participants</title>
          <population>PK set included all participants who received study drug and had at least 1 measurable plasma concentration or amount of drug in the urine.</population>
          <units>h*ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1651" spread="644.79"/>
                    <measurement group_id="O2" value="5070" spread="3802.0"/>
                    <measurement group_id="O3" value="15640" spread="5944.7"/>
                    <measurement group_id="O4" value="30980" spread="5932.8"/>
                    <measurement group_id="O5" value="49550" spread="33766"/>
                    <measurement group_id="O6" value="106000" spread="19610"/>
                    <measurement group_id="O7" value="132700" spread="46773"/>
                    <measurement group_id="O8" value="162100" spread="69191"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUC∞: Area Under the Concentration-Time Curve From Time 0 to Infinity, Calculated Using the Observed Value of the Last Quantifiable Concentration for TAK-071 SRD Non-Japanese Participants TAK-071 + Donepezil</title>
        <time_frame>Pre-dose on Day 1 and at multiple time points [up to 168 hours] post-dose</time_frame>
        <population>PK set included all participants who received study drug and had at least 1 measurable plasma concentration or amount of drug in the urine.</population>
        <group_list>
          <group group_id="O1">
            <title>SRD: Cohort 20: TAK-071 40 mg+Donepezil</title>
            <description>TAK-071 40 mg capsule, orally, once on Day 1 followed by donepezil 10 mg, tablets, orally, once on Day 2 to non-Japanese healthy participants. Dose of TAK-071 was based on 24-hour safety, tolerability, and preliminary plasma PK data from Cohort 19.</description>
          </group>
          <group group_id="O2">
            <title>SRD: Cohort 21: TAK-071 60 mg+Donepezil</title>
            <description>TAK-071 60 mg capsule, orally, once on Day 1 followed by donepezil 10 mg, tablets, orally, once on Day 2 to non-Japanese healthy participants. Dose of TAK-071 was based on 24-hour safety and tolerability data from Cohort 20.</description>
          </group>
          <group group_id="O3">
            <title>SRD: Cohort 22: TAK-071 80 mg+Donepezil</title>
            <description>TAK-071 80 mg capsule, orally, once on Day 1, followed by donepezil 10 mg, tablets, orally, once on Day 2 to non-Japanese healthy participants. Dose of TAK-071 was based on 24-hour safety and tolerability data from Cohort 21.</description>
          </group>
        </group_list>
        <measure>
          <title>AUC∞: Area Under the Concentration-Time Curve From Time 0 to Infinity, Calculated Using the Observed Value of the Last Quantifiable Concentration for TAK-071 SRD Non-Japanese Participants TAK-071 + Donepezil</title>
          <population>PK set included all participants who received study drug and had at least 1 measurable plasma concentration or amount of drug in the urine.</population>
          <units>h*ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97640" spread="22123"/>
                    <measurement group_id="O2" value="48750" spread="12598"/>
                    <measurement group_id="O3" value="46370" spread="6094.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AUClast: Area Under the Concentration-time Curve From Time 0 to Time of the Last Quantifiable Concentration for TAK-071 MRD Non-Japanese Participants</title>
        <time_frame>Pre-dose on Day 1 and at multiple time points (up to 168 hours) post-dose</time_frame>
        <population>PK set included all participants who received study drug and had at least 1 measurable plasma concentration or amount of drug in the urine.</population>
        <group_list>
          <group group_id="O1">
            <title>SRD: Cohort 1: TAK-071 1 mg</title>
            <description>TAK-071 1 mg, capsule, orally, once on Day 1 to non-Japanese healthy participants.</description>
          </group>
          <group group_id="O2">
            <title>SRD: Cohort 2: TAK-071 3 mg</title>
            <description>TAK-071 3 mg capsule, orally, once on Day 1 to non-Japanese healthy participants. Dose of TAK-071 was based on the 24-hour post-dose safety, tolerability and pharmacokinetic (PK) data from cohort 1.</description>
          </group>
          <group group_id="O3">
            <title>SRD: Cohort 3: TAK-071 9 mg</title>
            <description>TAK-071 9 mg capsule, orally, once on Day 1 to non-Japanese healthy participants. Dose of TAK-071 was based on 24-hour safety, tolerability, and preliminary plasma PK and 12-hour CSF PK data.</description>
          </group>
          <group group_id="O4">
            <title>SRD: Cohort 4: TAK-071 20 mg</title>
            <description>TAK-071 20 mg capsule, orally, once on Day 1 to non-Japanese healthy participants. Dose of TAK-071 was based on the 24-hour post-dose safety and tolerability data from previous cohort.</description>
          </group>
          <group group_id="O5">
            <title>SRD: Cohort 5: TAK-071 40 mg</title>
            <description>TAK-071 40 mg capsule, orally, once on Day 1 to non-Japanese healthy participants. Dose of TAK-071 will be based on 24-hour safety, tolerability, and preliminary plasma PK data from Cohort 4.</description>
          </group>
          <group group_id="O6">
            <title>SRD: Cohort 6: TAK-071 80 mg</title>
            <description>TAK-071 80 mg capsules, orally, once on Day 1 to non-Japanese healthy participants. Dose of TAK-071 was based on 24-hour safety, tolerability, and preliminary plasma PK data from Cohort 5</description>
          </group>
          <group group_id="O7">
            <title>SRD: Cohort 18: TAK-071 120 mg</title>
            <description>TAK-071 120 mg capsule, orally, once on Day 1 to non-Japanese healthy participants. Dose of TAK-071 was based on 24-hour safety, tolerability, and preliminary plasma PK data from Cohort 6.</description>
          </group>
          <group group_id="O8">
            <title>SRD: Cohort 19: TAK-071 160 mg</title>
            <description>TAK-071 160 mg capsule, orally, once on Day 1 to non-Japanese healthy participants. Dose of TAK-071 was based on 24-hour safety, tolerability, and preliminary plasma PK data from Cohort 18.</description>
          </group>
        </group_list>
        <measure>
          <title>AUClast: Area Under the Concentration-time Curve From Time 0 to Time of the Last Quantifiable Concentration for TAK-071 MRD Non-Japanese Participants</title>
          <population>PK set included all participants who received study drug and had at least 1 measurable plasma concentration or amount of drug in the urine.</population>
          <units>h*ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1220" spread="397.35"/>
                    <measurement group_id="O2" value="3945" spread="1784.9"/>
                    <measurement group_id="O3" value="12450" spread="2466.5"/>
                    <measurement group_id="O4" value="26010" spread="3656.6"/>
                    <measurement group_id="O5" value="40240" spread="23644"/>
                    <measurement group_id="O6" value="90350" spread="13944"/>
                    <measurement group_id="O7" value="111700" spread="31926"/>
                    <measurement group_id="O8" value="133000" spread="45126"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AUClast: Area Under the Concentration-time Curve From Time 0 to Time of the Last Quantifiable Concentration for TAK-071 MRD Non-Japanese Participants</title>
        <time_frame>Pre-dose on Day 1 and multiple timepoints (up to 24 hrs) post-dose for Cohorts 7 and 8 and Pre-dose on Day 1 and multiple timepoints (up to 96 hrs) post-dose for Cohort 9</time_frame>
        <population>PK set included all participants who received study drug and had at least 1 measurable plasma concentration or amount of drug in the urine.</population>
        <group_list>
          <group group_id="O1">
            <title>MRD: Cohort 7: TAK-071 3 mg</title>
            <description>TAK-071 3 mg capsules, orally, once daily from Day 1 up to Day 21 to non-Japanese healthy participants. Dose of TAK-071 was based on 24-hour safety and tolerability from Cohort 4 and the 24-hour preliminary plasma PK and 12-hour CSF PK data from Cohort 3.</description>
          </group>
          <group group_id="O2">
            <title>MRD: Cohort 8: TAK-071 9 mg</title>
            <description>TAK-071 9 mg capsules, orally, once daily from Day 1 up to Day 21 to non-Japanese healthy participants. Dose of TAK-071 was based on safety, tolerability and available PK data arising from the ongoing SRD part and previous MRD cohort.</description>
          </group>
          <group group_id="O3">
            <title>MRD: Cohort 9: TAK-071 15 mg</title>
            <description>TAK-071 15 mg capsule, orally, once on Day 1, followed by a washout period of 7 days, then TAK-071 once daily for 21 days to non-Japanese healthy participants. Dose of TAK-071 will be based on safety, tolerability and available PK data arising from the ongoing SRD part and previous MRD cohort.</description>
          </group>
        </group_list>
        <measure>
          <title>AUClast: Area Under the Concentration-time Curve From Time 0 to Time of the Last Quantifiable Concentration for TAK-071 MRD Non-Japanese Participants</title>
          <population>PK set included all participants who received study drug and had at least 1 measurable plasma concentration or amount of drug in the urine.</population>
          <units>h*ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1347" spread="302.98"/>
                    <measurement group_id="O2" value="3550" spread="765.01"/>
                    <measurement group_id="O3" value="16880" spread="4514.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AUClast: Area Under the Concentration-time Curve From Time 0 to Time of the Last Quantifiable Concentration for TAK-071 MRD Japanese Participants</title>
        <time_frame>Pre-dose on Day 1 and multiple time points (up to 96 hours) post-dose and Pre-dose on Day 8 and multiple time points (up to 24 hours) post-dose</time_frame>
        <population>PK set included all participants who received study drug and had at least 1 measurable plasma concentration or amount of drug in the urine.</population>
        <group_list>
          <group group_id="O1">
            <title>MRD: Cohort 13: TAK-071 3 mg</title>
            <description>TAK-071 3 mg capsule, orally, once on Day 1, followed by a washout period of 7 days, then TAK-071 once daily for 21 days to Japanese healthy participants. Dose of TAK-071 was same as the dose used in MRD Cohort 7.</description>
          </group>
          <group group_id="O2">
            <title>MRD: Cohort 14: TAK-071 9 mg</title>
            <description>TAK-071 9 mg capsule or matching placebo, orally, once on Day 1, followed by a washout period of 7 days, then TAK-071 once daily for 21 days to Japanese healthy participants. Dose of TAK-071 was same as the dose used in MRD Cohort 8.</description>
          </group>
          <group group_id="O3">
            <title>MRD: Cohort 15: TAK-071 15 mg</title>
            <description>TAK-071 15 mg capsule, orally, once on Day 1, followed by a washout period of 7 days, then TAK-071 once daily for 21 days to Japanese healthy participants. Dose of TAK-071 was same as the dose used in MRD Cohort 9.</description>
          </group>
        </group_list>
        <measure>
          <title>AUClast: Area Under the Concentration-time Curve From Time 0 to Time of the Last Quantifiable Concentration for TAK-071 MRD Japanese Participants</title>
          <population>PK set included all participants who received study drug and had at least 1 measurable plasma concentration or amount of drug in the urine.</population>
          <units>h*ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3773" spread="968.76"/>
                    <measurement group_id="O2" value="11930" spread="2764.4"/>
                    <measurement group_id="O3" value="15790" spread="3273.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1529" spread="344.00"/>
                    <measurement group_id="O2" value="4634" spread="787.02"/>
                    <measurement group_id="O3" value="6110" spread="1217.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AUClast: Area Under the Concentration-time Curve From Time 0 to Time of the Last Quantifiable Concentration for TAK-071 MRD Non-Japanese</title>
        <time_frame>Pre-dose on Day 1 and at multiple time points (up to 24 hours) post-dose</time_frame>
        <population>PK set included all participants who received study drug and had at least 1 measurable plasma concentration or amount of drug in the urine.</population>
        <group_list>
          <group group_id="O1">
            <title>MRD: Cohort 10: TAK-071 3 mg+Donepezil 5 mg</title>
            <description>TAK-071 3 mg capsules, orally, once daily along with donepezil 5 mg, tablets, orally, once daily from Day 1 up to Day 21 to non-Japanese healthy participants who were pre-treated with donepezil 5 mg, tablet, once daily for 3 weeks prior to administration of TAK-071. Dose of TAK-071 was same as the dose used in MRD Cohort 7.</description>
          </group>
          <group group_id="O2">
            <title>MRD: Cohort 11: TAK-071 9 mg + Donepezil 5 mg</title>
            <description>TAK-071 9 mg capsules, orally, once daily along with donepezil 5 mg, tablets, orally, once daily from Day 1 up to Day 21 to non-Japanese healthy participants who were pre-treated with donepezil 5 mg, tablet, once daily for 3 weeks prior to administration of TAK-071. Dose of TAK-071 was same as the dose used in MRD Cohort 8.</description>
          </group>
          <group group_id="O3">
            <title>MRD: Cohort 12: TAK-071 15 mg+Donepezil 5 mg</title>
            <description>TAK-071 15 mg capsule, orally, once daily along with donepezil 5 mg, tablets, orally, once daily from Day 1 up to Day 21 to non-Japanese healthy participants who were pre-treated with donepezil 5 mg, tablet, once daily for 3 weeks prior to administration of TAK-071. Dose of TAK-071 was same as the dose used in MRD Cohort 9.</description>
          </group>
        </group_list>
        <measure>
          <title>AUClast: Area Under the Concentration-time Curve From Time 0 to Time of the Last Quantifiable Concentration for TAK-071 MRD Non-Japanese</title>
          <population>PK set included all participants who received study drug and had at least 1 measurable plasma concentration or amount of drug in the urine.</population>
          <units>h*ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1442" spread="251.62"/>
                    <measurement group_id="O2" value="3636" spread="286.83"/>
                    <measurement group_id="O3" value="5832" spread="921.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AUClast: Area Under the Concentration-time Curve From Time 0 to Time of the Last Quantifiable Concentration for TAK-071 Relative Bioavailability and Food Effect</title>
        <time_frame>Pre-dose on Day 1 and multiple time points (up to 168 hours) post-dose</time_frame>
        <population>PK set included all participants who received study drug and had at least 1 measurable plasma concentration or amount of drug in the urine.</population>
        <group_list>
          <group group_id="O1">
            <title>Bioavailability (BA)/Food Effect: Cohort 17 Regimen A</title>
            <description>TAK-071 10 mg capsule, orally once on Day 1 in the fasted state in Period 1 or Period 2 or Period 3</description>
          </group>
          <group group_id="O2">
            <title>BA/Food Effect: Cohort 17 Regimen B</title>
            <description>TAK-071 10 mg tablet, orally, once on Day 1 in the fasted state in Period 1 or Period 2 or Period 3</description>
          </group>
          <group group_id="O3">
            <title>BA/Food Effect: Cohort 17 Regimen C</title>
            <description>TAK-071 10 mg tablet, orally, once on Day 1 in the fed state in Period 1 or Period 2 or Period 3</description>
          </group>
        </group_list>
        <measure>
          <title>AUClast: Area Under the Concentration-time Curve From Time 0 to Time of the Last Quantifiable Concentration for TAK-071 Relative Bioavailability and Food Effect</title>
          <population>PK set included all participants who received study drug and had at least 1 measurable plasma concentration or amount of drug in the urine.</population>
          <units>h*ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14210" spread="3392.5"/>
                    <measurement group_id="O2" value="13260" spread="2983.9"/>
                    <measurement group_id="O3" value="14610" spread="3324.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AUClast: Area Under the Concentration-time Curve From Time 0 to Time of the Last Quantifiable Concentration for TAK-071 SRD Non-Japanese Participants TAK-071+Donepezil</title>
        <time_frame>Pre-dose on Day 1 and multiple time points (up to 168 hours) post-dose</time_frame>
        <population>PK set included all participants who received study drug and had at least 1 measurable plasma concentration or amount of drug in the urine.</population>
        <group_list>
          <group group_id="O1">
            <title>SRD: Cohort 20: TAK-071 40 mg+Donepezil</title>
            <description>TAK-071 40 mg capsule, orally, once on Day 1 followed by donepezil 10 mg, tablets, orally, once on Day 2 to non-Japanese healthy participants. Dose of TAK-071 was based on 24-hour safety, tolerability, and preliminary plasma PK data from Cohort 19.</description>
          </group>
          <group group_id="O2">
            <title>SRD: Cohort 21: TAK-071 60 mg+Donepezil</title>
            <description>TAK-071 60 mg capsule, orally, once on Day 1 followed by donepezil 10 mg, tablets, orally, once on Day 2 to non-Japanese healthy participants. Dose of TAK-071 was based on 24-hour safety and tolerability data from Cohort 20.</description>
          </group>
          <group group_id="O3">
            <title>SRD: Cohort 22: TAK-071 80 mg+Donepezil</title>
            <description>TAK-071 80 mg capsule, orally, once on Day 1, followed by donepezil 10 mg, tablets, orally, once on Day 2 to non-Japanese healthy participants. Dose of TAK-071 was based on 24-hour safety and tolerability data from Cohort 21.</description>
          </group>
        </group_list>
        <measure>
          <title>AUClast: Area Under the Concentration-time Curve From Time 0 to Time of the Last Quantifiable Concentration for TAK-071 SRD Non-Japanese Participants TAK-071+Donepezil</title>
          <population>PK set included all participants who received study drug and had at least 1 measurable plasma concentration or amount of drug in the urine.</population>
          <units>h*ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85650" spread="13013"/>
                    <measurement group_id="O2" value="45970" spread="10798"/>
                    <measurement group_id="O3" value="41070" spread="4387.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Terminal Disposition Phase Half-life (t1/2z) for TAK-071 SRD Non-Japanese Participants</title>
        <time_frame>Pre-dose on Day 1 and at multiple time points (up to 168 hours) post-dose</time_frame>
        <population>PK set included all participants who received study drug and had at least 1 measurable plasma concentration or amount of drug in the urine.</population>
        <group_list>
          <group group_id="O1">
            <title>SRD: Cohort 1: TAK-071 1 mg</title>
            <description>TAK-071 1 mg, capsule, orally, once on Day 1 to non-Japanese healthy participants.</description>
          </group>
          <group group_id="O2">
            <title>SRD: Cohort 2: TAK-071 3 mg</title>
            <description>TAK-071 3 mg capsule, orally, once on Day 1 to non-Japanese healthy participants. Dose of TAK-071 was based on the 24-hour post-dose safety, tolerability and pharmacokinetic (PK) data from cohort 1.</description>
          </group>
          <group group_id="O3">
            <title>SRD: Cohort 3: TAK-071 9 mg</title>
            <description>TAK-071 9 mg capsule, orally, once on Day 1 to non-Japanese healthy participants. Dose of TAK-071 was based on 24-hour safety, tolerability, and preliminary plasma PK and 12-hour CSF PK data.</description>
          </group>
          <group group_id="O4">
            <title>SRD: Cohort 4: TAK-071 20 mg</title>
            <description>TAK-071 20 mg capsule, orally, once on Day 1 to non-Japanese healthy participants. Dose of TAK-071 was based on the 24-hour post-dose safety and tolerability data from previous cohort.</description>
          </group>
          <group group_id="O5">
            <title>SRD: Cohort 5: TAK-071 40 mg</title>
            <description>TAK-071 40 mg capsule, orally, once on Day 1 to non-Japanese healthy participants. Dose of TAK-071 will be based on 24-hour safety, tolerability, and preliminary plasma PK data from Cohort 4.</description>
          </group>
          <group group_id="O6">
            <title>SRD: Cohort 6: TAK-071 80 mg</title>
            <description>TAK-071 80 mg capsules, orally, once on Day 1 to non-Japanese healthy participants. Dose of TAK-071 was based on 24-hour safety, tolerability, and preliminary plasma PK data from Cohort 5</description>
          </group>
          <group group_id="O7">
            <title>SRD: Cohort 18: TAK-071 120 mg</title>
            <description>TAK-071 120 mg capsule, orally, once on Day 1 to non-Japanese healthy participants. Dose of TAK-071 was based on 24-hour safety, tolerability, and preliminary plasma PK data from Cohort 6.</description>
          </group>
          <group group_id="O8">
            <title>SRD: Cohort 19: TAK-071 160 mg</title>
            <description>TAK-071 160 mg capsule, orally, once on Day 1 to non-Japanese healthy participants. Dose of TAK-071 was based on 24-hour safety, tolerability, and preliminary plasma PK data from Cohort 18.</description>
          </group>
        </group_list>
        <measure>
          <title>Terminal Disposition Phase Half-life (t1/2z) for TAK-071 SRD Non-Japanese Participants</title>
          <population>PK set included all participants who received study drug and had at least 1 measurable plasma concentration or amount of drug in the urine.</population>
          <units>hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.894" lower_limit="30.41" upper_limit="57.35"/>
                    <measurement group_id="O2" value="35.567" lower_limit="23.34" upper_limit="132.30"/>
                    <measurement group_id="O3" value="54.998" lower_limit="24.53" upper_limit="106.28"/>
                    <measurement group_id="O4" value="57.504" lower_limit="41.58" upper_limit="84.66"/>
                    <measurement group_id="O5" value="53.219" lower_limit="22.51" upper_limit="99.01"/>
                    <measurement group_id="O6" value="55.246" lower_limit="32.94" upper_limit="68.05"/>
                    <measurement group_id="O7" value="51.933" lower_limit="32.02" upper_limit="84.96"/>
                    <measurement group_id="O8" value="58.165" lower_limit="32.58" upper_limit="87.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Terminal Disposition Phase Half-life (t1/2z) for TAK-071 Relative Bioavailability and Food Effect</title>
        <time_frame>Pre-dose on Day 21 and multiple time points (up to 168 hours) post-dose</time_frame>
        <population>PK set included all participants who received study drug and had at least 1 measurable plasma concentration or amount of drug in the urine.</population>
        <group_list>
          <group group_id="O1">
            <title>Bioavailability (BA)/Food Effect: Cohort 17 Regimen A</title>
            <description>TAK-071 10 mg capsule, orally once on Day 1 in the fasted state in Period 1 or Period 2 or Period 3</description>
          </group>
          <group group_id="O2">
            <title>BA/Food Effect: Cohort 17 Regimen B</title>
            <description>TAK-071 10 mg tablet, orally, once on Day 1 in the fasted state in Period 1 or Period 2 or Period 3</description>
          </group>
          <group group_id="O3">
            <title>BA/Food Effect: Cohort 17 Regimen C</title>
            <description>TAK-071 10 mg tablet, orally, once on Day 1 in the fed state in Period 1 or Period 2 or Period 3</description>
          </group>
        </group_list>
        <measure>
          <title>Terminal Disposition Phase Half-life (t1/2z) for TAK-071 Relative Bioavailability and Food Effect</title>
          <population>PK set included all participants who received study drug and had at least 1 measurable plasma concentration or amount of drug in the urine.</population>
          <units>hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.804" lower_limit="23.44" upper_limit="92.82"/>
                    <measurement group_id="O2" value="50.590" lower_limit="23.31" upper_limit="94.14"/>
                    <measurement group_id="O3" value="49.796" lower_limit="23.35" upper_limit="100.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Terminal Disposition Phase Half-life (t1/2z) for TAK-071 SRD Non-Japanese Participants TAK-071+Donepezil</title>
        <time_frame>Pre-dose on Day 1 and multiple time points (up to 168 hours) post-dose</time_frame>
        <population>PK set included all participants who received study drug and had at least 1 measurable plasma concentration or amount of drug in the urine.</population>
        <group_list>
          <group group_id="O1">
            <title>SRD: Cohort 20: TAK-071 40 mg+Donepezil</title>
            <description>TAK-071 40 mg capsule, orally, once on Day 1 followed by donepezil 10 mg, tablets, orally, once on Day 2 to non-Japanese healthy participants. Dose of TAK-071 was based on 24-hour safety, tolerability, and preliminary plasma PK data from Cohort 19.</description>
          </group>
          <group group_id="O2">
            <title>SRD: Cohort 21: TAK-071 60 mg+Donepezil</title>
            <description>TAK-071 60 mg capsule, orally, once on Day 1 followed by donepezil 10 mg, tablets, orally, once on Day 2 to non-Japanese healthy participants. Dose of TAK-071 was based on 24-hour safety and tolerability data from Cohort 20.</description>
          </group>
          <group group_id="O3">
            <title>SRD: Cohort 22: TAK-071 80 mg+Donepezil</title>
            <description>TAK-071 80 mg capsule, orally, once on Day 1, followed by donepezil 10 mg, tablets, orally, once on Day 2 to non-Japanese healthy participants. Dose of TAK-071 was based on 24-hour safety and tolerability data from Cohort 21.</description>
          </group>
        </group_list>
        <measure>
          <title>Terminal Disposition Phase Half-life (t1/2z) for TAK-071 SRD Non-Japanese Participants TAK-071+Donepezil</title>
          <population>PK set included all participants who received study drug and had at least 1 measurable plasma concentration or amount of drug in the urine.</population>
          <units>hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.923" lower_limit="40.47" upper_limit="67.70"/>
                    <measurement group_id="O2" value="33.505" lower_limit="21.92" upper_limit="56.08"/>
                    <measurement group_id="O3" value="50.077" lower_limit="37.37" upper_limit="63.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>CL/F: Apparent Clearance After Extravascular Administration for TAK-071 SRD Non-Japanese Participants</title>
        <time_frame>Pre-dose on Day 1 and at multiple time points (up to 168 hours) post-dose</time_frame>
        <population>PK set included all participants who received study drug and had at least 1 measurable plasma concentration or amount of drug in the urine.</population>
        <group_list>
          <group group_id="O1">
            <title>SRD: Cohort 1: TAK-071 1 mg</title>
            <description>TAK-071 1 mg, capsule, orally, once on Day 1 to non-Japanese healthy participants.</description>
          </group>
          <group group_id="O2">
            <title>SRD: Cohort 2: TAK-071 3 mg</title>
            <description>TAK-071 3 mg capsule, orally, once on Day 1 to non-Japanese healthy participants. Dose of TAK-071 was based on the 24-hour post-dose safety, tolerability and pharmacokinetic (PK) data from cohort 1.</description>
          </group>
          <group group_id="O3">
            <title>SRD: Cohort 3: TAK-071 9 mg</title>
            <description>TAK-071 9 mg capsule, orally, once on Day 1 to non-Japanese healthy participants. Dose of TAK-071 was based on 24-hour safety, tolerability, and preliminary plasma PK and 12-hour CSF PK data.</description>
          </group>
          <group group_id="O4">
            <title>SRD: Cohort 4: TAK-071 20 mg</title>
            <description>TAK-071 20 mg capsule, orally, once on Day 1 to non-Japanese healthy participants. Dose of TAK-071 was based on the 24-hour post-dose safety and tolerability data from previous cohort.</description>
          </group>
          <group group_id="O5">
            <title>SRD: Cohort 5: TAK-071 40 mg</title>
            <description>TAK-071 40 mg capsule, orally, once on Day 1 to non-Japanese healthy participants. Dose of TAK-071 will be based on 24-hour safety, tolerability, and preliminary plasma PK data from Cohort 4.</description>
          </group>
          <group group_id="O6">
            <title>SRD: Cohort 6: TAK-071 80 mg</title>
            <description>TAK-071 80 mg capsules, orally, once on Day 1 to non-Japanese healthy participants. Dose of TAK-071 was based on 24-hour safety, tolerability, and preliminary plasma PK data from Cohort 5</description>
          </group>
          <group group_id="O7">
            <title>SRD: Cohort 18: TAK-071 120 mg</title>
            <description>TAK-071 120 mg capsule, orally, once on Day 1 to non-Japanese healthy participants. Dose of TAK-071 was based on 24-hour safety, tolerability, and preliminary plasma PK data from Cohort 6.</description>
          </group>
          <group group_id="O8">
            <title>SRD: Cohort 19: TAK-071 160 mg</title>
            <description>TAK-071 160 mg capsule, orally, once on Day 1 to non-Japanese healthy participants. Dose of TAK-071 was based on 24-hour safety, tolerability, and preliminary plasma PK data from Cohort 18.</description>
          </group>
        </group_list>
        <measure>
          <title>CL/F: Apparent Clearance After Extravascular Administration for TAK-071 SRD Non-Japanese Participants</title>
          <population>PK set included all participants who received study drug and had at least 1 measurable plasma concentration or amount of drug in the urine.</population>
          <units>L/h</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.7222" spread="0.36130"/>
                    <measurement group_id="O2" value="0.7998" spread="0.36546"/>
                    <measurement group_id="O3" value="0.6494" spread="0.24348"/>
                    <measurement group_id="O4" value="0.6644" spread="0.12027"/>
                    <measurement group_id="O5" value="3.844" spread="7.3558"/>
                    <measurement group_id="O6" value="0.7762" spread="0.13868"/>
                    <measurement group_id="O7" value="1.008" spread="0.36826"/>
                    <measurement group_id="O8" value="1.141" spread="0.45838"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>CL/F: Apparent Clearance After Extravascular Administration for TAK-071 Relative Bioavailability and Food Effect</title>
        <time_frame>Pre-dose on Day 21 and multiple time points (up to 168 hours) post-dose</time_frame>
        <population>PK set included all participants who received study drug and had at least 1 measurable plasma concentration or amount of drug in the urine.</population>
        <group_list>
          <group group_id="O1">
            <title>Bioavailability (BA)/Food Effect: Cohort 17 Regimen A</title>
            <description>TAK-071 10 mg capsule, orally once on Day 1 in the fasted state in Period 1 or Period 2 or Period 3</description>
          </group>
          <group group_id="O2">
            <title>BA/Food Effect: Cohort 17 Regimen B</title>
            <description>TAK-071 10 mg tablet, orally, once on Day 1 in the fasted state in Period 1 or Period 2 or Period 3</description>
          </group>
          <group group_id="O3">
            <title>BA/Food Effect: Cohort 17 Regimen C</title>
            <description>TAK-071 10 mg tablet, orally, once on Day 1 in the fed state in Period 1 or Period 2 or Period 3</description>
          </group>
        </group_list>
        <measure>
          <title>CL/F: Apparent Clearance After Extravascular Administration for TAK-071 Relative Bioavailability and Food Effect</title>
          <population>PK set included all participants who received study drug and had at least 1 measurable plasma concentration or amount of drug in the urine.</population>
          <units>L/h</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.6925" spread="0.27468"/>
                    <measurement group_id="O2" value="0.7232" spread="0.26191"/>
                    <measurement group_id="O3" value="0.6663" spread="0.25695"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>CL/F: Apparent Clearance After Extravascular Administration for TAK-071 SRD Non-Japanese Participants TAK-071+Donepezil</title>
        <time_frame>Pre-dose on Day 1 and at multiple time points (up to 168 hours) post-dose</time_frame>
        <population>PK set included all participants who received study drug and had at least 1 measurable plasma concentration or amount of drug in the urine.</population>
        <group_list>
          <group group_id="O1">
            <title>SRD: Cohort 20: TAK-071 40 mg+Donepezil</title>
            <description>TAK-071 40 mg capsule, orally, once on Day 1 followed by donepezil 10 mg, tablets, orally, once on Day 2 to non-Japanese healthy participants. Dose of TAK-071 was based on 24-hour safety, tolerability, and preliminary plasma PK data from Cohort 19.</description>
          </group>
          <group group_id="O2">
            <title>SRD: Cohort 21: TAK-071 60 mg+Donepezil</title>
            <description>TAK-071 60 mg capsule, orally, once on Day 1 followed by donepezil 10 mg, tablets, orally, once on Day 2 to non-Japanese healthy participants. Dose of TAK-071 was based on 24-hour safety and tolerability data from Cohort 20.</description>
          </group>
          <group group_id="O3">
            <title>SRD: Cohort 22: TAK-071 80 mg+Donepezil</title>
            <description>TAK-071 80 mg capsule, orally, once on Day 1, followed by donepezil 10 mg, tablets, orally, once on Day 2 to non-Japanese healthy participants. Dose of TAK-071 was based on 24-hour safety and tolerability data from Cohort 21.</description>
          </group>
        </group_list>
        <measure>
          <title>CL/F: Apparent Clearance After Extravascular Administration for TAK-071 SRD Non-Japanese Participants TAK-071+Donepezil</title>
          <population>PK set included all participants who received study drug and had at least 1 measurable plasma concentration or amount of drug in the urine.</population>
          <units>L/h</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8453" spread="0.17228"/>
                    <measurement group_id="O2" value="1.304" spread="0.34484"/>
                    <measurement group_id="O3" value="0.8742" spread="0.11009"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Vz/F: Apparent Volume of Distribution During the Terminal Disposition Phase After Extravascular Administration for TAK-071 SRD Non-Japanese Participants</title>
        <time_frame>Pre-dose on Day 1 and at multiple time points (up to 168 hours) post-dose</time_frame>
        <population>PK set included all participants who received study drug and had at least 1 measurable plasma concentration or amount of drug in the urine.</population>
        <group_list>
          <group group_id="O1">
            <title>SRD: Cohort 1: TAK-071 1 mg</title>
            <description>TAK-071 1 mg, capsule, orally, once on Day 1 to non-Japanese healthy participants.</description>
          </group>
          <group group_id="O2">
            <title>SRD: Cohort 2: TAK-071 3 mg</title>
            <description>TAK-071 3 mg capsule, orally, once on Day 1 to non-Japanese healthy participants. Dose of TAK-071 was based on the 24-hour post-dose safety, tolerability and pharmacokinetic (PK) data from cohort 1.</description>
          </group>
          <group group_id="O3">
            <title>SRD: Cohort 3: TAK-071 9 mg</title>
            <description>TAK-071 9 mg capsule, orally, once on Day 1 to non-Japanese healthy participants. Dose of TAK-071 was based on 24-hour safety, tolerability, and preliminary plasma PK and 12-hour CSF PK data.</description>
          </group>
          <group group_id="O4">
            <title>SRD: Cohort 4: TAK-071 20 mg</title>
            <description>TAK-071 20 mg capsule, orally, once on Day 1 to non-Japanese healthy participants. Dose of TAK-071 was based on the 24-hour post-dose safety and tolerability data from previous cohort.</description>
          </group>
          <group group_id="O5">
            <title>SRD: Cohort 5: TAK-071 40 mg</title>
            <description>TAK-071 40 mg capsule, orally, once on Day 1 to non-Japanese healthy participants. Dose of TAK-071 will be based on 24-hour safety, tolerability, and preliminary plasma PK data from Cohort 4.</description>
          </group>
          <group group_id="O6">
            <title>SRD: Cohort 6: TAK-071 80 mg</title>
            <description>TAK-071 80 mg capsules, orally, once on Day 1 to non-Japanese healthy participants. Dose of TAK-071 was based on 24-hour safety, tolerability, and preliminary plasma PK data from Cohort 5</description>
          </group>
          <group group_id="O7">
            <title>SRD: Cohort 18: TAK-071 120 mg</title>
            <description>TAK-071 120 mg capsule, orally, once on Day 1 to non-Japanese healthy participants. Dose of TAK-071 was based on 24-hour safety, tolerability, and preliminary plasma PK data from Cohort 6.</description>
          </group>
          <group group_id="O8">
            <title>SRD: Cohort 19: TAK-071 160 mg</title>
            <description>TAK-071 160 mg capsule, orally, once on Day 1 to non-Japanese healthy participants. Dose of TAK-071 was based on 24-hour safety, tolerability, and preliminary plasma PK data from Cohort 18.</description>
          </group>
        </group_list>
        <measure>
          <title>Vz/F: Apparent Volume of Distribution During the Terminal Disposition Phase After Extravascular Administration for TAK-071 SRD Non-Japanese Participants</title>
          <population>PK set included all participants who received study drug and had at least 1 measurable plasma concentration or amount of drug in the urine.</population>
          <units>L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.63" spread="10.532"/>
                    <measurement group_id="O2" value="44.96" spread="5.7176"/>
                    <measurement group_id="O3" value="48.10" spread="9.0985"/>
                    <measurement group_id="O4" value="54.62" spread="9.8917"/>
                    <measurement group_id="O5" value="321.0" spread="656.95"/>
                    <measurement group_id="O6" value="59.54" spread="11.499"/>
                    <measurement group_id="O7" value="70.25" spread="9.1042"/>
                    <measurement group_id="O8" value="84.47" spread="16.851"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Vz/F: Apparent Volume of Distribution During the Terminal Disposition Phase After Extravascular Administration for TAK-071 Relative Bioavailability and Food Effect</title>
        <time_frame>Pre-dose on Day 21 and multiple time points (up to 168 hours) post-dose</time_frame>
        <population>PK set included all participants who received study drug and had at least 1 measurable plasma concentration or amount of drug in the urine.</population>
        <group_list>
          <group group_id="O1">
            <title>Bioavailability (BA)/Food Effect: Cohort 17 Regimen A</title>
            <description>TAK-071 10 mg capsule, orally once on Day 1 in the fasted state in Period 1 or Period 2 or Period 3</description>
          </group>
          <group group_id="O2">
            <title>BA/Food Effect: Cohort 17 Regimen B</title>
            <description>TAK-071 10 mg tablet, orally, once on Day 1 in the fasted state in Period 1 or Period 2 or Period 3</description>
          </group>
          <group group_id="O3">
            <title>BA/Food Effect: Cohort 17 Regimen C</title>
            <description>TAK-071 10 mg tablet, orally, once on Day 1 in the fed state in Period 1 or Period 2 or Period 3</description>
          </group>
        </group_list>
        <measure>
          <title>Vz/F: Apparent Volume of Distribution During the Terminal Disposition Phase After Extravascular Administration for TAK-071 Relative Bioavailability and Food Effect</title>
          <population>PK set included all participants who received study drug and had at least 1 measurable plasma concentration or amount of drug in the urine.</population>
          <units>L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.43" spread="7.1688"/>
                    <measurement group_id="O2" value="46.74" spread="7.3595"/>
                    <measurement group_id="O3" value="43.82" spread="6.3235"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Vz/F: Apparent Volume of Distribution During the Terminal Disposition Phase After Extravascular Administration for TAK-071 SRD Non-Japanese Participants TAK-071 + Donepezil</title>
        <time_frame>Pre-dose on Day 1 and at multiple time points (up to 168 hours) post-dose</time_frame>
        <population>PK set included all participants who received study drug and had at least 1 measurable plasma concentration or amount of drug in the urine.</population>
        <group_list>
          <group group_id="O1">
            <title>SRD: Cohort 20: TAK-071 40 mg+Donepezil</title>
            <description>TAK-071 40 mg capsule, orally, once on Day 1 followed by donepezil 10 mg, tablets, orally, once on Day 2 to non-Japanese healthy participants. Dose of TAK-071 was based on 24-hour safety, tolerability, and preliminary plasma PK data from Cohort 19.</description>
          </group>
          <group group_id="O2">
            <title>SRD: Cohort 21: TAK-071 60 mg+Donepezil</title>
            <description>TAK-071 60 mg capsule, orally, once on Day 1 followed by donepezil 10 mg, tablets, orally, once on Day 2 to non-Japanese healthy participants. Dose of TAK-071 was based on 24-hour safety and tolerability data from Cohort 20.</description>
          </group>
          <group group_id="O3">
            <title>SRD: Cohort 22: TAK-071 80 mg+Donepezil</title>
            <description>TAK-071 80 mg capsule, orally, once on Day 1, followed by donepezil 10 mg, tablets, orally, once on Day 2 to non-Japanese healthy participants. Dose of TAK-071 was based on 24-hour safety and tolerability data from Cohort 21.</description>
          </group>
        </group_list>
        <measure>
          <title>Vz/F: Apparent Volume of Distribution During the Terminal Disposition Phase After Extravascular Administration for TAK-071 SRD Non-Japanese Participants TAK-071 + Donepezil</title>
          <population>PK set included all participants who received study drug and had at least 1 measurable plasma concentration or amount of drug in the urine.</population>
          <units>L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59.03" spread="5.5208"/>
                    <measurement group_id="O2" value="62.40" spread="17.164"/>
                    <measurement group_id="O3" value="63.52" spread="11.895"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Accumulation Ratio Based on AUCτ (Rac[AUC]) for TAK-071 MRD Non-Japanese Participants</title>
        <time_frame>Pre-dose on Day 21 and at multiple time points (up to 24 hours) post-dose for Cohorts 7 and 8 and Pre-dose on Day 28 and at multiple time points (up to 36 hours) post-dose for Cohort 9</time_frame>
        <population>PK set included all participants who received study drug and had at least 1 measurable plasma concentration or amount of drug in the urine.</population>
        <group_list>
          <group group_id="O1">
            <title>MRD: Cohort 7: TAK-071 3 mg</title>
            <description>TAK-071 3 mg capsules, orally, once daily from Day 1 up to Day 21 to non-Japanese healthy participants. Dose of TAK-071 was based on 24-hour safety and tolerability from Cohort 4 and the 24-hour preliminary plasma PK and 12-hour CSF PK data from Cohort 3.</description>
          </group>
          <group group_id="O2">
            <title>MRD: Cohort 8: TAK-071 9 mg</title>
            <description>TAK-071 9 mg capsules, orally, once daily from Day 1 up to Day 21 to non-Japanese healthy participants. Dose of TAK-071 was based on safety, tolerability and available PK data arising from the ongoing SRD part and previous MRD cohort.</description>
          </group>
          <group group_id="O3">
            <title>MRD: Cohort 9: TAK-071 15 mg</title>
            <description>TAK-071 15 mg capsule, orally, once on Day 1, followed by a washout period of 7 days, then TAK-071 once daily for 21 days to non-Japanese healthy participants. Dose of TAK-071 will be based on safety, tolerability and available PK data arising from the ongoing SRD part and previous MRD cohort.</description>
          </group>
        </group_list>
        <measure>
          <title>Accumulation Ratio Based on AUCτ (Rac[AUC]) for TAK-071 MRD Non-Japanese Participants</title>
          <population>PK set included all participants who received study drug and had at least 1 measurable plasma concentration or amount of drug in the urine.</population>
          <units>Ratio</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.568" spread="0.71765"/>
                    <measurement group_id="O2" value="3.713" spread="1.1916"/>
                    <measurement group_id="O3" value="3.778" spread="1.2626"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Accumulation Ratio Based on AUCτ (Rac[AUC]) for TAK-071 MRD Japanese Participants</title>
        <time_frame>Pre-dose on Day 28 and at multiple time points [up to 24 hours] post-dose</time_frame>
        <population>PK set included all participants who received study drug and had at least 1 measurable plasma concentration or amount of drug in the urine.</population>
        <group_list>
          <group group_id="O1">
            <title>MRD: Cohort 13: TAK-071 3 mg</title>
            <description>TAK-071 3 mg capsule, orally, once on Day 1, followed by a washout period of 7 days, then TAK-071 once daily for 21 days to Japanese healthy participants. Dose of TAK-071 was same as the dose used in MRD Cohort 7.</description>
          </group>
          <group group_id="O2">
            <title>MRD: Cohort 14: TAK-071 9 mg</title>
            <description>TAK-071 9 mg capsule or matching placebo, orally, once on Day 1, followed by a washout period of 7 days, then TAK-071 once daily for 21 days to Japanese healthy participants. Dose of TAK-071 was same as the dose used in MRD Cohort 8.</description>
          </group>
          <group group_id="O3">
            <title>MRD: Cohort 15: TAK-071 15 mg</title>
            <description>TAK-071 15 mg capsule, orally, once on Day 1, followed by a washout period of 7 days, then TAK-071 once daily for 21 days to Japanese healthy participants. Dose of TAK-071 was same as the dose used in MRD Cohort 9.</description>
          </group>
        </group_list>
        <measure>
          <title>Accumulation Ratio Based on AUCτ (Rac[AUC]) for TAK-071 MRD Japanese Participants</title>
          <population>PK set included all participants who received study drug and had at least 1 measurable plasma concentration or amount of drug in the urine.</population>
          <units>Ratio</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.973" spread="0.38747"/>
                    <measurement group_id="O2" value="3.241" spread="0.56613"/>
                    <measurement group_id="O3" value="3.096" spread="1.4212"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Accumulation Ratio Based on AUCτ (Rac[AUC]) for TAK-071 MRD Non-Japanese Participants</title>
        <time_frame>Pre-dose on Day 21 and at multiple time points [up to 24 hours] post-dose</time_frame>
        <population>PK set included all participants who received study drug and had at least 1 measurable plasma concentration or amount of drug in the urine.</population>
        <group_list>
          <group group_id="O1">
            <title>MRD: Cohort 10: TAK-071 3 mg+Donepezil 5 mg</title>
            <description>TAK-071 3 mg capsules, orally, once daily along with donepezil 5 mg, tablets, orally, once daily from Day 1 up to Day 21 to non-Japanese healthy participants who were pre-treated with donepezil 5 mg, tablet, once daily for 3 weeks prior to administration of TAK-071. Dose of TAK-071 was same as the dose used in MRD Cohort 7.</description>
          </group>
          <group group_id="O2">
            <title>MRD: Cohort 11: TAK-071 9 mg + Donepezil 5 mg</title>
            <description>TAK-071 9 mg capsules, orally, once daily along with donepezil 5 mg, tablets, orally, once daily from Day 1 up to Day 21 to non-Japanese healthy participants who were pre-treated with donepezil 5 mg, tablet, once daily for 3 weeks prior to administration of TAK-071. Dose of TAK-071 was same as the dose used in MRD Cohort 8.</description>
          </group>
          <group group_id="O3">
            <title>MRD: Cohort 12: TAK-071 15 mg+Donepezil 5 mg</title>
            <description>TAK-071 15 mg capsule, orally, once daily along with donepezil 5 mg, tablets, orally, once daily from Day 1 up to Day 21 to non-Japanese healthy participants who were pre-treated with donepezil 5 mg, tablet, once daily for 3 weeks prior to administration of TAK-071. Dose of TAK-071 was same as the dose used in MRD Cohort 9.</description>
          </group>
        </group_list>
        <measure>
          <title>Accumulation Ratio Based on AUCτ (Rac[AUC]) for TAK-071 MRD Non-Japanese Participants</title>
          <population>PK set included all participants who received study drug and had at least 1 measurable plasma concentration or amount of drug in the urine.</population>
          <units>Ratio</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.099" spread="0.75130"/>
                    <measurement group_id="O2" value="3.749" spread="0.55862"/>
                    <measurement group_id="O3" value="3.350" spread="0.92710"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Accumulation Ratio Based on Plasma Cmax (Rac[Cmax]) for TAK-071 MRD Non-Japanese Participants</title>
        <time_frame>Pre-dose on Day 21 and at multiple time points [up to 24 hours] post-dose for Cohorts 7 and 8 and Pre-dose on Day 28 and at multiple time points (up to 36 hours) post-dose for Cohort 9</time_frame>
        <population>PK set included all participants who received study drug and had at least 1 measurable plasma concentration or amount of drug in the urine.</population>
        <group_list>
          <group group_id="O1">
            <title>MRD: Cohort 7: TAK-071 3 mg</title>
            <description>TAK-071 3 mg capsules, orally, once daily from Day 1 up to Day 21 to non-Japanese healthy participants. Dose of TAK-071 was based on 24-hour safety and tolerability from Cohort 4 and the 24-hour preliminary plasma PK and 12-hour CSF PK data from Cohort 3.</description>
          </group>
          <group group_id="O2">
            <title>MRD: Cohort 8: TAK-071 9 mg</title>
            <description>TAK-071 9 mg capsules, orally, once daily from Day 1 up to Day 21 to non-Japanese healthy participants. Dose of TAK-071 was based on safety, tolerability and available PK data arising from the ongoing SRD part and previous MRD cohort.</description>
          </group>
          <group group_id="O3">
            <title>MRD: Cohort 9: TAK-071 15 mg</title>
            <description>TAK-071 15 mg capsule, orally, once on Day 1, followed by a washout period of 7 days, then TAK-071 once daily for 21 days to non-Japanese healthy participants. Dose of TAK-071 will be based on safety, tolerability and available PK data arising from the ongoing SRD part and previous MRD cohort.</description>
          </group>
        </group_list>
        <measure>
          <title>Accumulation Ratio Based on Plasma Cmax (Rac[Cmax]) for TAK-071 MRD Non-Japanese Participants</title>
          <population>PK set included all participants who received study drug and had at least 1 measurable plasma concentration or amount of drug in the urine.</population>
          <units>Ratio</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.297" spread="0.59164"/>
                    <measurement group_id="O2" value="3.578" spread="1.2955"/>
                    <measurement group_id="O3" value="3.541" spread="0.86317"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Accumulation Ratio Based on Plasma Cmax (Rac[Cmax]) for TAK-071 MRD Japanese Participants</title>
        <time_frame>Pre-dose on Day 28 and at multiple time points [up to 24 hours] post-dose</time_frame>
        <population>PK set included all participants who received study drug and had at least 1 measurable plasma concentration or amount of drug in the urine.</population>
        <group_list>
          <group group_id="O1">
            <title>MRD: Cohort 13: TAK-071 3 mg</title>
            <description>TAK-071 3 mg capsule, orally, once on Day 1, followed by a washout period of 7 days, then TAK-071 once daily for 21 days to Japanese healthy participants. Dose of TAK-071 was same as the dose used in MRD Cohort 7.</description>
          </group>
          <group group_id="O2">
            <title>MRD: Cohort 14: TAK-071 9 mg</title>
            <description>TAK-071 9 mg capsule or matching placebo, orally, once on Day 1, followed by a washout period of 7 days, then TAK-071 once daily for 21 days to Japanese healthy participants. Dose of TAK-071 was same as the dose used in MRD Cohort 8.</description>
          </group>
          <group group_id="O3">
            <title>MRD: Cohort 15: TAK-071 15 mg</title>
            <description>TAK-071 15 mg capsule, orally, once on Day 1, followed by a washout period of 7 days, then TAK-071 once daily for 21 days to Japanese healthy participants. Dose of TAK-071 was same as the dose used in MRD Cohort 9.</description>
          </group>
        </group_list>
        <measure>
          <title>Accumulation Ratio Based on Plasma Cmax (Rac[Cmax]) for TAK-071 MRD Japanese Participants</title>
          <population>PK set included all participants who received study drug and had at least 1 measurable plasma concentration or amount of drug in the urine.</population>
          <units>Ratio</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.960" spread="0.26180"/>
                    <measurement group_id="O2" value="3.327" spread="0.74832"/>
                    <measurement group_id="O3" value="3.285" spread="1.5406"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Accumulation Ratio Based on Plasma Cmax (Rac[Cmax]) for TAK-071 MRD Non-Japanese Participants</title>
        <time_frame>Pre-dose on Day 21 and at multiple time points [up to 24 hours] post-dose</time_frame>
        <population>PK set included all participants who received study drug and had at least 1 measurable plasma concentration or amount of drug in the urine.</population>
        <group_list>
          <group group_id="O1">
            <title>MRD: Cohort 10: TAK-071 3 mg+Donepezil 5 mg</title>
            <description>TAK-071 3 mg capsules, orally, once daily along with donepezil 5 mg, tablets, orally, once daily from Day 1 up to Day 21 to non-Japanese healthy participants who were pre-treated with donepezil 5 mg, tablet, once daily for 3 weeks prior to administration of TAK-071. Dose of TAK-071 was same as the dose used in MRD Cohort 7.</description>
          </group>
          <group group_id="O2">
            <title>MRD: Cohort 11: TAK-071 9 mg + Donepezil 5 mg</title>
            <description>TAK-071 9 mg capsules, orally, once daily along with donepezil 5 mg, tablets, orally, once daily from Day 1 up to Day 21 to non-Japanese healthy participants who were pre-treated with donepezil 5 mg, tablet, once daily for 3 weeks prior to administration of TAK-071. Dose of TAK-071 was same as the dose used in MRD Cohort 8.</description>
          </group>
          <group group_id="O3">
            <title>MRD: Cohort 12: TAK-071 15 mg+Donepezil 5 mg</title>
            <description>TAK-071 15 mg capsule, orally, once daily along with donepezil 5 mg, tablets, orally, once daily from Day 1 up to Day 21 to non-Japanese healthy participants who were pre-treated with donepezil 5 mg, tablet, once daily for 3 weeks prior to administration of TAK-071. Dose of TAK-071 was same as the dose used in MRD Cohort 9.</description>
          </group>
        </group_list>
        <measure>
          <title>Accumulation Ratio Based on Plasma Cmax (Rac[Cmax]) for TAK-071 MRD Non-Japanese Participants</title>
          <population>PK set included all participants who received study drug and had at least 1 measurable plasma concentration or amount of drug in the urine.</population>
          <units>Ratio</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.929" spread="0.55096"/>
                    <measurement group_id="O2" value="3.527" spread="0.57233"/>
                    <measurement group_id="O3" value="3.257" spread="0.95527"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AEt: Amount of Drug Excreted in Urine From Time 0 to Time t for TAK-071 SRD Non-Japanese Participants</title>
        <time_frame>Pre-dose on Day 1 and at multiple time points [up to 96 hours] post-dose</time_frame>
        <population>PK set included all participants who received study drug and had at least 1 measurable plasma concentration or amount of drug in the urine. Measurable TAK-071 was not detected in urine for Cohort 1 (TAK-071 1 mg). Here, number analyzed is the number of participants with data available for analysis at the given time-point.</population>
        <group_list>
          <group group_id="O1">
            <title>SRD: Cohort 2: TAK-071 3 mg</title>
            <description>TAK-071 3 mg capsule, orally, once on Day 1 to non-Japanese healthy participants. Dose of TAK-071 was based on the 24-hour post-dose safety, tolerability and pharmacokinetic (PK) data from cohort 1.</description>
          </group>
          <group group_id="O2">
            <title>SRD: Cohort 3: TAK-071 9 mg</title>
            <description>TAK-071 9 mg capsule, orally, once on Day 1 to non-Japanese healthy participants. Dose of TAK-071 was based on 24-hour safety, tolerability, and preliminary plasma PK and 12-hour CSF PK data.</description>
          </group>
          <group group_id="O3">
            <title>SRD: Cohort 4: TAK-071 20 mg</title>
            <description>TAK-071 20 mg capsule, orally, once on Day 1 to non-Japanese healthy participants. Dose of TAK-071 was based on the 24-hour post-dose safety and tolerability data from previous cohort.</description>
          </group>
          <group group_id="O4">
            <title>SRD: Cohort 5: TAK-071 40 mg</title>
            <description>TAK-071 40 mg capsule, orally, once on Day 1 to non-Japanese healthy participants. Dose of TAK-071 will be based on 24-hour safety, tolerability, and preliminary plasma PK data from Cohort 4.</description>
          </group>
          <group group_id="O5">
            <title>SRD: Cohort 6: TAK-071 80 mg</title>
            <description>TAK-071 80 mg capsules, orally, once on Day 1 to non-Japanese healthy participants. Dose of TAK-071 was based on 24-hour safety, tolerability, and preliminary plasma PK data from Cohort 5</description>
          </group>
          <group group_id="O6">
            <title>SRD: Cohort 18: TAK-071 120 mg</title>
            <description>TAK-071 120 mg capsule, orally, once on Day 1 to non-Japanese healthy participants. Dose of TAK-071 was based on 24-hour safety, tolerability, and preliminary plasma PK data from Cohort 6.</description>
          </group>
          <group group_id="O7">
            <title>SRD: Cohort 19: TAK-071 160 mg</title>
            <description>TAK-071 160 mg capsule, orally, once on Day 1 to non-Japanese healthy participants. Dose of TAK-071 was based on 24-hour safety, tolerability, and preliminary plasma PK data from Cohort 18.</description>
          </group>
        </group_list>
        <measure>
          <title>AEt: Amount of Drug Excreted in Urine From Time 0 to Time t for TAK-071 SRD Non-Japanese Participants</title>
          <population>PK set included all participants who received study drug and had at least 1 measurable plasma concentration or amount of drug in the urine. Measurable TAK-071 was not detected in urine for Cohort 1 (TAK-071 1 mg). Here, number analyzed is the number of participants with data available for analysis at the given time-point.</population>
          <units>mg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="5"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.001731" spread="0.0015806"/>
                    <measurement group_id="O2" value="0.01632" spread="0.0062545"/>
                    <measurement group_id="O3" value="0.05753" spread="0.023868"/>
                    <measurement group_id="O4" value="0.08559" spread="0.052157"/>
                    <measurement group_id="O5" value="0.09052" spread="0.044805"/>
                    <measurement group_id="O6" value="0.1652" spread="0.097242"/>
                    <measurement group_id="O7" value="0.1505" spread="0.10905"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AEt: Amount of Drug Excreted in Urine From Time 0 to Time t for TAK-071 MRD Non-Japanese Participants</title>
        <time_frame>Pre-dose on Day 1 and 21 and at multiple time points (up to 24 hours) post-dose for Cohorts 7 and 8, and pre-dose on Day 1 and 28 and multiple time points (up to 96 hours) post-dose for Cohort 9</time_frame>
        <population>PK set included all participants who received study drug and had at least 1 measurable plasma concentration or amount of drug in the urine. Here, number analyzed is the number of participants with data available for analysis at the given time-point.</population>
        <group_list>
          <group group_id="O1">
            <title>MRD: Cohort 7: TAK-071 3 mg</title>
            <description>TAK-071 3 mg capsules, orally, once daily from Day 1 up to Day 21 to non-Japanese healthy participants. Dose of TAK-071 was based on 24-hour safety and tolerability from Cohort 4 and the 24-hour preliminary plasma PK and 12-hour CSF PK data from Cohort 3.</description>
          </group>
          <group group_id="O2">
            <title>MRD: Cohort 8: TAK-071 9 mg</title>
            <description>TAK-071 9 mg capsules, orally, once daily from Day 1 up to Day 21 to non-Japanese healthy participants. Dose of TAK-071 was based on safety, tolerability and available PK data arising from the ongoing SRD part and previous MRD cohort.</description>
          </group>
          <group group_id="O3">
            <title>MRD: Cohort 9: TAK-071 15 mg</title>
            <description>TAK-071 15 mg capsule, orally, once on Day 1, followed by a washout period of 7 days, then TAK-071 once daily for 21 days to non-Japanese healthy participants. Dose of TAK-071 will be based on safety, tolerability and available PK data arising from the ongoing SRD part and previous MRD cohort.</description>
          </group>
        </group_list>
        <measure>
          <title>AEt: Amount of Drug Excreted in Urine From Time 0 to Time t for TAK-071 MRD Non-Japanese Participants</title>
          <population>PK set included all participants who received study drug and had at least 1 measurable plasma concentration or amount of drug in the urine. Here, number analyzed is the number of participants with data available for analysis at the given time-point.</population>
          <units>mg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.001501" spread="0.0017987"/>
                    <measurement group_id="O2" value="0.005973" spread="0.0034636"/>
                    <measurement group_id="O3" value="0.04929" spread="0.019263"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 21</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.009066" spread="0.0042349"/>
                    <measurement group_id="O2" value="0.02393" spread="0.014412"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 28</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="0.1119" spread="0.079021"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AEt: Amount of Drug Excreted in Urine From Time 0 to Time t for TAK-071 MRD Japanese Participants</title>
        <time_frame>Pre-dose on Day 1 and at multiple time points (up to 96 hours) post-dose and pre-dose on Day 28 and multiple time points (up to 24 hours) post-dose</time_frame>
        <population>PK set included all participants who received study drug and had at least 1 measurable plasma concentration or amount of drug in the urine.</population>
        <group_list>
          <group group_id="O1">
            <title>MRD: Cohort 13: TAK-071 3 mg</title>
            <description>TAK-071 3 mg capsule, orally, once on Day 1, followed by a washout period of 7 days, then TAK-071 once daily for 21 days to Japanese healthy participants. Dose of TAK-071 was same as the dose used in MRD Cohort 7.</description>
          </group>
          <group group_id="O2">
            <title>MRD: Cohort 14: TAK-071 9 mg</title>
            <description>TAK-071 9 mg capsule or matching placebo, orally, once on Day 1, followed by a washout period of 7 days, then TAK-071 once daily for 21 days to Japanese healthy participants. Dose of TAK-071 was same as the dose used in MRD Cohort 8.</description>
          </group>
          <group group_id="O3">
            <title>MRD: Cohort 15: TAK-071 15 mg</title>
            <description>TAK-071 15 mg capsule, orally, once on Day 1, followed by a washout period of 7 days, then TAK-071 once daily for 21 days to Japanese healthy participants. Dose of TAK-071 was same as the dose used in MRD Cohort 9.</description>
          </group>
        </group_list>
        <measure>
          <title>AEt: Amount of Drug Excreted in Urine From Time 0 to Time t for TAK-071 MRD Japanese Participants</title>
          <population>PK set included all participants who received study drug and had at least 1 measurable plasma concentration or amount of drug in the urine.</population>
          <units>mg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.003436" spread="0.0031125"/>
                    <measurement group_id="O2" value="0.02083" spread="0.0094853"/>
                    <measurement group_id="O3" value="0.03224" spread="0.023202"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 28</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.01202" spread="0.010480"/>
                    <measurement group_id="O2" value="0.03394" spread="0.022682"/>
                    <measurement group_id="O3" value="0.06482" spread="0.062816"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Fet: Fraction of Administered Dose of Drug Excreted in Urine From Time 0 to Time t for TAK-071 SRD Non-Japanese Participants</title>
        <time_frame>Pre-dose on Day 1 and at multiple time points (up to 96 hours) post-dose</time_frame>
        <population>PK set included all participants who received study drug and had at least 1 measurable plasma concentration or amount of drug in the urine. Measurable TAK-071 was not detected in urine for Cohort 1 (TAK-071 1 mg). Here, number analyzed is the number of participants with data available for analysis at the given time-point.</population>
        <group_list>
          <group group_id="O1">
            <title>SRD: Cohort 2: TAK-071 3 mg</title>
            <description>TAK-071 3 mg capsule, orally, once on Day 1 to non-Japanese healthy participants. Dose of TAK-071 was based on the 24-hour post-dose safety, tolerability and pharmacokinetic (PK) data from cohort 1.</description>
          </group>
          <group group_id="O2">
            <title>SRD: Cohort 3: TAK-071 9 mg</title>
            <description>TAK-071 9 mg capsule, orally, once on Day 1 to non-Japanese healthy participants. Dose of TAK-071 was based on 24-hour safety, tolerability, and preliminary plasma PK and 12-hour CSF PK data.</description>
          </group>
          <group group_id="O3">
            <title>SRD: Cohort 4: TAK-071 20 mg</title>
            <description>TAK-071 20 mg capsule, orally, once on Day 1 to non-Japanese healthy participants. Dose of TAK-071 was based on the 24-hour post-dose safety and tolerability data from previous cohort.</description>
          </group>
          <group group_id="O4">
            <title>SRD: Cohort 5: TAK-071 40 mg</title>
            <description>TAK-071 40 mg capsule, orally, once on Day 1 to non-Japanese healthy participants. Dose of TAK-071 will be based on 24-hour safety, tolerability, and preliminary plasma PK data from Cohort 4.</description>
          </group>
          <group group_id="O5">
            <title>SRD: Cohort 6: TAK-071 80 mg</title>
            <description>TAK-071 80 mg capsules, orally, once on Day 1 to non-Japanese healthy participants. Dose of TAK-071 was based on 24-hour safety, tolerability, and preliminary plasma PK data from Cohort 5</description>
          </group>
          <group group_id="O6">
            <title>SRD: Cohort 18: TAK-071 120 mg</title>
            <description>TAK-071 120 mg capsule, orally, once on Day 1 to non-Japanese healthy participants. Dose of TAK-071 was based on 24-hour safety, tolerability, and preliminary plasma PK data from Cohort 6.</description>
          </group>
          <group group_id="O7">
            <title>SRD: Cohort 19: TAK-071 160 mg</title>
            <description>TAK-071 160 mg capsule, orally, once on Day 1 to non-Japanese healthy participants. Dose of TAK-071 was based on 24-hour safety, tolerability, and preliminary plasma PK data from Cohort 18.</description>
          </group>
        </group_list>
        <measure>
          <title>Fet: Fraction of Administered Dose of Drug Excreted in Urine From Time 0 to Time t for TAK-071 SRD Non-Japanese Participants</title>
          <population>PK set included all participants who received study drug and had at least 1 measurable plasma concentration or amount of drug in the urine. Measurable TAK-071 was not detected in urine for Cohort 1 (TAK-071 1 mg). Here, number analyzed is the number of participants with data available for analysis at the given time-point.</population>
          <units>fraction of drug excreted</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="5"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.05771" spread="0.052687"/>
                    <measurement group_id="O2" value="0.1813" spread="0.069494"/>
                    <measurement group_id="O3" value="0.2877" spread="0.11934"/>
                    <measurement group_id="O4" value="0.2140" spread="0.13039"/>
                    <measurement group_id="O5" value="0.1131" spread="0.056006"/>
                    <measurement group_id="O6" value="0.1377" spread="0.081035"/>
                    <measurement group_id="O7" value="0.09408" spread="0.068159"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Fet: Fraction of Administered Dose of Drug Excreted in Urine From Time 0 to Time t for TAK-071 MRD Non-Japanese Participants</title>
        <time_frame>Pre-dose on Days 1 and 21 and at multiple time points (up to 24 hours) post-dose for Cohorts 7 and 8 and Pre-dose on Days 1 and 28 and multiple time points (up to 96 hours) post-dose for Cohort 9</time_frame>
        <population>PK set included all participants who received study drug and had at least 1 measurable plasma concentration or amount of drug in the urine. Here, number analyzed is the number of participants with data available for analysis at the given time-point.</population>
        <group_list>
          <group group_id="O1">
            <title>MRD: Cohort 7: TAK-071 3 mg</title>
            <description>TAK-071 3 mg capsules, orally, once daily from Day 1 up to Day 21 to non-Japanese healthy participants. Dose of TAK-071 was based on 24-hour safety and tolerability from Cohort 4 and the 24-hour preliminary plasma PK and 12-hour CSF PK data from Cohort 3.</description>
          </group>
          <group group_id="O2">
            <title>MRD: Cohort 8: TAK-071 9 mg</title>
            <description>TAK-071 9 mg capsules, orally, once daily from Day 1 up to Day 21 to non-Japanese healthy participants. Dose of TAK-071 was based on safety, tolerability and available PK data arising from the ongoing SRD part and previous MRD cohort.</description>
          </group>
          <group group_id="O3">
            <title>MRD: Cohort 9: TAK-071 15 mg</title>
            <description>TAK-071 15 mg capsule, orally, once on Day 1, followed by a washout period of 7 days, then TAK-071 once daily for 21 days to non-Japanese healthy participants. Dose of TAK-071 will be based on safety, tolerability and available PK data arising from the ongoing SRD part and previous MRD cohort.</description>
          </group>
        </group_list>
        <measure>
          <title>Fet: Fraction of Administered Dose of Drug Excreted in Urine From Time 0 to Time t for TAK-071 MRD Non-Japanese Participants</title>
          <population>PK set included all participants who received study drug and had at least 1 measurable plasma concentration or amount of drug in the urine. Here, number analyzed is the number of participants with data available for analysis at the given time-point.</population>
          <units>fraction of drug excreted</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.05003" spread="0.059956"/>
                    <measurement group_id="O2" value="0.06636" spread="0.038484"/>
                    <measurement group_id="O3" value="0.3286" spread="0.12842"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 21</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3022" spread="0.14116"/>
                    <measurement group_id="O2" value="0.2659" spread="0.16013"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 28</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="0.7460" spread="0.52680"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Fet: Fraction of Administered Dose of Drug Excreted in Urine From Time 0 to Time t for TAK-071 MRD Japanese Participants</title>
        <time_frame>Pre-dose on Day 1 and at multiple time points (up to 96 hours) post-dose and pre-dose on Day 28 and multiple time points (up to 24 hours) post-dose</time_frame>
        <population>PK set included all participants who received study drug and had at least 1 measurable plasma concentration or amount of drug in the urine.</population>
        <group_list>
          <group group_id="O1">
            <title>MRD: Cohort 13: TAK-071 3 mg</title>
            <description>TAK-071 3 mg capsule, orally, once on Day 1, followed by a washout period of 7 days, then TAK-071 once daily for 21 days to Japanese healthy participants. Dose of TAK-071 was same as the dose used in MRD Cohort 7.</description>
          </group>
          <group group_id="O2">
            <title>MRD: Cohort 14: TAK-071 9 mg</title>
            <description>TAK-071 9 mg capsule or matching placebo, orally, once on Day 1, followed by a washout period of 7 days, then TAK-071 once daily for 21 days to Japanese healthy participants. Dose of TAK-071 was same as the dose used in MRD Cohort 8.</description>
          </group>
          <group group_id="O3">
            <title>MRD: Cohort 15: TAK-071 15 mg</title>
            <description>TAK-071 15 mg capsule, orally, once on Day 1, followed by a washout period of 7 days, then TAK-071 once daily for 21 days to Japanese healthy participants. Dose of TAK-071 was same as the dose used in MRD Cohort 9.</description>
          </group>
        </group_list>
        <measure>
          <title>Fet: Fraction of Administered Dose of Drug Excreted in Urine From Time 0 to Time t for TAK-071 MRD Japanese Participants</title>
          <population>PK set included all participants who received study drug and had at least 1 measurable plasma concentration or amount of drug in the urine.</population>
          <units>fraction of drug excreted</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1145" spread="0.10375"/>
                    <measurement group_id="O2" value="0.2314" spread="0.10539"/>
                    <measurement group_id="O3" value="0.2150" spread="0.15468"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 28</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4005" spread="0.34935"/>
                    <measurement group_id="O2" value="0.3771" spread="0.25202"/>
                    <measurement group_id="O3" value="0.4321" spread="0.41878"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>CLR: Renal Clearance for TAK-071 SRD Non-Japanese Participants</title>
        <time_frame>Pre-dose on Day 1 and at multiple time points [up to 96 hours] post-dose</time_frame>
        <population>PK set included all participants who received study drug and had at least 1 measurable plasma concentration or amount of drug in the urine. Measurable TAK-071 was not detected in urine for Cohort 1 (TAK-071 1 mg). Here, number analyzed is the number of participants with data available for analysis at the given time-point.</population>
        <group_list>
          <group group_id="O1">
            <title>SRD: Cohort 2: TAK-071 3 mg</title>
            <description>TAK-071 3 mg capsule, orally, once on Day 1 to non-Japanese healthy participants. Dose of TAK-071 was based on the 24-hour post-dose safety, tolerability and pharmacokinetic (PK) data from cohort 1.</description>
          </group>
          <group group_id="O2">
            <title>SRD: Cohort 3: TAK-071 9 mg</title>
            <description>TAK-071 9 mg capsule, orally, once on Day 1 to non-Japanese healthy participants. Dose of TAK-071 was based on 24-hour safety, tolerability, and preliminary plasma PK and 12-hour CSF PK data.</description>
          </group>
          <group group_id="O3">
            <title>SRD: Cohort 4: TAK-071 20 mg</title>
            <description>TAK-071 20 mg capsule, orally, once on Day 1 to non-Japanese healthy participants. Dose of TAK-071 was based on the 24-hour post-dose safety and tolerability data from previous cohort.</description>
          </group>
          <group group_id="O4">
            <title>SRD: Cohort 5: TAK-071 40 mg</title>
            <description>TAK-071 40 mg capsule, orally, once on Day 1 to non-Japanese healthy participants. Dose of TAK-071 will be based on 24-hour safety, tolerability, and preliminary plasma PK data from Cohort 4.</description>
          </group>
          <group group_id="O5">
            <title>SRD: Cohort 6: TAK-071 80 mg</title>
            <description>TAK-071 80 mg capsules, orally, once on Day 1 to non-Japanese healthy participants. Dose of TAK-071 was based on 24-hour safety, tolerability, and preliminary plasma PK data from Cohort 5</description>
          </group>
          <group group_id="O6">
            <title>SRD: Cohort 18: TAK-071 120 mg</title>
            <description>TAK-071 120 mg capsule, orally, once on Day 1 to non-Japanese healthy participants. Dose of TAK-071 was based on 24-hour safety, tolerability, and preliminary plasma PK data from Cohort 6.</description>
          </group>
          <group group_id="O7">
            <title>SRD: Cohort 19: TAK-071 160 mg</title>
            <description>TAK-071 160 mg capsule, orally, once on Day 1 to non-Japanese healthy participants. Dose of TAK-071 was based on 24-hour safety, tolerability, and preliminary plasma PK data from Cohort 18.</description>
          </group>
        </group_list>
        <measure>
          <title>CLR: Renal Clearance for TAK-071 SRD Non-Japanese Participants</title>
          <population>PK set included all participants who received study drug and had at least 1 measurable plasma concentration or amount of drug in the urine. Measurable TAK-071 was not detected in urine for Cohort 1 (TAK-071 1 mg). Here, number analyzed is the number of participants with data available for analysis at the given time-point.</population>
          <units>L/h</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="5"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0006354" spread="0.00072647"/>
                    <measurement group_id="O2" value="0.001668" spread="0.00058267"/>
                    <measurement group_id="O3" value="0.002775" spread="0.00098052"/>
                    <measurement group_id="O4" value="0.002453" spread="0.0015795"/>
                    <measurement group_id="O5" value="0.001425" spread="0.00071797"/>
                    <measurement group_id="O6" value="0.001870" spread="0.0010016"/>
                    <measurement group_id="O7" value="0.001696" spread="0.0015594"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>CLR: Renal Clearance for TAK-071 MRD Non-Japanese Participants</title>
        <time_frame>Pre-dose on Days 1 and 21 and at multiple time points (up to 24 hours) post-dose for Cohorts 7 and 8 and Pre-dose on Days 1 and 28 multiple time points (up to 96 hours) post-dose for Cohort 9</time_frame>
        <population>PK set included all participants who received study drug and had at least 1 measurable plasma concentration or amount of drug in the urine. Here, number analyzed is the number of participants with data available for analysis at the given time-point.</population>
        <group_list>
          <group group_id="O1">
            <title>MRD: Cohort 7: TAK-071 3 mg</title>
            <description>TAK-071 3 mg capsules, orally, once daily from Day 1 up to Day 21 to non-Japanese healthy participants. Dose of TAK-071 was based on 24-hour safety and tolerability from Cohort 4 and the 24-hour preliminary plasma PK and 12-hour CSF PK data from Cohort 3.</description>
          </group>
          <group group_id="O2">
            <title>MRD: Cohort 8: TAK-071 9 mg</title>
            <description>TAK-071 9 mg capsules, orally, once daily from Day 1 up to Day 21 to non-Japanese healthy participants. Dose of TAK-071 was based on safety, tolerability and available PK data arising from the ongoing SRD part and previous MRD cohort.</description>
          </group>
          <group group_id="O3">
            <title>MRD: Cohort 9: TAK-071 15 mg</title>
            <description>TAK-071 15 mg capsule, orally, once on Day 1, followed by a washout period of 7 days, then TAK-071 once daily for 21 days to non-Japanese healthy participants. Dose of TAK-071 will be based on safety, tolerability and available PK data arising from the ongoing SRD part and previous MRD cohort.</description>
          </group>
        </group_list>
        <measure>
          <title>CLR: Renal Clearance for TAK-071 MRD Non-Japanese Participants</title>
          <population>PK set included all participants who received study drug and had at least 1 measurable plasma concentration or amount of drug in the urine. Here, number analyzed is the number of participants with data available for analysis at the given time-point.</population>
          <units>L/h</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.001133" spread="0.0015553"/>
                    <measurement group_id="O2" value="0.001686" spread="0.00092928"/>
                    <measurement group_id="O3" value="0.003163" spread="0.0016448"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 21</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.001937" spread="0.00099073"/>
                    <measurement group_id="O2" value="0.001991" spread="0.0012947"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 28</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="0.005431" spread="0.0032772"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>CLR: Renal Clearance for TAK-071 MRD Japanese Participants</title>
        <time_frame>Pre-dose on Day 1 and at multiple time points (up to 96 hours) post-dose and pre-dose on Day 28 and multiple time points (up to 24 hours) post-dose</time_frame>
        <population>PK set included all participants who received study drug and had at least 1 measurable plasma concentration or amount of drug in the urine.</population>
        <group_list>
          <group group_id="O1">
            <title>MRD: Cohort 13: TAK-071 3 mg</title>
            <description>TAK-071 3 mg capsule, orally, once on Day 1, followed by a washout period of 7 days, then TAK-071 once daily for 21 days to Japanese healthy participants. Dose of TAK-071 was same as the dose used in MRD Cohort 7.</description>
          </group>
          <group group_id="O2">
            <title>MRD: Cohort 14: TAK-071 9 mg</title>
            <description>TAK-071 9 mg capsule or matching placebo, orally, once on Day 1, followed by a washout period of 7 days, then TAK-071 once daily for 21 days to Japanese healthy participants. Dose of TAK-071 was same as the dose used in MRD Cohort 8.</description>
          </group>
          <group group_id="O3">
            <title>MRD: Cohort 15: TAK-071 15 mg</title>
            <description>TAK-071 15 mg capsule, orally, once on Day 1, followed by a washout period of 7 days, then TAK-071 once daily for 21 days to Japanese healthy participants. Dose of TAK-071 was same as the dose used in MRD Cohort 9.</description>
          </group>
        </group_list>
        <measure>
          <title>CLR: Renal Clearance for TAK-071 MRD Japanese Participants</title>
          <population>PK set included all participants who received study drug and had at least 1 measurable plasma concentration or amount of drug in the urine.</population>
          <units>L/h</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0008641" spread="0.00063849"/>
                    <measurement group_id="O2" value="0.001783" spread="0.00090441"/>
                    <measurement group_id="O3" value="0.002093" spread="0.0016105"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 28</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.002494" spread="0.0014594"/>
                    <measurement group_id="O2" value="0.002680" spread="0.0019001"/>
                    <measurement group_id="O3" value="0.003426" spread="0.0021244"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>CSF Cmax: Maximum Observed Concentration in Cerebrospinal Fluid (CSF) for TAK-071</title>
        <time_frame>Pre-dose on Day 1 and at multiple time points (up to 12 hours) post-dose</time_frame>
        <population>PK set included all participants who received study drug and had at least 1 measurable plasma concentration or amount of drug in the urine.</population>
        <group_list>
          <group group_id="O1">
            <title>SRD: Cohort 3: TAK-071 9 mg</title>
            <description>TAK-071 9 mg capsule, orally, once on Day 1 to non-Japanese healthy participants. Dose of TAK-071 was based on 24-hour safety, tolerability, and preliminary plasma PK and 12-hour CSF PK data.</description>
          </group>
        </group_list>
        <measure>
          <title>CSF Cmax: Maximum Observed Concentration in Cerebrospinal Fluid (CSF) for TAK-071</title>
          <population>PK set included all participants who received study drug and had at least 1 measurable plasma concentration or amount of drug in the urine.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.008988" spread="0.0051582"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>CSF Cmax: Maximum Observed Concentration in Cerebrospinal Fluid (CSF) for TAK-071</title>
        <time_frame>Pre-dose on Day 28 and at multiple time points (up to 36 hours) post-dose</time_frame>
        <population>PK set included all participants who received study drug and had at least 1 measurable plasma concentration or amount of drug in the urine. Here, number analyzed is the number of participants with data available for analysis at the given time-point.</population>
        <group_list>
          <group group_id="O1">
            <title>MRD: Cohort 9: TAK-071 15 mg</title>
            <description>TAK-071 15 mg capsule, orally, once on Day 1, followed by a washout period of 7 days, then TAK-071 once daily for 21 days to non-Japanese healthy participants. Dose of TAK-071 will be based on safety, tolerability and available PK data arising from the ongoing SRD part and previous MRD cohort.</description>
          </group>
        </group_list>
        <measure>
          <title>CSF Cmax: Maximum Observed Concentration in Cerebrospinal Fluid (CSF) for TAK-071</title>
          <population>PK set included all participants who received study drug and had at least 1 measurable plasma concentration or amount of drug in the urine. Here, number analyzed is the number of participants with data available for analysis at the given time-point.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.01144" spread="0.0012682"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>CSF AUC(0-12): Area Under the CSF Concentration-time Curve From Time 0 to 12 Hours for TAK-071</title>
        <time_frame>Pre-dose on Day 1 and at multiple time points (up to 12 hours) post-dose</time_frame>
        <population>PK set included all participants who received study drug and had at least 1 measurable plasma concentration or amount of drug in the urine. Here, number analyzed is the number of participants with data available for analysis at the given time-point.</population>
        <group_list>
          <group group_id="O1">
            <title>SRD: Cohort 3: TAK-071 9 mg</title>
            <description>TAK-071 9 mg capsule, orally, once on Day 1 to non-Japanese healthy participants. Dose of TAK-071 was based on 24-hour safety, tolerability, and preliminary plasma PK and 12-hour CSF PK data.</description>
          </group>
        </group_list>
        <measure>
          <title>CSF AUC(0-12): Area Under the CSF Concentration-time Curve From Time 0 to 12 Hours for TAK-071</title>
          <population>PK set included all participants who received study drug and had at least 1 measurable plasma concentration or amount of drug in the urine. Here, number analyzed is the number of participants with data available for analysis at the given time-point.</population>
          <units>h*ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.68" spread="3.9324"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>CSF AUC(0-36): Area Under the CSF Concentration-time Curve From Time 0 to 36 Hours for TAK-071</title>
        <time_frame>Pre-dose on Day 28 and multiple time points (up to 36 hours) post-dose</time_frame>
        <population>PK set included all participants who received study drug and had at least 1 measurable plasma concentration or amount of drug in the urine. Here, number analyzed is the number of participants with data available for analysis at the given time-point.</population>
        <group_list>
          <group group_id="O1">
            <title>MRD: Cohort 9: TAK-071 15 mg</title>
            <description>TAK-071 15 mg capsule, orally, once on Day 1, followed by a washout period of 7 days, then TAK-071 once daily for 21 days to non-Japanese healthy participants. Dose of TAK-071 will be based on safety, tolerability and available PK data arising from the ongoing SRD part and previous MRD cohort.</description>
          </group>
        </group_list>
        <measure>
          <title>CSF AUC(0-36): Area Under the CSF Concentration-time Curve From Time 0 to 36 Hours for TAK-071</title>
          <population>PK set included all participants who received study drug and had at least 1 measurable plasma concentration or amount of drug in the urine. Here, number analyzed is the number of participants with data available for analysis at the given time-point.</population>
          <units>h*ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="360.9" spread="73.780"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ratio of CSF AUC(0-12) to the Plasma AUC(0-12) for TAK-071</title>
        <time_frame>Pre-dose on Day 1 and at multiple time points [up to 168 hours] post-dose</time_frame>
        <population>PK set included all participants who received study drug and had at least 1 measurable plasma concentration or amount of drug in the urine. Here, number analyzed is the number of participants with data available for analysis at the given time-point.</population>
        <group_list>
          <group group_id="O1">
            <title>SRD: Cohort 3: TAK-071 9 mg</title>
            <description>TAK-071 9 mg capsule, orally, once on Day 1 to non-Japanese healthy participants. Dose of TAK-071 was based on 24-hour safety, tolerability, and preliminary plasma PK and 12-hour CSF PK data.</description>
          </group>
        </group_list>
        <measure>
          <title>Ratio of CSF AUC(0-12) to the Plasma AUC(0-12) for TAK-071</title>
          <population>PK set included all participants who received study drug and had at least 1 measurable plasma concentration or amount of drug in the urine. Here, number analyzed is the number of participants with data available for analysis at the given time-point.</population>
          <units>Ratio</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.009098" spread="0.0034530"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ratio of CSF AUC(0-36) to the Plasma AUC(0-36) for TAK-071</title>
        <time_frame>Pre-dose on Day 28 and multiple time points (up to 36 hours) post-dose Cohort 9</time_frame>
        <population>PK set included all participants who received study drug and had at least 1 measurable plasma concentration or amount of drug in the urine. Here, number analyzed is the number of participants with data available for analysis at the given time-point.</population>
        <group_list>
          <group group_id="O1">
            <title>MRD: Cohort 9: TAK-071 15 mg</title>
            <description>TAK-071 15 mg capsule, orally, once on Day 1, followed by a washout period of 7 days, then TAK-071 once daily for 21 days to non-Japanese healthy participants. Dose of TAK-071 will be based on safety, tolerability and available PK data arising from the ongoing SRD part and previous MRD cohort.</description>
          </group>
        </group_list>
        <measure>
          <title>Ratio of CSF AUC(0-36) to the Plasma AUC(0-36) for TAK-071</title>
          <population>PK set included all participants who received study drug and had at least 1 measurable plasma concentration or amount of drug in the urine. Here, number analyzed is the number of participants with data available for analysis at the given time-point.</population>
          <units>Ratio</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.01140" spread="0.0014959"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for Donepezil MRD Non-Japanese Participants</title>
        <time_frame>Pre-dose on Days -1 and 21 and multiple time points (up to 24 hours) post-dose</time_frame>
        <population>PK set included all participants who received study drug and had at least 1 measurable plasma concentration or amount of drug in the urine.</population>
        <group_list>
          <group group_id="O1">
            <title>MRD: Cohort 10: TAK-071 3 mg+Donepezil 5 mg</title>
            <description>TAK-071 3 mg capsules, orally, once daily along with donepezil 5 mg, tablets, orally, once daily from Day 1 up to Day 21 to non-Japanese healthy participants who were pre-treated with donepezil 5 mg, tablet, once daily for 3 weeks prior to administration of TAK-071. Dose of TAK-071 was same as the dose used in MRD Cohort 7.</description>
          </group>
          <group group_id="O2">
            <title>MRD: Cohort 11: TAK-071 9 mg + Donepezil 5 mg</title>
            <description>TAK-071 9 mg capsules, orally, once daily along with donepezil 5 mg, tablets, orally, once daily from Day 1 up to Day 21 to non-Japanese healthy participants who were pre-treated with donepezil 5 mg, tablet, once daily for 3 weeks prior to administration of TAK-071. Dose of TAK-071 was same as the dose used in MRD Cohort 8.</description>
          </group>
          <group group_id="O3">
            <title>MRD: Cohort 12: TAK-071 15 mg+Donepezil 5 mg</title>
            <description>TAK-071 15 mg capsule, orally, once daily along with donepezil 5 mg, tablets, orally, once daily from Day 1 up to Day 21 to non-Japanese healthy participants who were pre-treated with donepezil 5 mg, tablet, once daily for 3 weeks prior to administration of TAK-071. Dose of TAK-071 was same as the dose used in MRD Cohort 9.</description>
          </group>
        </group_list>
        <measure>
          <title>Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for Donepezil MRD Non-Japanese Participants</title>
          <population>PK set included all participants who received study drug and had at least 1 measurable plasma concentration or amount of drug in the urine.</population>
          <units>hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day -1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.000" lower_limit="1.00" upper_limit="3.00"/>
                    <measurement group_id="O2" value="3.000" lower_limit="2.00" upper_limit="4.00"/>
                    <measurement group_id="O3" value="3.008" lower_limit="2.00" upper_limit="6.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 21</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.508" lower_limit="1.00" upper_limit="10.03"/>
                    <measurement group_id="O2" value="3.500" lower_limit="2.00" upper_limit="8.00"/>
                    <measurement group_id="O3" value="2.500" lower_limit="1.00" upper_limit="3.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cmax: Maximum Observed Plasma Concentration for Donepezil MRD Non-Japanese Participants</title>
        <time_frame>Pre-dose on Days -1 and 21 and multiple time points (up to 24 hours) post-dose</time_frame>
        <population>PK set included all participants who received study drug and had at least 1 measurable plasma concentration or amount of drug in the urine.</population>
        <group_list>
          <group group_id="O1">
            <title>MRD: Cohort 10: TAK-071 3 mg+Donepezil 5 mg</title>
            <description>TAK-071 3 mg capsules, orally, once daily along with donepezil 5 mg, tablets, orally, once daily from Day 1 up to Day 21 to non-Japanese healthy participants who were pre-treated with donepezil 5 mg, tablet, once daily for 3 weeks prior to administration of TAK-071. Dose of TAK-071 was same as the dose used in MRD Cohort 7.</description>
          </group>
          <group group_id="O2">
            <title>MRD: Cohort 11: TAK-071 9 mg + Donepezil 5 mg</title>
            <description>TAK-071 9 mg capsules, orally, once daily along with donepezil 5 mg, tablets, orally, once daily from Day 1 up to Day 21 to non-Japanese healthy participants who were pre-treated with donepezil 5 mg, tablet, once daily for 3 weeks prior to administration of TAK-071. Dose of TAK-071 was same as the dose used in MRD Cohort 8.</description>
          </group>
          <group group_id="O3">
            <title>MRD: Cohort 12: TAK-071 15 mg+Donepezil 5 mg</title>
            <description>TAK-071 15 mg capsule, orally, once daily along with donepezil 5 mg, tablets, orally, once daily from Day 1 up to Day 21 to non-Japanese healthy participants who were pre-treated with donepezil 5 mg, tablet, once daily for 3 weeks prior to administration of TAK-071. Dose of TAK-071 was same as the dose used in MRD Cohort 9.</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax: Maximum Observed Plasma Concentration for Donepezil MRD Non-Japanese Participants</title>
          <population>PK set included all participants who received study drug and had at least 1 measurable plasma concentration or amount of drug in the urine.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day -1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.07" spread="3.6855"/>
                    <measurement group_id="O2" value="30.65" spread="5.9433"/>
                    <measurement group_id="O3" value="22.63" spread="4.2697"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 21</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.58" spread="2.3659"/>
                    <measurement group_id="O2" value="29.95" spread="6.4071"/>
                    <measurement group_id="O3" value="25.97" spread="5.6163"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AUC(0-24): Area Under the Plasma Concentration-Time Curve From Time 0 to 24 Hours Post-dose for Donepezil</title>
        <time_frame>Pre-dose on Days -1 and 21 and multiple time points (up to 24 hours) post-dose</time_frame>
        <population>PK set included all participants who received study drug and had at least 1 measurable plasma concentration or amount of drug in the urine.</population>
        <group_list>
          <group group_id="O1">
            <title>MRD: Cohort 10: TAK-071 3 mg+Donepezil 5 mg</title>
            <description>TAK-071 3 mg capsules, orally, once daily along with donepezil 5 mg, tablets, orally, once daily from Day 1 up to Day 21 to non-Japanese healthy participants who were pre-treated with donepezil 5 mg, tablet, once daily for 3 weeks prior to administration of TAK-071. Dose of TAK-071 was same as the dose used in MRD Cohort 7.</description>
          </group>
          <group group_id="O2">
            <title>MRD: Cohort 11: TAK-071 9 mg + Donepezil 5 mg</title>
            <description>TAK-071 9 mg capsules, orally, once daily along with donepezil 5 mg, tablets, orally, once daily from Day 1 up to Day 21 to non-Japanese healthy participants who were pre-treated with donepezil 5 mg, tablet, once daily for 3 weeks prior to administration of TAK-071. Dose of TAK-071 was same as the dose used in MRD Cohort 8.</description>
          </group>
          <group group_id="O3">
            <title>MRD: Cohort 12: TAK-071 15 mg+Donepezil 5 mg</title>
            <description>TAK-071 15 mg capsule, orally, once daily along with donepezil 5 mg, tablets, orally, once daily from Day 1 up to Day 21 to non-Japanese healthy participants who were pre-treated with donepezil 5 mg, tablet, once daily for 3 weeks prior to administration of TAK-071. Dose of TAK-071 was same as the dose used in MRD Cohort 9.</description>
          </group>
        </group_list>
        <measure>
          <title>AUC(0-24): Area Under the Plasma Concentration-Time Curve From Time 0 to 24 Hours Post-dose for Donepezil</title>
          <population>PK set included all participants who received study drug and had at least 1 measurable plasma concentration or amount of drug in the urine.</population>
          <units>h*ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day -1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="410.1" spread="79.220"/>
                    <measurement group_id="O2" value="543.8" spread="113.62"/>
                    <measurement group_id="O3" value="399.5" spread="96.519"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 21</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="472.5" spread="62.377"/>
                    <measurement group_id="O2" value="567.2" spread="135.33"/>
                    <measurement group_id="O3" value="430.5" spread="111.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ratio of Geometric Mean of Cmax for Donepezil After 21 Daily Doses of TAK-071</title>
        <description>A linear mixed effect model on the natural log-transformed parameters was performed with day as a fixed effect and participant as a random effect. Ratio is the exponentiated geometric mean value Day 21/Day -1 on the original scale.</description>
        <time_frame>Pre-dose on Days -1 and 21 and multiple time points (up to 24 hours) post-dose</time_frame>
        <population>PK set included all participants who received study drug and had at least 1 measurable plasma concentration or amount of drug in the urine. Here, number analyzed is the number of participants with data available for analysis at the given time-point.</population>
        <group_list>
          <group group_id="O1">
            <title>MRD: Cohort 10: TAK-071 3 mg+Donepezil 5 mg</title>
            <description>TAK-071 3 mg capsules, orally, once daily along with donepezil 5 mg, tablets, orally, once daily from Day 1 up to Day 21 to non-Japanese healthy participants who were pre-treated with donepezil 5 mg, tablet, once daily for 3 weeks prior to administration of TAK-071. Dose of TAK-071 was same as the dose used in MRD Cohort 7.</description>
          </group>
          <group group_id="O2">
            <title>MRD: Cohort 11: TAK-071 9 mg + Donepezil 5 mg</title>
            <description>TAK-071 9 mg capsules, orally, once daily along with donepezil 5 mg, tablets, orally, once daily from Day 1 up to Day 21 to non-Japanese healthy participants who were pre-treated with donepezil 5 mg, tablet, once daily for 3 weeks prior to administration of TAK-071. Dose of TAK-071 was same as the dose used in MRD Cohort 8.</description>
          </group>
          <group group_id="O3">
            <title>MRD: Cohort 12: TAK-071 15 mg+Donepezil 5 mg</title>
            <description>TAK-071 15 mg capsule, orally, once daily along with donepezil 5 mg, tablets, orally, once daily from Day 1 up to Day 21 to non-Japanese healthy participants who were pre-treated with donepezil 5 mg, tablet, once daily for 3 weeks prior to administration of TAK-071. Dose of TAK-071 was same as the dose used in MRD Cohort 9.</description>
          </group>
        </group_list>
        <measure>
          <title>Ratio of Geometric Mean of Cmax for Donepezil After 21 Daily Doses of TAK-071</title>
          <description>A linear mixed effect model on the natural log-transformed parameters was performed with day as a fixed effect and participant as a random effect. Ratio is the exponentiated geometric mean value Day 21/Day -1 on the original scale.</description>
          <population>PK set included all participants who received study drug and had at least 1 measurable plasma concentration or amount of drug in the urine. Here, number analyzed is the number of participants with data available for analysis at the given time-point.</population>
          <units>Ratio</units>
          <param>Number</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.160" lower_limit="1.072" upper_limit="1.256"/>
                    <measurement group_id="O2" value="0.969" lower_limit="0.914" upper_limit="1.028"/>
                    <measurement group_id="O3" value="1.121" lower_limit="1.027" upper_limit="1.224"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ratio of Geometric Mean of AUC(0-24) for Donepezil After 21 Daily Doses of TAK-071</title>
        <description>A linear mixed effect model on the natural log-transformed parameters was performed with day as a fixed effect and participant as a random effect. Ratio is the exponentiated geometric mean value Day 21/Day -1 on the original scale.</description>
        <time_frame>Pre-dose on Days -1 and 21 and multiple time points (up to 24 hours) post-dose</time_frame>
        <population>PK set included all participants who received study drug and had at least 1 measurable plasma concentration or amount of drug in the urine. Here, number analyzed is the number of participants with data available for analysis at the given time-point.</population>
        <group_list>
          <group group_id="O1">
            <title>MRD: Cohort 10: TAK-071 3 mg+Donepezil 5 mg</title>
            <description>TAK-071 3 mg capsules, orally, once daily along with donepezil 5 mg, tablets, orally, once daily from Day 1 up to Day 21 to non-Japanese healthy participants who were pre-treated with donepezil 5 mg, tablet, once daily for 3 weeks prior to administration of TAK-071. Dose of TAK-071 was same as the dose used in MRD Cohort 7.</description>
          </group>
          <group group_id="O2">
            <title>MRD: Cohort 11: TAK-071 9 mg + Donepezil 5 mg</title>
            <description>TAK-071 9 mg capsules, orally, once daily along with donepezil 5 mg, tablets, orally, once daily from Day 1 up to Day 21 to non-Japanese healthy participants who were pre-treated with donepezil 5 mg, tablet, once daily for 3 weeks prior to administration of TAK-071. Dose of TAK-071 was same as the dose used in MRD Cohort 8.</description>
          </group>
          <group group_id="O3">
            <title>MRD: Cohort 12: TAK-071 15 mg+Donepezil 5 mg</title>
            <description>TAK-071 15 mg capsule, orally, once daily along with donepezil 5 mg, tablets, orally, once daily from Day 1 up to Day 21 to non-Japanese healthy participants who were pre-treated with donepezil 5 mg, tablet, once daily for 3 weeks prior to administration of TAK-071. Dose of TAK-071 was same as the dose used in MRD Cohort 9.</description>
          </group>
        </group_list>
        <measure>
          <title>Ratio of Geometric Mean of AUC(0-24) for Donepezil After 21 Daily Doses of TAK-071</title>
          <description>A linear mixed effect model on the natural log-transformed parameters was performed with day as a fixed effect and participant as a random effect. Ratio is the exponentiated geometric mean value Day 21/Day -1 on the original scale.</description>
          <population>PK set included all participants who received study drug and had at least 1 measurable plasma concentration or amount of drug in the urine. Here, number analyzed is the number of participants with data available for analysis at the given time-point.</population>
          <units>Ratio</units>
          <param>Number</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.155" lower_limit="1.059" upper_limit="1.260"/>
                    <measurement group_id="O2" value="1.055" lower_limit="0.989" upper_limit="1.126"/>
                    <measurement group_id="O3" value="1.106" lower_limit="1.014" upper_limit="1.207"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Day 1 up to Day 41</time_frame>
      <desc>At each visit the investigator had to document any occurrence of adverse events and abnormal laboratory findings. Any event spontaneously reported by the participant or observed by the investigator was recorded, irrespective of the relation to study treatment.</desc>
      <group_list>
        <group group_id="E1">
          <title>SRD: Placebo Cohorts 1-6, 18 and 19</title>
          <description>TAK-071 placebo-matching capsules, orally, once on Day 1 to non-Japanese healthy participants in the single-rising dose (SRD) period.</description>
        </group>
        <group group_id="E2">
          <title>SRD: Cohort 1: TAK-071 1 mg</title>
          <description>TAK-071 1 mg, capsule, orally, once on Day 1 to non-Japanese healthy participants.</description>
        </group>
        <group group_id="E3">
          <title>SRD: Cohort 2: TAK-071 3 mg</title>
          <description>TAK-071 3 mg capsule, orally, once on Day 1 to non-Japanese healthy participants. Dose of TAK-071 was based on the 24-hour post-dose safety, tolerability and pharmacokinetic (PK) data from cohort 1.</description>
        </group>
        <group group_id="E4">
          <title>SRD: Cohort 3: TAK-071 9 mg</title>
          <description>TAK-071 9 mg capsule, orally, once on Day 1 to non-Japanese healthy participants. Dose of TAK-071 was based on 24-hour safety, tolerability, and preliminary plasma PK and 12-hour CSF PK data.</description>
        </group>
        <group group_id="E5">
          <title>SRD: Cohort 4: TAK-071 20 mg</title>
          <description>TAK-071 20 mg capsule, orally, once on Day 1 to non-Japanese healthy participants. Dose of TAK-071 was based on the 24-hour post-dose safety and tolerability data from previous cohort.</description>
        </group>
        <group group_id="E6">
          <title>SRD: Cohort 5: TAK-071 40 mg</title>
          <description>TAK-071 40 mg capsule, orally, once on Day 1 to non-Japanese healthy participants. Dose of TAK-071 will be based on 24-hour safety, tolerability, and preliminary plasma PK data from Cohort 4.</description>
        </group>
        <group group_id="E7">
          <title>SRD: Cohort 6: TAK-071 80 mg</title>
          <description>TAK-071 80 mg capsules, orally, once on Day 1 to non-Japanese healthy participants. Dose of TAK-071 was based on 24-hour safety, tolerability, and preliminary plasma PK data from Cohort 5</description>
        </group>
        <group group_id="E8">
          <title>MRD: Placebo Cohorts 7-9</title>
          <description>TAK-071 placebo-matching capsule, orally, once on Day 1 to non-Japanese healthy participants in the multiple-rising dose (MRD) period.</description>
        </group>
        <group group_id="E9">
          <title>MRD: Cohort 7: TAK-071 3 mg</title>
          <description>TAK-071 3 mg capsules, orally, once daily from Day 1 up to Day 21 to non-Japanese healthy participants. Dose of TAK-071 was based on 24-hour safety and tolerability from Cohort 4 and the 24-hour preliminary plasma PK and 12-hour CSF PK data from Cohort 3.</description>
        </group>
        <group group_id="E10">
          <title>MRD: Cohort 8: TAK-071 9 mg</title>
          <description>TAK-071 9 mg capsules, orally, once daily from Day 1 up to Day 21 to non-Japanese healthy participants. Dose of TAK-071 was based on safety, tolerability and available PK data arising from the ongoing SRD part and previous MRD cohort.</description>
        </group>
        <group group_id="E11">
          <title>MRD: Cohort 9: TAK-071 15 mg</title>
          <description>TAK-071 15 mg capsule, orally, once on Day 1, followed by a washout period of 7 days, then TAK-071 once daily for 21 days to non-Japanese healthy participants. Dose of TAK-071 will be based on safety, tolerability and available PK data arising from the ongoing SRD part and previous MRD cohort.</description>
        </group>
        <group group_id="E12">
          <title>MRD: TAK-071 Placebo Cohorts 10-12+Donepezil</title>
          <description>TAK-071 placebo-matching capsule, orally, once daily along with donepezil 5 mg, tablets, orally, once daily from Day 1 up to Day 21 to non-Japanese healthy participants who were pre-treated with donepezil 5 mg, tablet, once daily for 3 weeks prior to administration of TAK-071.</description>
        </group>
        <group group_id="E13">
          <title>MRD: Cohort 10: TAK-071 3 mg+Donepezil 5 mg</title>
          <description>TAK-071 3 mg capsules, orally, once daily along with donepezil 5 mg, tablets, orally, once daily from Day 1 up to Day 21 to non-Japanese healthy participants who were pre-treated with donepezil 5 mg, tablet, once daily for 3 weeks prior to administration of TAK-071. Dose of TAK-071 was same as the dose used in MRD Cohort 7.</description>
        </group>
        <group group_id="E14">
          <title>MRD: Cohort 11: TAK-071 9 mg + Donepezil 5 mg</title>
          <description>TAK-071 9 mg capsules, orally, once daily along with donepezil 5 mg, tablets, orally, once daily from Day 1 up to Day 21 to non-Japanese healthy participants who were pre-treated with donepezil 5 mg, tablet, once daily for 3 weeks prior to administration of TAK-071. Dose of TAK-071 was same as the dose used in MRD Cohort 8.</description>
        </group>
        <group group_id="E15">
          <title>MRD: Cohort 12: TAK-071 15 mg+Donepezil 5 mg</title>
          <description>TAK-071 15 mg capsule, orally, once daily along with donepezil 5 mg, tablets, orally, once daily from Day 1 up to Day 21 to non-Japanese healthy participants who were pre-treated with donepezil 5 mg, tablet, once daily for 3 weeks prior to administration of TAK-071. Dose of TAK-071 was same as the dose used in MRD Cohort 9.</description>
        </group>
        <group group_id="E16">
          <title>MRD: Placebo Cohorts 13-15</title>
          <description>TAK-071 placebo-matching capsule, orally, once on Day 1 to Japanese healthy participants.</description>
        </group>
        <group group_id="E17">
          <title>MRD: Cohort 13: TAK-071 3 mg</title>
          <description>TAK-071 3 mg capsule, orally, once on Day 1, followed by a washout period of 7 days, then TAK-071 once daily for 21 days to Japanese healthy participants. Dose of TAK-071 was same as the dose used in MRD Cohort 7.</description>
        </group>
        <group group_id="E18">
          <title>MRD: Cohort 14: TAK-071 9 mg</title>
          <description>TAK-071 9 mg capsule or matching placebo, orally, once on Day 1, followed by a washout period of 7 days, then TAK-071 once daily for 21 days to Japanese healthy participants. Dose of TAK-071 was same as the dose used in MRD Cohort 8.</description>
        </group>
        <group group_id="E19">
          <title>MRD: Cohort 15: TAK-071 15 mg</title>
          <description>TAK-071 15 mg capsule, orally, once on Day 1, followed by a washout period of 7 days, then TAK-071 once daily for 21 days to Japanese healthy participants. Dose of TAK-071 was same as the dose used in MRD Cohort 9.</description>
        </group>
        <group group_id="E20">
          <title>Cohort 16</title>
          <description>TAK-071 capsule, orally, once on Day 1 for 21 days, followed by a washout period of 21 days, or placebo matching tablets, orally, once on Day 1 for 21 days. Donepezil was delivered as 5 mg tablet, orally, once followed by 10 mg tablet, orally, once in run-in period.</description>
        </group>
        <group group_id="E21">
          <title>Bioavailability (BA)/Food Effect: Cohort 17 Regimen A</title>
          <description>TAK-071 10 mg capsule, orally once on Day 1 in the fasted state in Period 1 or Period 2 or Period 3</description>
        </group>
        <group group_id="E22">
          <title>BA/Food Effect: Cohort 17 Regimen B</title>
          <description>TAK-071 10 mg tablet, orally, once on Day 1 in the fasted state in Period 1 or Period 2 or Period 3</description>
        </group>
        <group group_id="E23">
          <title>BA/Food Effect: Cohort 17 Regimen C</title>
          <description>TAK-071 10 mg tablet, orally, once on Day 1 in the fed state in Period 1 or Period 2 or Period 3</description>
        </group>
        <group group_id="E24">
          <title>SRD: Cohort 18: TAK-071 120 mg</title>
          <description>TAK-071 120 mg capsule, orally, once on Day 1 to non-Japanese healthy participants. Dose of TAK-071 was based on 24-hour safety, tolerability, and preliminary plasma PK data from Cohort 6.</description>
        </group>
        <group group_id="E25">
          <title>SRD: Cohort 19: TAK-071 160 mg</title>
          <description>TAK-071 160 mg capsule, orally, once on Day 1 to non-Japanese healthy participants. Dose of TAK-071 was based on 24-hour safety, tolerability, and preliminary plasma PK data from Cohort 18.</description>
        </group>
        <group group_id="E26">
          <title>SRD: TAK-071 Placebo+Donepezil Placebo</title>
          <description>TAK-071 placebo-matching capsule, orally, once on Day 1 followed by donepezil placebo-matching tablet, orally on Day 2 to non-Japanese healthy participants.</description>
        </group>
        <group group_id="E27">
          <title>SRD: TAK-071 Placebo+Donepezil</title>
          <description>TAK-071 placebo-matching capsule, orally, once on Day 1 followed by donepezil 10 mg tablet, orally, on Day 2 to non-Japanese healthy participants.</description>
        </group>
        <group group_id="E28">
          <title>SRD: Cohort 20: TAK-071 40 mg+Donepezil</title>
          <description>TAK-071 40 mg capsule, orally, once on Day 1 followed by donepezil 10 mg, tablets, orally, once on Day 2 to non-Japanese healthy participants. Dose of TAK-071 was based on 24-hour safety, tolerability, and preliminary plasma PK data from Cohort 19.</description>
        </group>
        <group group_id="E29">
          <title>SRD: Cohort 21: TAK-071 60 mg+Donepezil</title>
          <description>TAK-071 60 mg capsule, orally, once on Day 1 followed by donepezil 10 mg, tablets, orally, once on Day 2 to non-Japanese healthy participants. Dose of TAK-071 was based on 24-hour safety and tolerability data from Cohort 20.</description>
        </group>
        <group group_id="E30">
          <title>SRD: Cohort 22: TAK-071 80 mg+Donepezil</title>
          <description>TAK-071 80 mg capsule, orally, once on Day 1, followed by donepezil 10 mg, tablets, orally, once on Day 2 to non-Japanese healthy participants. Dose of TAK-071 was based on 24-hour safety and tolerability data from Cohort 21.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E23" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E24" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E25" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E26" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E27" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E28" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E29" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E30" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E23" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E24" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E25" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E26" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E27" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E28" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E29" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E30" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA version: 20.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E13" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E14" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E15" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E16" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E17" subjects_affected="2" subjects_at_risk="5"/>
                <counts group_id="E18" subjects_affected="2" subjects_at_risk="5"/>
                <counts group_id="E19" subjects_affected="3" subjects_at_risk="5"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E21" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E22" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E23" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E24" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E25" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E26" subjects_affected="4" subjects_at_risk="9"/>
                <counts group_id="E27" subjects_affected="5" subjects_at_risk="9"/>
                <counts group_id="E28" subjects_affected="4" subjects_at_risk="5"/>
                <counts group_id="E29" subjects_affected="6" subjects_at_risk="6"/>
                <counts group_id="E30" subjects_affected="5" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E19" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E23" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E24" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E25" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E26" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E27" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E28" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E29" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E30" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E14" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E15" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E19" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E23" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E24" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E25" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E26" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E27" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E28" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E29" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E30" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E23" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E24" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E25" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E26" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E27" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E28" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E29" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E30" subjects_affected="2" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E23" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E24" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E25" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E26" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E27" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E28" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E29" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E30" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E23" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E24" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E25" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E26" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E27" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E28" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E29" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E30" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E23" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E24" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E25" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E26" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E27" subjects_affected="3" subjects_at_risk="9"/>
                <counts group_id="E28" subjects_affected="2" subjects_at_risk="5"/>
                <counts group_id="E29" subjects_affected="6" subjects_at_risk="6"/>
                <counts group_id="E30" subjects_affected="4" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Sensitivity of teeth</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E23" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E24" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E25" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E26" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E27" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E28" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E29" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E30" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E19" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E23" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E24" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E25" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E26" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E27" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E28" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E29" subjects_affected="4" subjects_at_risk="6"/>
                <counts group_id="E30" subjects_affected="3" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E23" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E24" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E25" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E26" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E27" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E28" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E29" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E30" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E23" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E24" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E25" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E26" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E27" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E28" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E29" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E30" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Abdominal discomfort</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E19" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E23" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E24" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E25" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E26" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E27" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E28" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E29" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E30" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Frequent bowel movements</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E23" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E24" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E25" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E26" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E27" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E28" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E29" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E30" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E21" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E23" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E24" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E25" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E26" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E27" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E28" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E29" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E30" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E23" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E24" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E25" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E26" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E27" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E28" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E29" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E30" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Puncture site pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E23" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E24" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E25" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E26" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E27" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E28" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E29" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E30" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Vessel puncture site bruise</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E23" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E24" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E25" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E26" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E27" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E28" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E29" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E30" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Injection site haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E23" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E24" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E25" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E26" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E27" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E28" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E29" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E30" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E19" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E23" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E24" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E25" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E26" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E27" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E28" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E29" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E30" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E19" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E23" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E24" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E25" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E26" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E27" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E28" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E29" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E30" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Influenza like illness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E23" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E24" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E25" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E26" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E27" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E28" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E29" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E30" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E18" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E23" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E24" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E25" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E26" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E27" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E28" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E29" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E30" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Post lumbar puncture syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E23" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E24" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E25" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E26" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E27" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E28" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E29" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E30" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Arthropod bite</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E23" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E24" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E25" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E26" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E27" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E28" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E29" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E30" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Laceration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E19" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E23" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E24" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E25" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E26" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E27" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E28" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E29" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E30" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Procedural pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E23" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E24" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E25" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E26" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E27" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E28" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E29" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E30" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E19" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E23" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E24" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E25" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E26" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E27" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E28" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E29" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E30" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E19" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E23" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E24" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E25" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E26" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E27" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E28" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E29" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E30" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E18" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E23" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E24" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E25" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E26" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E27" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E28" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E29" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E30" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E23" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E24" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E25" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E26" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E27" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E28" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E29" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E30" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E23" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E24" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E25" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E26" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E27" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E28" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E29" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E30" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E15" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E23" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E24" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E25" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E26" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E27" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E28" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E29" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E30" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E23" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E24" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E25" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E26" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E27" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E28" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E29" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E30" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E15" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E18" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E19" subjects_affected="2" subjects_at_risk="5"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E23" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E24" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E25" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E26" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E27" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E28" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E29" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E30" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E23" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E24" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E25" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E26" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E27" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E28" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E29" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E30" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E23" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E24" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E25" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E26" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E27" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E28" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E29" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E30" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E19" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E23" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E24" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E25" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E26" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E27" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E28" subjects_affected="2" subjects_at_risk="5"/>
                <counts group_id="E29" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E30" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Parosmia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E15" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E23" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E24" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E25" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E26" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E27" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E28" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E29" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E30" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E18" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E23" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E24" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E25" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E26" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E27" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E28" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E29" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E30" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E21" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E23" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E24" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E25" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E26" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E27" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E28" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E29" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E30" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Irritability</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E19" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E23" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E24" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E25" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E26" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E27" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E28" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E29" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E30" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Abnormal dreams</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E23" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E24" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E25" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E26" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E27" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E28" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E29" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E30" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E22" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E23" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E24" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E25" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E26" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E27" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E28" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E29" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E30" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E15" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E23" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E24" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E25" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E26" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E27" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E28" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E29" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E30" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E18" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E23" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E24" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E25" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E26" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E27" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E28" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E29" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E30" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E23" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E24" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E25" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E26" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E27" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E28" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E29" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E30" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Sneezing</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E23" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E24" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E25" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E26" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E27" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E28" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E29" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E30" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Increased upper airway secretion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E23" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E24" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E25" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E26" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E27" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E28" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E29" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E30" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E23" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E24" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E25" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E26" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E27" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E28" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E29" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E30" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Rash generalised</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E23" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E24" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E25" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E26" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E27" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E28" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E29" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E30" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E15" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E18" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E23" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E24" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E25" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E26" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E27" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E28" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E29" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E30" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Pruritus generalised</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E15" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E23" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E24" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E25" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E26" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E27" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E28" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E29" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E30" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Papule</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E23" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E24" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E25" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E26" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E27" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E28" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E29" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E30" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hot flush</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E23" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E24" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E25" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E26" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E27" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E28" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E29" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E30" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Medical Director, Clinical Science</name_or_title>
      <organization>Takeda</organization>
      <phone>+1-877-825-3327</phone>
      <email>trialdisclosures@takeda.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

